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SUMMARY 
‘Formularies’ represent a compendium of pharmaceutical products and services selected by 
the medical staff of an institution to reflect current drug preferences of healthcare 
practitioners and patients.  
Successful formularies restrict access to or discourage the use of those drugs for which there 
are lower – cost substitutes available, thereby encouraging the use of more efficient 
medications.  
When compiling and revising formularies, the most frequently used criteria for selecting 
among alternative drugs are clinical efficacy, risk of adverse effects and daily cost of drug. 
Too often, such selection processes focus on a search for the least costly alternative, without 
an explicit analysis of overall cost-effectiveness. 
For an institution or organization assessing drug costs however, the more relevant issue is, 
how much a drug therapy costs in the context of overall patient care for a given disease. As 
such a reassessment of the role of the formulary and the manner of its implementation is 
taking place. 
The purpose of today’s formulary is to promote the efficient use of drugs.  
The importance of pharmacoeconomics in formulary decision-making lies in the information 
provided about the value and efficiency of alternative pharmaceutical products compared with 
other relevant treatment alternatives when both costs and consequences are considered 
simultaneously.  
However if Pharmacoeconomics is to contribute to formulary decision-making P & T 
Committees must appreciate the potential role of that discipline in such decisions; at the same 
time, pharmacoeconomists must demonstrate that their analyses can lead to more efficient 
allocation of limited resources in the purchase of drugs without compromising the quality of 
healthcare. 
 Initial exploratory surveys of pharmacists in Singapore clearly established the need and scope 
for use of pharmacoeconomics in hospital settings in the country. 
Contending that pharmacoeconomics has a definite role in formulary decisions the researcher 
endeavored to test this hypothesis in the setting of the university hospital through a means 
deemed appropriate by her. This was to evaluate one or two products for each P&T 
Committee meeting through 3-4 meetings and submit the evaluations for facilitating P&T 
Committee decision-making.  
An objective measure of the success of the process would be an assessment of the percentage 
change in the number of P&T approvals and potential cost savings to the organization as a 
result of pharmacoeconomic assessments. However, due to the inherent nature of the project 
and a lack of time it was not possible to consider them as primary outcome measures. 
Economic evaluations (as proposed and demonstrated by the researcher), in addition to the 
primarily pharmacotherapeutic (efficacy and safety) based considerations currently taken into 
account by the P&T Committee at the NUH would entail a more comprehensive or in-depth 
evaluation of formulary actions (addition or deletion) leading to increased user satisfaction. 
Hence, the primary outcome measure was taken to be user satisfaction to be measured or 
gauged by a questionnaire at the end of 3 or 4 P&T committee meetings. 
The responses clearly revealed that a majority of the decision-makers expressed 
satisfaction with the researcher’s approach to formulary decision-making and would 
even be willing to consider a health economist as a member of the committee. 
Therefore, the researcher was successful in demonstrating to the relevant decision-
makers the role of pharmacoeconomics in formulary decision-making. Support for 
this claim can be found on Page 90: table 19 - P&T Committee members’ opinion of 
the required constitution of the Committee  - clearly shows that a substantial 
proportion (60%) feels that health economists should be considered as ‘must be’ 
members. Though 30% have not unambiguously declared that health economists 
‘must be’ members, they remain unsure about the issue. Only 10% (or 1 respondent) 











































SECTION 1.  ‘PHARMACOECONOMICS’ IN THE CONTEXT OF “COST-
CONTROL” IN THE HEALTH CARE SECTOR 
 
1.1 Historical background 
1.1.1 The big expansion 
In the 50s and 60s in the context of social solidarity, the welfare state and the great society, 
universal access to health care, generally publicly financed, was seen as a right for all 
citizens. Health care systems expanded rapidly, as public and private financing supported and 
helped create new effective demand and delivery system capacity. 1 An important indicator of 
such expansive growth on the demand side included per capita use of inpatient care∗ that 
increased, for example – from 2.1 in 1960 to 3.4 in 1980 in Japan. 2 On the supply side such 
indicators include – number of physicians per 1,000 capita that increased by 4.2 percentage 
points on an average (low of 0.9 percent in Austria to a high of 11.6 percents in Finland) for 
Organization for Economic Co-operation and Development (OECD) member countries 
between 1960 and 1980.2 
 
1.1.2 Growing pain – unbridled expenditure  
This expansive growth came about with its own pain – in the form of extraordinary increases 
in expenditure. Most governments in the early post-World War II era in developed countries 
felt it their moral and ethical obligation to try and provide universal coverage to their citizens.  
But, beginning in the 70s and continuing into the 80s, the recessions in most OECD countries 
engendered by the oil shocks, coupled with rapid increases in health care expenditures, put 
governments under strong financial pressures. An increasing challenge emanated from the 
                                                
∗
 as measured by hospital bed-days per person and per year 
growing inability of different governments to cope with the increasing expenses and a 
heightened concern about the sustained capacity to meet the rising demand in health care 
services. Pressures for health care reform started mounting in most countries. 1- 10 
Among reasons most often cited by analysts, experts and government officials behind these 
increasing health care costs, the most important ones were an increasing demand for health 
care (propelled by a rapidly ageing population, technological advancements and a real income 
growth), the way health care systems were structured and financed, and an emphasis on acute 
care rather than prevention. 1, 11, 12  
From the 1970s member economies of the Organization for Economic Cooperation and 
Development (OECD), responding to increasing concern with regard to growth in health care 
expenditures, conducted several studies,1-7 which, revealed important facts about health care 
systems in different countries and firmly established the need for cost-control. It was being 
felt in most countries that rising health care expenditure had two major aspects associated 
with it: 
1. The ‘real’ expense levels 
 
2. additional expenditure that could be warranted due to an increasing proportion of 
‘ageing’ population  
 
 
1.1.2.1 Real expense levels spelt danger 
Let us take some figures from 1984 data to see how grave the situation was.  
In 1984, 780million citizens in 24 OECD countries consumed over US$800billion worth of 
health services, approximating greater than $1000 per person. On an average almost 80% of 
the expenditure was financed by the public sector. Health care expenditure accounted for 
almost 15% of all public spending and 25% of all social spending* (the second largest social 
expenditure item).♣ Public expenditure on health accounted for 6% of the GDP while overall 
it accounted for 8% of the GDP.1  
 
1.1.2.2 Future forecasts did not show much hope – the ageing population 
The projected trends also did not show any significant improvements. Rather, a steep increase 
was predicted for most countries. Some nations going by projections made then would have 
had to spend on average some 30% higher on health care by the year 2030, due to population 
ageing, which seemed unacceptable by any standards.1, 12 In the face of the demographic 
configurations of the population and the rapid progresses made in science and technology 
these projections did not appear too unrealistic.  
A statistical estimate of the years 2010 and 2030 in terms of demographics of the young and 
old looked like this: 1  
Table 1: Trends in Percentage of National population aged 65 and above 
 1980 2010 2030 
Switzerland 13.83 20.49 27.49 
Germany 15.51 20.35 25.82 
Netherlands 11.51 15.13 22.96 
Canada 9.51 14.61 22.39 
Italy 13.45 17.28 21.92 
France 13.96 16.26 21.76 
Sweden 16.29 17.47 21.70 
Belgium 14.37 15.90 20.78 
Japan 9.10 18.62 19.97 
United States 11.29 12.79 19.49 
United Kingdom 14.87 14.61 19.24 
Australia 9.62 12.59 18.22 
Ireland 10.72 11.08 14.74 
Denmark 14.41 16.67 22.56 
Finland 11.98 16.76 23.78 
New Zealand 9.73 12.01 19.35 
Average 12.62 15.94 21.27 
                                                
♣
 Social spending would include other spending for societal benefit. This could include expenditure on 
education, public housing, public transportation, recreation facilities like parks etc. 
 The above figures meant, substantial ageing of the populations was predicted for most 
countries. Again, as has been observed old people generally consume more health care 
resources than younger people. In fact, health care expenditures were observed to be the 
highest for the very old and the very young. It was noted that medical care expenditures on 
those 65 and over could on average be 4 times greater than expenditures on those below 65. 
Expenditures on those 75 and older could be more than 7 times greater than on those under 
65. 1, 7, 12, 13  
That meant two things: first, there would be a greater need for health care resources, as an 
increased proportion of the population was growing ‘old’. Secondly, ‘increased proportion of 
old’ would mean there would be a decreased proportion of young or productive population to 
support the older population. Naturally, it was being felt that the burden on the economy 
would become very high. In addition, the giant strides made by technological and scientific 
innovations meant that the life expectancy in general, was increasing which was to bring with 
it additional medical ‘needs’ and thus additional expenditure. 
 
1.1.3 A case for controlling costs 
Given the rate of progress in medical technology, the estimated future demographic change 
(associated with a higher-than-ever demand) and the anticipated potential future financing 
constraints, governments started becoming increasingly concerned about their ability to 
provide universal access to necessary services.1,11,12 Governments that until the 70s 
concentrated on expanding the facilities and capacities of their health care systems became 
increasingly preoccupied with devising various methods of cost control discussed later. 1, 2, 4, 7, 
9, 10, 12, 14
 
That this concern of different countries was not in vain can be well understood today by 
looking at the corresponding figures captured: the global health expenditure in 1995 stood at 
US $1,800 billion just over 8% of the world’s total gross product. In the U.K, the inflation-
adjusted per capita rate of growth of health care expenditure has been 4%, slightly lower than 
the US at 5% and only half of the staggering rate of 8% in Japan.15 
A pertinent question here may be, “Patients are covered by some form of insurance; therefore 
they do not pay anyway. Why bother?” In reality, however, consumers pay in one form or the 
other, for example, in the form of reduced pay and greater premiums or higher taxes.16  
 
1.1.4 Compelling reasons for cost-control 
The most significant reasons for embarking upon cost-control in the health care sector seem 
to have been the following: 
 
1. Higher expenditures did not necessarily correlate to better “quality” of healthcare 
Quality in health care is difficult to measure. 1, 4, 6, 7, 11, 12 It is not easy to evaluate the effects of 
the many billions of dollars spent in this sector. If improvement in life expectancy or death 
rate is an index of quality in health care, then increased expenditures can be no guarantee for 
“better” health.  
Among the more developed countries no clear pattern can be discovered between health care 
spending and life expectancy.7 For instance among OECD countries, the US, one of the 
highest spenders on health care in the world, ranked 21st in terms of infant mortality and was 
in the bottom half in terms of life expectancy at birth. 11 However, countries like Canada, the 
United Kingdom, Switzerland and Australia while spending less have much better infant 
mortality rates than the US.10  
Moreover, although an index such as infant mortality is a meaningful way of evaluating the 
impact of health care and public health programs in less developed countries, it is 
questionable whether such crude measures can accurately gauge the impact of health care 
services in wealthier industrialized nations. In industrialized nations, much of health care 
focuses on “softer” health outcomes, such as enhancement of functional status and quality of 
life in individuals with chronic diseases --- aspects of health status more difficult to monitor at 
the population level than death rates and related vital statistics. Additionally, when evaluating 
population health, it is usually difficult to disentangle the influence of health care from the 
impact of such basic social factors as poverty, education, lifestyle and social cohesiveness.1, 5, 
7, 17
 Because, health services by themselves can do little to bring about an improvement in the 
life expectancy of populations, other than by immunization.7  
 
2. ‘Value’ in health care is difficult to measure - Convoluted healthcare delivery 
chain 
Important questions raised in different countries were: “How is value for money to be 
measured in the case of health care?” “Which aspects of health systems provide the most 
value for money and which the least?”1,7  
Unfortunately, precise answers to these questions could not be given and answers to these 
questions evade us even to this day. In fact, there was no assurance that the value society was 
receiving in return for the rapidly rising expenditures was growing in tandem with the costs 
being paid. Unlike the Fast Moving Consumer Goods (FMCG) market, the health care market 
is a notoriously “not efficient” market. For most consumer products market, competition 
(though not perfect) amidst other factors is one very crucial element that determines which 
products remain in the market. The health care sector however, is distinguished by its 
inability to have a perfect market competition. This problem results from the fact that 
consumers who actually consume the products and services of this sector are unable by 
themselves to decide what they “need” or to judge whether they can “buy” it. They have to 
rely on their more knowledgeable health care professionals for this important judgment. 
Moreover, whether they are willing and able to buy cannot be estimated correctly as they 
hardly ever pay wholly (out-of-pocket) for the care (especially in developed countries). 
Exactly what it is that consumers are paying for (in some form or the other) no one knows. 
And no one knows either, whether the consumer really would want to buy that product if he 
were given a full understanding about it. Moreover, it is not quite believable that anybody 
would ever “want” to “buy” health care (if not compelled to do so).  
The result is that only a few people (namely, the health care professionals) know what is good 
for consumers but they do not know whether the product is the ‘best value’ for the price being 
paid.  
As an example, if there is a medical treatment that can affect the same cure in the same time 
as a more expensive surgical treatment, efficiency in consumption can be increased by 
substituting medicine for surgery. If however, the consumer’s health insurance scheme pays 
for surgery but not for medicine, a choice, which is inefficient from society’s point of view, is 
likely to be made. An imperfect market thus is more often the norm in the health care sector .  
 
3. ‘Law of Diminishing Returns’ in health care  
 Additionally, “more” may not necessarily be “better” either. In this respect, health care 
behaves like any other economic good in the sense that, the cost-benefit curve has a 
diminishing slope as increasing investment of resources yields less marginal improvements in 
the health of the population (Law of Diminishing Returns).16, 17 
To summarize, the important findings that mooted the whole idea or contemplation of health-
care cost control were the following:  
• Health care costs were growing at an unsustainable rate 
• To keep pace with such growth meant cannibalizing into other sectors of the economy 
that also demanded share of the public budget 
• The tremendous growth in expenditure was not necessarily translating into superior 
quality, for two reasons: quality was difficult to measure and whatever indicators 
were available did not necessarily show any direct correlation with high expenses  
• The Law of Diminishing Returns in health care also meant that the concept of “limits 
in expenditure” was gradually finding appeal to most decision-makers. 
1.1.4.1 “Health care cost-control” Ethical/ political hot potato 
However, “cost-control” in the healthcare sector was and is, not taken too lightly. There is 
invariably a degree of suspicion. Will fewer people have access to health care? Can’t the 
government take stock of other sectors? The moment ‘cost control’ is mentioned it also raises 
doubts about the issue of ‘quality’. Will the quality of care be compromised? Eyebrows are 
raised about the “ethics” of “controlling” costs in health care.16 Questions about the quality of 
care are an integral part of the debate on cost containment policies for health care for the 
elderly and the consequences of adopted policies.13 That quality issues in this sector are 
politically sensitive issues is undoubted.1, 5, 11, 12  
 
1.2 The governments’ will to change – ‘cost control’ methods implemented 
1.2.1 Demand control methods 
1.2.1.1 Restrictions on reimbursement 
These measures were based on the philosophy that consumer demand is limitless, unless some 
kind of restraint is placed on it by way of requiring patients to pay for part or whole of 
treatment.  When a good is provided “free” it almost always brings with it the issue of moral 
hazard. People tend to be insensitive to the cost of the good and overuse or abuse it because 
they “lose nothing” by doing so.  
In the health care arena it was being increasingly felt that with virtually “no costs’ borne by 
the patients the issue of moral hazard was a big possibility. Hence, one of the most important 
policies aimed at patients was that of restrictions on reimbursement (particularly prescription 
charges). By limiting the reimbursement of products, such policies are aimed at providing an 
incentive for patients to reduce their consumption of drugs. These could include co-payments 
that may require patients to pay a proportion of the cost of a prescribed product or a fixed 
charge. 11, 12, 18 Patient caps constitute limiting the number of reimbursable prescriptions per 
patient. 11, 18 The withdrawal of reimbursement of a drug may also be used in attempts to 
reduce prescribing.18 
Thus in France co-payment requirements were increased either by cutting reimbursement 
rates or by removing some treatment from coverage. This was most pronounced with 
prescription medications. A list of reimbursable drugs (positive list) was drawn up by the 
Ministry for Social Affairs, and each year the list kept growing smaller.11 In some countries 
like Greece, negative lists that provide the list of products that would not be reimbursed.19 
However, it has been suggested that policies to limit the level of reimbursement of drugs 
reduce the use of essential as well as non-essential drugs and may do more harm than good. 20 
 
1.2.1.2 Patient co-pays 
In the UK changes were implemented in certain areas previously covered for free by the 
National Health Service (NHS). Patients were required to pay a portion of their bill for 
medicine and appliances prescribed by the doctor. This measure serves dual purposes. The 
doctor becomes more cost-conscious and so prescribes only if the situation demands it. The 
patient also becomes more sensitive to costs and does not demand extra unnecessary care.11 
However, user charges are perceived as taxing the ill by shifting some of the burden out of 
government budgets. Such practice is of a regressive nature in the sense that, after a certain 
stage the expenditure levels tend to be distributed around a mean value. They cannot be 
decreased any more. Moreover, increasing user charges may reduce government expenditure 
but not enhance efficient use of drugs.18 
 
1.2.1.3 Supply restrictions 
The National Health Service was set up to control costs by having the general practitioners 
(GPs) act as gatekeepers to secondary and usually more costly care, a form of supply 
restriction. 7, 11, 21, 22  
 
1.2.1.4 Health service providing organizations and policies 
The concept of managed care in the US emerged as a strategy to reduce demand. After trying 
a number of regulatory approaches during the 70s and the 80s, the cornerstone of cost 
containment policy during the 1990s has been managed care.23 It is based on the philosophy 
that many of the health services provided to consumers are unnecessary or inappropriate and 
since consumers are not able to evaluate the care given, Managed Care Organizations can act 
on the consumers’ behalf. Use of the term “managed” underlines the fact that the health care 
sector lacks some of the basic features of a “free” market, such as full consumer information 
or real pricing mechanisms and competition. Managed care acts to curtail costs by limiting or 
influencing patients’ choice of providers, reviewing and intervening in decisions about health 
services to be provided either prospectively or retrospectively, and negotiating different 
payment terms with providers.7, 11 The two primary types of managed care organizations 
Health Maintenance Organizations and Preferred Provider Organizations by engendering 
competition among the providers relied on the philosophy of free markets to control costs.  
In 1983, Medicare began its Prospective Payment System to reimburse hospitals. This system 
is based on Diagnostic Related Groups (DRG s). Hospitals are given a fixed payment related 
to the expected costs of treatment for specific diagnoses, for each hospital admission. Should 
the hospital spend less on caring for the individual, the hospital retains the extra funds. 
Conversely the hospital is at financial risk for treatment costs beyond the fixed amount. Thus, 
hospitals have an incentive to operate efficiently and to discharge patients at the earliest 
medically feasible time. 11 However the down side of this scheme is that, in a bid to make 
more profits, the hospitals might discharge patients prematurely.  
However, it has been seen that piecemeal initiatives tend to leave untouched the full set of 
forces that give health care spending its momentum.11 
 
1.2.2 Supply control methods 
1.2.2.1 Generics 
On the supply side, attempts were made to place limits on prescribing practices by fostering 
the use of generic (usually cheaper) substitutes.11 Use of generic drugs is encouraged in most 
countries, but only Germany, Denmark, the United States, and the Netherlands allow 
community pharmacists to substitute generic drugs for proprietary brands.23 Moreover, 
generic drugs may reduce spending on drugs, but it can tackle only part of the problem of 
containing costs as new drugs are patent protected and their increased use will not be 
affected.23   
 
1.2.2.2 Fund holding 
In the UK, in the 90s a system of “fund holding” of the GPs came to be practised. 7, 11 In the 
late 80s hospital and community health services were managed by general managers under the 
supervision of regional health authorities and district health authorities. However, under the 
fund holding system, GPs can control their own budgets and bypass the district health 
authorities in their provision of health care.  They can buy treatment from any source whether 
NHS or private. They are encouraged to shop competitively for hospitals that offer them the 
best quality and price. Private hospitals compete for patient referrals from the GP s.11 
One aim of fund holding was to secure better value for money by encouraging general 
practitioners to scrutinise their prescribing and referral patterns and to shop among competing 
providers for the best price and quality. Supporters of this approach argue that it constructs an 
internal market for some types of service and thus incentives to search for cost-effective 
alternatives. The GP acts as an agent for the patient, helping him to be a better-informed 
customer than would otherwise be the case. 7 However the impact of changing referral rates 
on the quality and appropriateness of care is not known. 22  
Another pertinent question could be “Is it time well-spent by the doctors?” Would it be more 
fruitful spending of time if they did not manage funds and concentrated instead on their 
clinical practice? As has been truly stated, with such an approach “paperwork grows; patient 
work shrinks”.21  
Another question that also seems pertinent here is “How can allocation efficiency be ensured 
under such a system?” In other words, how can we be certain that the GP allocates it properly 
as per patient needs? In one case, 27% of patients exhausted all the GP’s funds.22  
Hence, fund holding practices constitute methods of cost-control targeted at doctors for 
controlling pharmaceutical expenditure, and rightly so. After all, until adequate steps have 
been taken to tackle the health system and clinical behaviour, it is unfair to penalise patients, 
whose decisions are largely not responsible for health care costs.24 Other measures aimed at 
doctors for controlling pharmaceutical expenditure include, physician authorisation, 
budgetary restrictions and prescribing guidelines.25 
 
1.2.2.3 Physician authorization 
In France, social security employs 3,000 physicians who among other duties are charged with 
granting prior authorizations for certain elective treatment - e.g. cosmetic surgery.11 
Retrospective utilisation reviews of physician practices are conducted. The criteria employed 
are, numbers of patient visits, number of treatments, number of tests ordered etc. A median is 
developed and anybody exceeding 50% over the median is given 6 months to rectify or 
sanctions are imposed against him.  Media campaign is widely used to discourage consumers 
from over relying on medications.11 
 
1.2.2.4 Other supply side restrictions  
Other policies aimed at doctors include budgetary restrictions, information and feed back to 
physicians, prescribing guidelines or even control on the prescribing advice disseminated to 
doctors by the drug industry.  
In Germany, budgetary restrictions were introduced in 1993 that placed a limit on drug costs. 
The first DM280m spent above this limit was supposed to be paid for out of physicians’ 
remuneration budgets. Regardless of whether such policy could lead to a pronounced 
reduction in prescribing rate and lead to substantial savings, such an approach does not 
definitely look into issues of quality of prescribing and hence may not encourage cost-
effectiveness in health care.7, 25 
Prescribing guidelines with strict enforcement mechanisms and suitable incentives for 
compliance or penalties for otherwise, were instituted in France and were instrumental in a 
15% reduction in prescribing of antibiotics in the first six months of 1994 (even though the 
results may have been confounded due to other factors). 24, 25 However, just using guidelines 
to inform professional behaviour, including the cost-effectiveness of prescribing as done by 
the Agency for Health Care Policy and Research in the US or by the Department of Health in 
Britain may just serve as advisory schemes without clear incentives to reward compliance.25 
Taking a slightly modified approach, in Germany, guidelines were introduced to define the 
average prescription volume for each medical specialty according to therapeutic use and 
category of drug.25 In New Zealand part of the Preferred Medicines Concept aims to give 
general practitioners information on drugs to provide administrative support to help them 
develop their own ‘preferred medicines lists’ in a “critical and rational” manner. 25, 26  
 
1.2.3 Market control methods 
1.2.3.1 Price/ budget control 
Market controls take the form of price or profit controls or both. However, price and profit 
controls contain few incentives for improving cost-effective use of drugs, and focus on cost 
containment and profitability of domestic industry. Without the use of carefully monitored 
economic evaluation (such as in Australia), price regulation remains a crude method of 
controlling costs and may result in poorer treatment of patients or increased overall costs to 
the health care system if expensive but cost effective drugs are discouraged. Carefully 
monitored economic evaluations could lead to improvements in efficiency and benefits to 
patients and the health care system.19 
Special boards and committees decide on price controls in the UK. Under the Voluntary Price 
Regulation Scheme, price is negotiated centrally to show that profits are fair and reasonable.11 
Companies earning excessive profits (more than 75% of their target 17-21 % rate of return on 
investment in research and development) may be required to cut prices to the NHS.19  
Though targeting drug company profits seems an attractive option for all cost cutting 
measures, such measures will serve to be a disincentive for producing and marketing 
potentially useful drugs and stifle the industry. Regulation of profits also overlooks the need 
to identify separately the costs of research and development and other costs for each 
product.27 It may result in perverse incentives, in particular by reducing inducements to 
control costs. It may also conflict with other measures to contain costs by allowing companies 
to increase prices when profits are threatened by reduced sales. Again, profit regulation, 
makes no attempt to link prescribing with cost effectiveness.19  
 
1.2.3.2 Reference Pricing 
In 1989, the reference price scheme for reimbursable drugs was introduced in Germany to 
reduce pharmaceutical expenditure, which had been steadily increasing in the past. Reference-
based pricing is a term describing any system that establishes a common reimbursement level 
for a group of comparable or interchangeable drugs.28 
In the Netherlands and Germany, the reference price for each product results from average 
prices calculated on a basket of four European countries (Germany, UK, Belgium and 
France). 29, 30, 31 In New Zealand the reference price is that of the lowest priced drug, while in 
Sweden it is the lowest priced generic drug plus some amount (10% in Sweden). 19 In 
reference price schemes, each company is free to fix its own price over the cap, with the 
difference being paid by the patient. There is therefore, a strong constraint on companies’ 
pricing policies. Generally, reference prices are fixed in the lower band of market prices, so 
companies are effectively forced to reduce the prices of many products that may be priced 
above the reference price.30 This occurred in Sweden after the introduction of the scheme in 
1993, as companies anticipated that consumers would not pay the higher price.32 The basic 
premise of reference-based pricing seems to be that governments can reduce drug costs 
without affecting quality of care by encouraging the use of less expensive but equally 
efficacious drugs while maintaining the freedom of manufacturers to set prices and of 
physicians and patients to choose the products they prefer.  
However, the key question is the extent to which the policy is reducing inappropriate 
utilisation and not acting as a barrier to appropriate care.28  
The pharmaceutical industry has been vehemently opposed to reference pricing, particularly 
because the strategy deliberately fails to distinguish between branded medicines, which 
reflect research and development costs, and cheap generic alternatives.30 
 
1.3 General Limitations of governments’ approaches 
Price and profit regulation focusing on cost containment and profitability of the 
pharmaceutical industry would most likely result in profit losses for companies and 
eventually might force less investment in Research & Development and prevent advances 
from benefiting mankind. 
Inadequate prescription drug coverage (as is the case for most Medicare enrollees) for 
outpatient drug expenditures –might result in less overall use of drugs but one must be careful 
to see that ‘less use’ does not mean ‘less use of clinically important medications’. Important 
medications when not taken may cause deterioration of health among those with serious and 
chronic illnesses. This policy could also potentially lead to increased hospitalization therefore 
incurring more expenses.  
Expenditure caps 20 on outpatient drugs (from an experience of Medicare HMOs in 
Massachusetts) or other kinds of limits such as limits on the number of prescriptions filled 
each month (as observed in the New Hampshire Medicaid program) 20 should be avoided to 
prevent unintended effects like increased hospitalization and nursing home admissions.  
As a cost-containment measure in November 1992, the UK government intended to widen the 
range of drugs available without a prescription to make individuals aware of personal health 
care as well as provide “significant savings”. 11 But at what cost would the government expect 
to accumulate such savings? The cost could be very high, because patients might take 
inappropriate medicines. Such measures would serve to just contain costs without keeping the 
good health of the community in perspective. 
Thus we have seen a variety of approaches being used to control health care costs in general. 
However, none of these approaches can guarantee “better value for money’ because they 
almost always face resistance from potential losers of reform. To be successful, all cost-
containment measures must provide incentives to managers at all levels in the system to 
acquire the relevant knowledge and make the best decisions, taking into consideration all the 
difficult trade-offs between the various possible uses of resources. It is through improved 
decisions that health care can be made more efficient, that is, give better value in all relevant 
aspects for the resources consumed. To improve decisions, continuous monitoring and 
evaluation of the individual steps taken are also needed.7 
 
1.3.1 Focus on pharmaceuticals – in all cost-control methods 
A look at the various measures would reveal that “drugs” were important targets in all 
initiatives. In spite of differences in cost-sharing approaches in the different countries, 
virtually all countries impose some kind of cost sharing on pharmaceuticals.23 Indeed, an 
offshoot of this massive movement to control increases in health care costs was a major war 
waged against the pharmaceutical industry primarily targeting drugs.1, 7, 11, 19, 30  
Several factors contributed to the increase in health care costs. In fact, contribution of drug 
costs to the total health care expenditures is minimal. 1, 11, 12 An important argument could be 
that drugs have good potential to substitute for other more costly interventions and 
therapies.33, 34 Hence, their use should be increased. Then why is the pharmaceutical industry 
drawing increasing attention? 
There could be several reasons: 
• In most of the countries in Europe and Australia, pharmaceuticals, is always a 
covered benefit.23 Pharmaceuticals make up a small yet significant portion of the 
health care sector. As governments try to control costs, expenditure on drugs, 
therefore, has been a prime target although generally drugs represent only about 10% 
of health costs. 1,7,11,12 
• In hospitals, pharmacy departments usually operate on a budget that is 5-10% of total 
hospital costs. Regardless of the percentage of the overall hospital’s budget, a 
pharmacy department’s costs – primarily drug supply costs have been increasing at a 
rate ranging from 9% to 20% annually.35 For both acute care and ambulatory care 
settings, the cost of drug therapy is projected to skyrocket.35  
• Drug expenditures in the US increased by 12.6% annually between 1994 and 97. This 
represents a more rapid average rate of growth than any other category of health 
services, almost 4 times the rate of growth of hospitalization expenses (3.4% per 
year).  20,36 Consequently drug costs and how to use this resource appropriately have 
become important health care issues. 
• New drugs and biotechnology products entering the market often expand the range of 
diseases treated with the result that patients are less likely to accept that nothing can 
be done.8,11, 12 The pressure to treat increases even when the benefit is marginal. In so 
far as these new innovations are concerned, they unambiguously increase costs.17, 37 
Even if long-term costs may be expected to decrease; initial capital costs certainly go 
up.8, 12 Moreover superior technology is almost always designed for “greater access” 
and in that sense it decreases “price” (it enables more people to use the product or 
service by lowering “price”) but certainly pushes up “total costs.”7 
• Governments realise that targeting pharmaceutical prices is far easier and less 
politically sensitive than curtailing number of hospital beds or medical personnel and 
their services 1, 11, 12.  
• Drugs form a conspicuous and easily identifiable component of medical treatment. 
However, most drugs, especially in chronic illnesses, only promise to prolong life or 
enhance the quality of life rather than offer an eradication of disease.  
• Pharmaceutical companies are seen as aggressive marketeers promoting their 
products to the doctors who make complete and final decisions about all drugs on 
behalf of the consumers, the patients. However, the demand-supply situation does not 
allow the customer to be ‘king’ like in the other sectors of the economy because 
demand determination in the health care sector is far more complex than that found in 
usual market situations.38 In addition, the environment in which this occurs is further 
defined by the presence of numerous government agencies and regulatory 
requirements.1, 7, 12, 38 
• In other sectors of the economy “over-priced” items get swept out of the market 
automatically by market dynamics. However in the health care arena, this could be a 
more difficult proposition. The customer or the ultimate consumer is heavily 
dependent on the decisions of the medical care provider who must act as an agent for 
the patient and must recommend the most appropriate product and/or service. 
However, due to the intrinsic role of the doctor as both the provider and the 
recommender, with often a financial incentive attached to the decisions, the doctor’s 
recommendations (especially about buying expensive services or products) are also 
coming under scrutiny.  
• Moreover, the fact that the consumer is most often subsidized by the government or 
by some form of insurance, presents an inappropriate picture of the “true costs” 
incurred during treatment. Since the consumer pays much less ‘out-of-pocket’ when 
subsidized by the government or insurance than he would have paid otherwise, there 
is a false notion about ‘costs’ – which policy makers want to draw attention to. 
• Drugs constitute an important node or focal point in the network of management of 




1.4 Emergence of Pharmacoeconomics 
To sum up, the following conditions primarily gave rise to a climate conducive to the 
emergence of pharmacoeconomics. 
• The health care sector is distinctively characterised by its concern with human lives.  
The traditional justification for regulating the drug market is a belief that left 
unregulated, marketeers will mislead clinicians and patients will suffer physical and 
economic harm from inappropriate prescriptions. 39 
• Secondly, the distribution of illness is not in any way related to the ability to pay. 
Therefore, if producers were left to operate solely under market incentives then 
certain illnesses (afflicting people with limited ability to pay) may not have had a 
treatment at all.  
However, enabling every kind of treatment to be available and accessible is equally difficult 
because of the limitation of scarce budgets. Therefore, policies benefiting the greatest number 
of people are to be implemented. Thus, most governments felt that intervention in the health 
care sector was definitely necessary to ensure allocative efficiency, fair access and 
distributional equity.  However, this had to be attained with as much efficiency as possible. 
Hence technical efficiency, which would enable minimum usage of resources in the 
attainment of the aforementioned objectives, was imperative. It was this growing need for a 
balance of cost and quality and issues of allocative and technical efficiency’ that gave rise to 
the discipline of pharmacoeconomics.  
Therefore, pharmacoeconomics emerged primarily as a response discipline to the immense 
challenge of health care cost control and a changing perspective in the adoption and use of 
newer and more sophisticated health care interventions (technologies). 11, 14, 40, 41, 42 
The change in perspective was a natural sequel to, or one could say, the product of, the 
Outcomes Movement that was born in mid 1970s.43, 44 It was from then that the term 
‘outcomes’ came to be increasingly used to describe the results and value of healthcare 
intervention. Until then, practitioners had traditionally been mainly concerned with the 
“clinical outcomes” of treatments. But with increasing costs, concern about resource usage or 
economic outcomes of health care decisions also started surfacing. Patients on their part 
started becoming increasingly knowledgeable and involved in decisions regarding their own 
healthcare.1, 11, 40 They increasingly wanted to know how their quality of life would be 
affected or how satisfied other patients with their condition had been with various 
treatments.40  
Howsoever necessary cost-control was, the concern for ‘quality’ could not be overlooked. 
Determining what was, ‘acceptable’ quality was a contentious issue. A plethora of definitions 
exist of the quality of health care, although there appears to be little agreement of how the 
quality should be measured.1, 11, 12  
It so appears that some consensus was emerging in this direction at least where 
pharmaceutical interventions were concerned. Acceptable ‘outcomes’ (clinical, economic and 
humanistic) were gradually being regarded as indicative of optimum quality.1, 11, 12, 40, 42 
A complete assessment of the “true value” of pharmaceuticals began to mean an assessment 
of outcomes on all the three dimensions – clinical, economic and humanistic – something that 
pharmacoeconomics is widely professed and believed to do.  However, it was not until 1986 
that the term “pharmacoeconomics” was formally coined and used by Townsend in the 
literature.40 Since then, the term has been defined, re-defined and newly defined so many 
times that it seems quite an exercise to attempt defining it without consciously or 
unconsciously plagiarizing! 14, 40, 42 
However, any exposition must begin with the researcher’s understanding of the key 
terms and issues. This would enable a clearer explanation of the researcher’s 
standpoint in view of his/her perceptions about the topic and improve comprehension 
of the readers. Following is offered as a basic understanding of what 
“pharmacoeconomics” is all about (no new definitions attempted) in light of the 
research objective, approach and relevance of findings.  
Pharmacoeconomics gives us an idea about what outcomes are obtained from what products 
and services based on evidence, from which decisions may be made about which products and 
services to adopt. As such, it gives more rationale to the spending rather than making a 
decision in a void/vacuum or with insufficient information. The intent of pharmacoeconomics 
is to facilitate the production, distribution and consumption of pharmaceutical products and 
other health care interventions in the most “efficient” manner. The word “efficient” implies 
greatest benefit derived from a particular level of resource usage.  
 “Pharmacoeconomics, a division of health care economics, is a tool, not a solution, designed 
to provide users and decision-makers with information about the cost-effectiveness of 
different pharmacotherapies. It is used in combination with outcomes research, - a process by 
which different therapies or drug regimens are evaluated to measure the extent to which a 
goal of therapy or desirable outcome can be reached.”42  
It identifies, measures and compares the costs (resources consumed) and consequences 
(clinical, economic and humanistic) of different alternatives (drugs, equipment, diagnostic 
procedures, disease screening, prevention, treatment programs and policy), and thus performs 
a complete assessment of their potential ‘value’ in the efficient delivery of healthcare. 
Thereby, it can assist in choosing between competing treatment alternatives, allowing 
decision-makers to balance cost with quality and patient outcomes.42 
Hence, pharmacoeconomics as a discipline gained prominence with most governments in 
developed countries zeroing in on ‘cost-control’ as the keyword in the healthcare sector. 16, 45 
 
1.4.1 How Pharmacoeconomics fits in the healthcare cost-control jigsaw 
It is undisputed therefore that “drugs” must demonstrate tangible “value” in terms of all three 
(clinical, economic and humanistic) outcomes if they are to be accepted by the society at 
large. Pharmacoeconomics can help in a good assessment of this “value” and place them in 
proper perspective in the management of disease. Pharmacoeconomics does not profess to 
bring down health care expenditures, or drug costs per se. Rather, what it does is to supply 
decision-makers with more information that would enable them to reduce subjectivity and 
intuition from their decision process. By helping assign ‘value’ to different products and 
services pharmacoeconomics enables us decide if what we are paying for is ‘worth’ the 
money. Removing subjectivity could also lead to a more scientifically determined price, a 
price that the drug is “worth” rather than fix price on a predetermined profit margin or cost-
plus basis or simply on whims.  Resources are scarce. Therefore, it would be wiser to employ 
available resources for the best possible use thus maximising the value of every dollar spent. 




Pharmacoeconomics as a discipline comes with its share of skepticism.   
For instance, what perspective should a pharmacoeconomic study take is a contentious issue. 
Some opine that a societal perspective is the most ideal.38, 46, 47 But, to a health care system 
more concerned with its day-to-day survival in an increasingly cost-conscious environment, 
the provider’s or payer’s perspective would look most ideal. Again, valuing indirect costs and 
benefits as also human life, are controversial areas where consensus has not emerged to date.1, 
39, 48
 A general criticism levelled against economics is that it offers ample opportunities for 
choosing assumptions and techniques so as to reach a preselected result. Researchers know 
what sponsors want to hear and what will affect the probability of subsequent support.39 This 
and the absence of any universally accepted methodology and decision criteria or 
standardised guidelines for studies leave a lot of scope for introduction of bias in the results.39, 
46, 49
 There is a great deal of interest in cost-effectiveness studies on drugs but there are 
concerns that studies can be manipulated.39 Bias is often suspected by medical journal peer 
reviewers simply because a study is funded by the pharmaceutical industry, a suspicion 
fuelled by the lack of standards and guidelines for performing the studies.39,50 Economic 
analyses carried out by the pharmaceutical industry are sometimes seen as thinly veiled 
marketing strategies. 16, 46, 51, 52  Additionally, there is also the concern about whether 
pharmacoeconomic data derived from clinical trials is generalizable or applicable to real-
world situations. This has also sparked off a new line of controversy about the whether the so-
called “naturalized studies” are better compared to the traditional clinical trials.53   
In spite of these controversies, pharmacoeconomics can be potentially useful. Every new 
thing emerges out of turmoil and confusion. There cannot be a consensus for some time to 
come. However, some informed decision-making with respect to cost-effectiveness of 
therapies is better than no considerations of cost-effectiveness at all. A particular critical issue 
in the success of this subject lies with the decision-makers who must have the skills to 
interpret pharmacoeconomic data submitted to them. In the absence of standardised 
guidelines this task becomes very difficult. Guidelines apart from being methodological 
standards ensuring scientific rigour lend an element of uniformity in the interpretation of the 
analyses. Hence more and more countries are developing standards and guidelines that will 
ensure studies of scientific rigour and simultaneously generate reliable cost-effectiveness 
data, generalizable to the standard population. Over the past several years, academic 
researchers, regulatory bodies, a pharmaceutical trade organization and individual countries 
have published pharmacoeconomic research guidelines 49.  Academic researchers in Europe 
and the United States have developed guidelines for the proper conduct of pharmacoeconomic 
studies.46, 50 These guidelines authored by highly credible health economic researchers had the 
general aim to develop consensus among the researchers, regulatory authorities, industry, and 
other interested parties to give credibility and comparability to pharmacoeconomic study 
results.54 The Division of Drug Marketing, Advertising and Communication (DDMAC) of the 
United States Food and Drug Administration (FDA); the Prevention Effectiveness Technical 
Work Group of the Centers for disease Control and Prevention,  and an expert panel 
commissioned by the United States Public Health Service have all published guidelines on the 
proper conduct of pharmacoeconomic studies.54-57 The Pharmaceutical Research and 
Manufacturers Association of America (PhRMA) has also developed a set of voluntary 
principles to guide industry members in conducting pharmacoeconomic studies to minimize 
bias and ensure transparency. 58  
Individual countries, including Australia, Canada, Italy, Spain, Switzerland, Germany, France, 
and the United Kingdom have developed guidelines for the proper conduct of 




1.4.3 Role of Pharmacoeconomics in healthcare cost-control   
Having firmly understood that costs need to be cut, and cut without accepting sub optimal 
quality, it is important to bear in mind that pharmacoeconomics lends an element of 
rationality in decision-making by helping decision-makers make informed choices. Whatever 
the method of cost-control, be it supply-oriented or demand-oriented, pharmacoeconomics 
may be used to enhance the process and ensure its success. When used as a decision-aid for 
different methods of cost-control, it can make them more acceptable by ensuring a ‘balance of 
cost and quality’. 
The goal of a good healthcare system is to deliver acceptable and optimum quality of 
healthcare at reasonable costs. Only then, would cost-effectiveness in health care be ensured. 
It is the researcher’s contention that all cost control methods should adopt the ‘value for 
money’ approach and taking pharmacoeconomic considerations into account when making 
decisions would most certainly facilitate the process. The following examples are used to 
substantiate the argument. 
For instance, instead of setting the reference price arbitrarily, to arrive at a more scientifically 
determined price based on cost-effectiveness would be a much better option. 
Pharmcoeconomics can be used for this purpose by arriving at a consensus-based price, one 
that could be justified by the effectiveness of the drug. 
The potential uses of pharmacoeconomics especially with respect to the hospital setting may 
be understood by looking at a few questions that pharmacoeconomics may help to address, 
which are as follows – 
• What drugs should be included in the hospital formulary? 
The answer to this question lies in an assessment of the value of pharmaceutical products and 
services. Such valuation when based on pharmacoeconomics allows a balance of cost with 
quality (incorporating patient outcomes). 
• What is the best drug for a particular group of patients?  
Some drugs may sometimes have only nominal benefits over existing alternatives for a 
relatively large increase in the marginal costs. If used in all patients, such products and 
services only serve to push up costs and unnecessarily tax the ill. Pharmacoeconomic analyses 
can supply decision-makers with the data regarding these products and services would 
represent ‘value for money’ in certain subgroups of patients.  
• What is the best drug for a particular disease (i.e. assessing clinical pathways)? 
There is usually more than one management approach to most disease conditions. Choosing 
between competing treatment options requires careful consideration of the various benefits 
offered by different approaches vis-à-vis the resources consumed. Pharmacoeconomics 
certainly facilitates such decisions by identifying and elaborating the different outcomes 
(including patient quality of life outcomes) offered by the various treatment modalities and 
the costs (resource use) incurred by each.  
Thus medication use decisions that can benefit from pharmacoeconomics especially in an 
institutional setting include formulary management, drug use policy, resource allocation and 
individual patient treatment decision.  
In conclusion, drugs apart from being safe and effective must demonstrate good 
‘pharmacoeconomic value’ if they are to be competitive in today’s healthcare environment.  
As our health care environment becomes increasingly cost-conscious, pharmacoeconomics 




SECTION 2: THE SINGAPORE PERSPECTIVE 
Singapore – a question closer to home  
Having discussed the awakening of most developed countries to the implications of 
increasing health care expenditures and the important steps being taken in the direction of 
ascertaining ‘value’ in health care delivery, it would now be most appropriate to examine 
whether Singapore faces any potential problems from increasing health care costs and 
whether policy-makers are taking any steps in that direction. 
Background 
Singapore is a small country with a total land area of 659.9 sq km. The total population is 
about 4.0 million, with a resident population of 3.22 million in 1999. Singapore has a 
relatively young population, with only 11% of the population above 60 years of age. 
However, the percentage of population over 60 years is projected to increase to 27% by the 
year 2030. 65 The age composition of the resident population, selected health-related vital 
statistics and health indicators are shown in Tables 2-4.   
Table 2: 3-Year Trend in Age and Race composition of resident population in Singapore∗ 
 1999 2000 2001  
Total Population ('000) 3,950.9 4,017.7 4,131.2 
 Resident Population ('000) 3,221.9 3,263.2 3,319.1 
Age % below 15 years 21.8 21.5 21.4 
% 15 - 64 years 71.1 71.2 71.2 
  
% 65 years & above 7.1 7.3 7.4 
Race % Chinese 76.8 76.8 76.7 
  % Malay 13.9 13.9 13.9 
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% Indian 7.9 7.9 7.9  
% Others 1.4 1.4 1.5 
 
 
Table 3: 3-Year trends in National Health-related Vital Statistics in Singapore∗ 
 
 1999 2000 2001 
Crude Birth Rate 12.8 13.7 11.9 
Crude Death Rate 4.5 4.5 4.4 
Infant Mortality Rate 3.3 2.5 2.2 
Maternal Mortality Ratio 0.9 1.7 0.7 
Life Expectancy at Birth (years)  77.6 78.1 78.4 
Male 75.6 76.1 76.4 
Female 79.7 80.1 80.4 
 
Table 4: 2001 Health Indicators - Singapore∗ 
  Year 2001  
Hospital Admission Rate per 1000 Population 93  
Hospital Beds to Population Ratio 1:348  
Doctor to Population Ratio 1:698  
 
 
Health Status  
The infant mortality rate in 1999 stood at 3.2 per 1000 live births while the average life 
expectancy rate was 77.6 years. Rising standards of living, high standards of education, good 
housing, safe water supply and sanitation, a high level of medical services and the active 
promotion of preventive medicine, have all helped to significantly boost the health of 
                                                
∗
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Singaporeans. The leading causes of morbidity and mortality are currently the major non-
communicable diseases such as cancer, coronary heart diseases, strokes, diabetes, 
hypertension and injuries. Cancer and cardiovascular diseases together accounted for 
approximately 62% of the total causes of death.65 
 
Healthcare Delivery System 
There is no denying the fact that Singapore’s health care system is the envy of many countries 
around the world. Singapore has managed to achieve the health care standards of a developed 
country at a fraction of the costs, and its health indicators are on par with that of other 
developed countries around the world. 66 In fact, in the World Health Organization’s first ever 
analysis of the health systems in different countries in the world, Singapore was ranked 
sixth.67  
In Singapore, there is a dual system of healthcare delivery. The public system is managed by 
the Government while the private system is provided by the private hospitals and general 
practitioners. The healthcare delivery system comprises primary health care provision at 
private medical practitioners' clinics and outpatient polyclinics, and secondary and tertiary 
specialist care in the private and public hospitals.   Following is a glimpse of health facilities 







Table 5: 3-year trend in Availability of Public and Private Healthcare Facilities in Singapore∗ 
  1999 2000 2001
No. of Hospitals/Specialty Centers 28 28 28 
 Public Sector 14 14 14 
 Private Sector 14 14 14 
Total No. of Hospital Beds 11,747 11,798 11,884 
 Acute Care 7,853 7,849 8,153 
 Extended Care 3,894 3,949 3,731 
Public Sector Hospital Beds 9,560 9,556 9,274 
 Acute Care 6,268 6,264 6,228 
 Extended Care 3,292 3,292 3,046 
Private Sector Hospital Beds 2,187 2,242 2,610 
 Acute Care 1,585 1,585 1,925 
 Extended Care 602 657 685 
No. of Polyclinics 18 16 16 
No. of Public Sector Dental Clinics 205 202 204 
 
The private practitioners provide 80% of the primary healthcare services while the 
government polyclinics provide the remaining 20%. For the more costly hospital care, it is the 
reverse situation with 80% of the hospital care being provided by the public sector and the 
remaining 20% by the private sector.  Following are healthcare facilities utilization trends as 
measured by hospital admission rates by sex and age per 1,000 population:  
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Table 6: 3-year Healthcare Facilities Utilization Trends in Singapore∗  
 1999 2000 2001 
Public Sector Hospitals 
Male 76.0 79.3 77.7 
0 – 14 years 63.8 69.2 62.7 
15 - 64 years 59.2 60.8 60.5 
Age 
65 years & above 306.2 312.4 309.0 
Female 76.3 77.1 74.7 
0 – 14 years 51.9 56.9 50.8 
15 - 64 years 62.9 60.7 58.5 
Age  
65 years & above 266.3 276.1 277.1 
Private Sector Hospitals 
Male 10.9 10.2 9.4 
0 - 14 years 21.4 20.3 18.1 
15 - 64 years 5.9 5.5 5.2 
Age  
65 years & above 30.0 26.5 25.6 
Female 23.3 22.6 20.4 
0 - 14 years 17.3 15.8 14.3 
15 - 64 years 23.8 23.3 21.1 
Age  
65 years & above 34.2 33.4 30.3 
 
Patients are free to choose the providers within the dual healthcare delivery system and can 
walk in for a consultation at any private clinic or any government polyclinic. For emergency 
services, patients have access at any time to the 24-hour Accident & Emergency Departments 
located in the government hospitals. The Singapore Civil Defence Force runs an Emergency 
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Ambulance Service to transport accident and trauma cases and medical emergencies to the 
acute general hospitals.   
Singapore today has about 5,154 doctors for its healthcare delivery system, giving a doctor to 
population ratio of 1:730. Slightly less than half of the doctors (48%) are in the private sector. 
About 42% of the doctors are trained specialists with postgraduate medical degrees and 
advanced specialty training.     
There are 942 dentists, giving a ratio of 1 dentist to 4,130 people. About 77% of the dentists 
are in private practice. 
The nurse to population ratio is 1:244, with a total of about 15,947 nurses. 55% of the nurses 
work in the public sector.   












Table 7: 3-Year trends for availability of Healthcare Workforce in Singapore∗ 
  1999 2000 2001
Total No. of Doctors 5,325 5,577 5,922 
 Public Sector 2,535 2,586 2,794 
 Private Sector 2,606 2,809 2,925 
 Not in Active Practice 184 182 203 
Doctor to Population Ratio 1:740 1:720 1:700 
Doctor per 1000 Population  1.3 1.4 1.4 
Total No. of Dentists 942 1,028 1,087 
 Public Sector 167 193 209 
 Private Sector 726 755 775 
 Not in Active Practice 49 80 103 
Dentist to Population Ratio 1: 4,190 1: 3,910 1: 3,800 
Dentist per 1000 Population 0.2 0.3 0.3 
Total No. of Nurses/Midwives 15,947 16,611 17,398 
 Public Sector 8,692 8,927 9,297 
 Private Sector 3,872 4,166 4,224 
 Not in Active Practice 3,383 3,518 3,877 
Nurse to Population Ratio 1:250 1:240 1:240 
Nurse per 1000 Population 4.0 4.1 4.2 
Total No. of Pharmacists 1,043 1,098 1,141 
 Public Sector 219 238 297 
 Private Sector 598 638 619 
 Not in Active Practice 226 222 225 
Pharmacist to Population Ratio 1: 3,790 1: 3,660 1: 3,620 
Pharmacist per 1000 Population 0.3 0.3 0.3 
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Healthcare Philosophy 
The Government ensures that good and affordable basic medical services are made available 
to all Singaporeans through the provision of heavily subsidized medical services at the public 
hospitals and government clinics. The Singapore health care delivery system is based on 
individual responsibility, coupled with Government subsidies to keep basic health care 
affordable. Patients are expected to pay part of the cost of medical services and pay more 
when they demand a higher level of services. The principle of co-payment applies even to the 
most heavily subsidized wards to avoid the pitfalls of providing free medical services (moral 
hazard).65  
To help Singaporeans pay for their medical expenses, the Government has put in place a 
financing framework, consisting of Medisave, Medishield, ElderShield and Medifund. 65  
Medisave, introduced in April 1984, is a national medical savings scheme, which helps 
individuals put aside part of their income into their Medisave Accounts to meet their future 
personal or immediate family’s hospitalization, day surgery and certain outpatient expenses.  
Under the Medisave scheme, every working person is required by law to set aside 6-8% of his 
income into his personal Medisave Account. 
MediShield, introduced in 1990, is a low cost catastrophic illness insurance scheme. It is 
designed to help members meet the medical expenses from major or prolonged illnesses for 
which their Medisave balance would not be sufficient to cover. MediShield operates on a co-
payment and deductibles system to avoid the problems associated with pre-paid insurance. 
The premiums for MediShield can be paid with the funds in the individual’s Medisave 
account.   
ElderShield, introduced in 2001, is an affordable severe disability insurance scheme designed 
to help Singaporeans meet with expenses incurred in the event of severe disability. The 
premiums of ElderShield can also be paid with the funds from the individual’s Medisave 
accounts.   
Medifund is an endowment fund set up by the Government in April 1993 to help needy 
Singaporeans who are unable to pay for their medical expenses. This is a safety net for those 
who cannot afford the heavily subsidized charges despite Medisave and Medishield. 
Medifund was established with an initial capital of S$200 million. Capital injections will be 
made when budget surpluses are available. The capital sum currently stands at S$800 million. 
Only the interest income from the capital sum maybe used. 
Therefore, no Singaporean is denied access into the healthcare system or turned away by the 
public hospitals because of the inability to pay.  
National Healthcare Expenditure 
In 1999, Singapore spent about S$4.3 billion or 3% of GDP on health care. Per capita health 
care spending was S$1,347. Government subsidy on the public health care services was 
S$1,089 million.65  
In 2000, Singapore spent about S$ 4.8 billion or 3% of GDP on healthcare. Out of which, 
Government expenditure on health services was S$1,212 million or 0.8% of GDP. 
Table 8: 3-year National Healthcare Expenditure trends in Singapore∗ 
  FY99 FY00 FY01 
Recurrent Health Expenditure (S$m) 936 1,072 1,446 
Development Health Expenditure (S$m) 153 140 146 
% Recurrent Health Expenditure/GDP 0.7 0.7 0.9 
% Of Total Government Health 4.3 4.3 5.7 
Total Government Health Expenditure per 338 371 480 
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Major Concerns and Future Challenges 
Based on the previously mentioned observations there are enough reasons to believe that the 
Singapore health care system is well managed and pretty much state-of-the-art. On the other 
hand, the future brings with it new challenges and concerns for the Singapore government. 
Among the challenges facing the government are advances in medical technology and 
knowledge, rising expectations and demand of the public, changes in disease patterns, 
shortage of manpower, the aging population and the rapidly escalating health care costs.   
The two particularly crucial concerns,  
• The demographic concern of an increasing proportion of the elderly (thereby 
increasing the aged dependency ratio): the proportion of those 60 years and above is 
estimated to increase from the present 10% to 27% by the year 2030 and,  
 The challenge of living up to increasing expectations of the public: even under the 
circumstances of an increased proportion of the elderly in the future, the government must 
accept responsibility for providing high-quality care at affordable prices and live up to the 
expectations of the increasingly affluent and more-informed society. 
Following are glimpses of a 6-month period average bill sizes in public hospitals based on 
Medisave claims submitted by the hospitals. The table shows data only for the class C 
inpatient charges (least of the lot). Notable point here is that the minimum average bill 
only for inpatient care is only marginally less than the per capita expenditure. Therefore, 
the scenario including higher expenditure classes and diseases (despite a higher co-




Table 9: Minimum 6-Month Average Medical Bills at Public hospitals in Singapore♣ 
Room Class C (Open Ward) 
 MEDICAL SPECIALTIES 
Hospitals∗ Average Per Day ($) 
Average Total 
Bill ($) 
Total Bill at 90th 
Percentile 
Total Bill at 95th 
Percentile 
AH 91 668 1,303 1,917 
CGH 108 731 1,353 1,997 
KKH++ 121 635 810 1,869 
KKH++++ 108 378 546 876 
NUH 160 979 2,326 3,829 
SGH 118 910 1,783 2,775 
TTSH 88 684 1,252 1,978 
NHC 375 1,807 4,459 5,465 
NNI 105 793 1,458 2,062 
 SURGICAL SPECIALTIES 
Hospitals* Average Per Day ($) 
Average Total 
Bill ($) 
Total Bill at 90th  
Percentile 
Total Bill at 95th  
Percentile 
AH 101 583 1,263 1,955 
CGH 150 786 1,575 2,361 
KKH 185 611 1,258 1,539 
NUH 191 1,111 2,220 3,919 
SGH 136 982 2,038 3,051 
TTS 123 778 1,653 2,548 
NHC 191 2,696 4,921 8,053 
NNI 124 999 2,446 3,828 
 
                                                
♣
 Data for Jan 2002 – June 2002, Hospital Statistics 2002, Ministry of Health, Government of 
Singapore 
∗
 AH: Alexandra Hospital, SGH: Singapore General Hospital, NUH: National University Hospital, 
KKH: KK Women's and Children's Hospital, CGH: Changi General Hospital, TTSH: Tan Tock Seng 
Hospital, NHC: National Heart Centre, NNI: National Neuroscience Institute 
This would mean that though there are no imminent problems from increased health care 
expenditures, there is also no room for complacency. Systems and processes should be 
reviewed continually to ensure maximum value from every dollar spent to avoid making the 
same mistakes made by other developed economies. This calls for a greater awareness of 
cost-effectiveness issues and only then would the best-informed decisions be made for its 
population. 
 
Government’s responses to the aforementioned Challenges  
The Government of Singapore is very proactive in its approach to these challenges.  In order 
to maintain the medium to long-term sustainability and viability of the healthcare system, 
plans are proposed to revamp geriatric care.  In addition, immediate actions were 
implemented to improve the efficiency of the existing healthcare delivery within the public 
sector. 
 
Care for the Elderly: 
To address the concerns on increasing health needs by the rapidly ageing population, the 
Inter-Ministerial Committee on Health Care for the Elderly (IMC) was set up in 1997 to put 
in place policies and strategies for the adequate provision of health care for the elderly, and to 
ensure that their long-term care is affordable to the individual, family, community and 
country.   
The IMC has recommended a two-pronged approach to looking after the health care needs of 
the elderly. Firstly, they have recommended health promotion and disease prevention to 
enable the elderly to remain healthy and active in the community. Secondly, when disease and 
disability set in, the system must be able to provide appropriate and cost-effective health care 
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according to each elderly person’s need, so as to achieve maximum functional capability. As 
the elderly generally want to live with their families, they are to be cared for in their own 
homes for as long as possible. Institutionalization of the elderly would be a measure of last 
resort.   
The key recommendations cover health promotion and disease prevention, screening and 
early detection of illness and disability, better training in geriatric care for medical 
undergraduates and general practitioners, development of long-term care facilities and 
services in partnership with Voluntary Welfare Organizations (VWOs), ensuring standards of 
health care services, and measures to finance long-term care. 
 
Using Diagnosis Related Groups (DRGs) for Hospital Funding  
Funding of hospitals may be based on several approaches. The simplest approach known as 
historical funding simply provides each hospital with the same funding it received the 
previous year, with allowances for inflation or a well-argued request for additional funds. 1, 11, 
12
 Hospitals may also be funded according to the population size and mix of their catchment 
area. A formula may be used to determine how much each hospital should receive according 
to the population taking into account other factors such as age, gender and socio-economic 
status.  
However none of these approaches directly funds or pays hospitals for the work they actually 
do, and therefore, does not encourage hospitals to do the work more efficiently and 
effectively. 
A funding system, which uses case-mix, can overcome this deficiency.40, 68, 69 In a case-mix 
funding arrangement, a funding authority may set a price to pay for each case of a particular 
diagnosis based on its cost. For example, the average cost of a certain surgical procedure may 
be $10,000. A funding authority may decide to pay hospitals $10,000 for each of these 
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procedures regardless of the actual cost for performing these procedures at individual 
hospitals. Therefore, hospitals that can perform these procedures with less than the pre-
specified amount may use the surplus to subsidize more expensive forms of health care. 
Hospitals that need more money to perform the same operation will need to absorb the 
difference. They will find it necessary to examine their cost structures, their resource use, and/ 
or their work practices in order to work within the assigned budget if they are to provide 
better and more efficient treatment to their patients.  
As such, case-mix-funding arrangement would be a more rational way of allocating of scarce 
resources with financial rewards for efficiency in service delivery. 
Case-mix funding signifies a shift from the traditional historical funding formula to an 
activity- based funding-formula for health care. “Case-mix” simply refers to the range and 
type of patients a hospital or health service treats. However, in health care policy and 
planning it has become a generic term for an information tool, which can be used to 
scientifically plan and manage health care. In general, it is the use of resources in treating 
patients, which is the key to understanding case-mix as a measure of hospital output and 
activities.  
Diagnosis Related Groups (DRGs) is the best known and most widely used case-mix 
classification used to classify in-patients receiving acute hospital care according to their 
principal diagnosis. They consist of a manageable number of distinct classes, which have 
been identified based on their clinical meaning and resource-use homogeneity. The DRG 
system was developed in the US to provide data for prospective payments for hospitals. 70  
The goal of the government in using such DRG system is to allocate public financial 
resources among hospitals in a way that better reflects their genuine level of activity.  
However, in the opinion of the researcher, in order for the case-mix funding to be a success, 
pharmacoeconomics needs to be incorporated routinely into decisions about health care 
interventions if Singapore is to at least sustain the same standards of medical care even in the 
future. The role of PE in case-mix funding environment is discussed in the next section. 
 
Relevance of Pharmacoeconomics in the new case-mix funding environment 
Some might argue that since every item has been assigned a cost according to resource 
consumption patterns, there is very little in the way that the application of pharmacoeconomic 
evaluation can change or improve this. However, the DRG system in itself has some 
problems. The DRG system necessitates the government to set prices based on average costs. 
This vestige of the regulated price model based on average costs is less efficient than pricing 
decisions made by individual providers on the basis of marginal costs. Hence, government 
will find adjustments for quality improvement and technological change difficult to arrive at. 
There may also be a tendency to bypass needed increases in DRG prices in order to hold 
down government fiscal outlays for health.  
DRGs also set a prospective rate once a patient is in for treatment but do not offer incentives 
for physicians to be more cost-conscious about hospitalising patients in the first place. 71  
Though such payments are expected to provide incentives for efficiency by attempting to 
equate reimbursement to “output”, they are more difficult to establish technically and can 
result in administrative problems when several physicians are involved in treating a particular 
case.1  
 In addition, a deeper thought would reveal that any shift in clinical practice in drug therapy, 
especially with newer drugs introduced in recent years increase the pressure on the 
pharmaceutical budget. For instance, an increase of 20% in drug cost over baseline (at which 
the drug cost is, say about 10% of the total cost) would increase the total cost by around 2%. 
As each DRG episode is paid a fixed amount by the funding authority, the hospital either has 
to absorb the extra cost, or other components of the DRG episode, for example, pathology or 
nursing care have to receive less cost as a compensation for overrun in drug cost. However, if 
the other components cannot be controlled, increase in drug costs will result in a 
proportionate increase in absolute dollars allocated for that DRG. Such an impact on all 
DRGs and in all episodes treated in a hospital would result in increase in dollar expenditure 
that could be potentially devastating for any health care budget.  
Obviously, none of the above is a sustainable alternative. Therefore, any less than optimal use 
of drug therapy in treating patients is going to have an impact on the treatment cost. 
When properly conducted, pharmacoeconomic analyses:  
• Can assist hospitals in choosing more cost-effective drug therapies without sacrificing 
the quality of care  
• Can help physicians, pharmacists and hospital administrators in establishing 
meaningful guidelines for appropriate use of individual drugs  
• Can help in creating an environment for interdepartmental “global” budgeting.  
Therefore, besides providing a means to assist in the choice of optimal drug therapy, 
pharmacoeconomics can serve the purposes of quality assurance and budget allocation. In 
essence, the practice of both pharmacoeconomics and case-mix involves the principle of 
optimising efficiency within the health care system. Based on these considerations, rather 
than becoming obsolete, pharmacoeconomics is going to be more relevant in the case-mix 
funding environment when there is increased need to be more accountable and more effective 




SECTION 3.  REASONS FOR CHOOSING ‘THE FORMULARY’ AS RESEARCH 
FOCUS 
There has been little research regarding the ways in which decision-makers use 
pharmacoeconomic studies in their practice.72 
The same feeling has been echoed in some published papers on the use of 
pharmacoeconomics. For example, following discussions with representatives of several 
pharmaceutical manufacturers and other health care entities, Frank Sloan and Henry 
Grabowski organised a two-day conference held at the Duke University on December 3-4, 
1995 on “Use of Cost-effectiveness Analysis in Decision-Making”. Studies presented as 
papers during the conference revealed that while cost-effectiveness analysis played a minor 
role in pharmaceutical decision-making in hospitals, whatever little was being used (and/or 
was being considered for use) either in the US, in Australia, UK or France, was mainly for 
making drug formulary decisions. 
Having felt that pharmacoeconomics could be potentially useful in health care decision-
making in Singapore, the researcher wanted to demonstrate and “showcase” the utility of this 
subject in one decision-area. The “formulary” was chosen for this purpose because the best 
example of the potential utility of pharmacoeconomics in Singapore - in the opinion of the 
researcher - is provided by the formulary. The “formulary” whether at the national 
(Australia), institutional (HMO) or state (Ontario) level is where, the subject has been most 
successfully used to date. Especially, Australia, the first country to have made a routine use of 
cost-effectiveness analysis a requirement in its “national formulary” (the Pharmaceutical 
Benefits Scheme) coverage decisions for pharmaceuticals, provides the best example. 59, 23, 
73,74,75,76
 
Use of pharmacoeconomics in hospital settings is usually restricted to creating and modifying 
formularies. Among some of the reasons cited for less use of pharmacoeconomic studies 
especially in hospital settings is inadequate in-house capacity to evaluate the quality of such 
studies.23 
 However, if use is to be increased, expertise is to be built. This would require potential users 
of information to be convinced of the utility and scope offered by of such information in 
facilitating decision-making. Of course, if that is to be, the end-users must not be confused by 
technical jargon. But, most pharmacoeconomic studies published in the literature do not take 
it to the end-user level.74 Therefore, if the issue of its use in actual practice needs to be 
addressed well, studies must be conducted and results elaborated in a form understood by the 
end-users. “… since, the ultimate utility of socio-economic assessments will depend as much 
on their being understood by decision-makers as upon their methodological rigour.”74  
Therefore, it was decided that using practical demonstrations in a formulary in a hospital 
setting would actually take it to the users. It would convince the end-users (the P&T 
Committee in this case) that pharmacoeconomics has very good potential to sharpen drug-
related decision-making in a hospital setting making it a cost-effective centre for health care 
delivery in the long-run.  
In the view of the researcher, the formulary, reflecting major drug-related pharmacy 
decisions, could be an important instrument for attaining the dual goals of efficient and 
quality health care delivery and customer (doctor and patient) satisfaction provided it 
incorporates the cost-effectiveness (pharmacoeconomic) principles. If, the relevant decision-
makers realise this, they will start a process of learning about the subject, knowing more and 
trying various ways and means to use such information. This will set into motion a new 
framework for formulary decision-making and will definitely encourage growth of 
pharmacoeconomics. Therefore, it is imperative that the decision-makers be convinced of the 
potential utility of the subject at least in the context of the formulary. 
 
SECTION 4: THE ROLE OF PHARMACOECONOMICS IN SHARPENING THE 
FORMULARY- AN INSTRUMENT FOR HEALTH CARE COST CONTROL IN THE 
HOSPITAL CONTEXT  
4.1.1 Importance of Formulary Management 
Good and effective formulary management has an immense potential to add a whole new 
dimension to healthcare delivery in the current fiscal climate – that of ensuring standard and 
appropriate care while reducing costs – ‘quality healthcare at affordable costs’. 
 
4.2 The Formulary: its traditional role and drawbacks 
Formularies have been an important governing instrument in hospitals for many years.35 
Formularies represent a compendium of pharmaceutical products and services selected by the 
medical staff of an institution to reflect current drug preferences of health care practitioners 
and patients.77 Regarded most often as cost-containment tools, they lower costs by limiting 
choice, which, is not viewed favorably by practicing physicians. With its emphasis on “cost” 
“the formulary” has rendered itself unacceptable to the practitioners who do not feel the need 
to comply unless compelled to do so. The formulary decision-making bodies on their part, 
being more concerned with the survival of their institution in this increasingly competitive 
and cost-conscious environment feel that they are justified in their ‘cost-approach’ to 
selection of drugs.  
The net result thus has been that there has traditionally been a ‘this was expected’ attitude of 
the health care practitioners towards the ‘formulary committees’ and vice-versa. The doctors 
have a feeling that they are deprived of their right to prescribe at will, to do what is ‘best’ or 
‘clinically most effective’ for their patients and the formulary committees feel that it is 
virtually impossible to satisfy the doctors. In reality, however, both are concerned in their 
own way about the patient’s benefit, albeit, on different levels. The doctor is more bothered 
about the patient on a one-to-one or individual level and the committee about the majority of 
the patients on a more macro level. That is precisely the reason why drugs used by the wide 
majority are most often subsidised by the formulary. In order to enable more patients, to 
benefit from the subsidy, quite often the so-called ‘cheapest’ generics when available are 
chosen. 35 77, 78 Cheaper brands are also often resorted to. However, whether these truly turn 
out to be ‘cheap’ is a different question altogether because sometimes these so-called cheaper 
brands may have potential costs associated with their use. Such costs could include drug, 
laboratory and medical personnel costs of retreating treatment failures and treating any 
adverse drug reactions identified with this agent. 
Thus, the major drawback with the traditional formulary decision process has been an undue 
emphasis on ‘cost’ resulting in a simple shifting of costs from one cost centre to another and a 
complete unwarranted overlook of the comprehensive effects of introducing a drug or 
intervention into the health care system. 78,79, 80, 81  
However, the “true value” of any medical intervention should be assessed in terms of its 
impact on total health care utilisation and cost. Pharmaceuticals are no exception; to view 
them in isolation might be penny wise and pound-foolish.81 Medical care providers are 
becoming increasingly aware of this fact and have started to examine the cost consequences 
of their actions.82 
The physicians on their part must broaden their perspective to balance the needs of individual 
patients directly under their care with the overall needs of the population served by the health 
care system whether the system is an HMO or the nation’s health care system. Professional 
ethics will have to incorporate social accountability for resource use and population health, as 
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also be reasonably expected to serve the logistic function of inventory control other than 
helping manage the institutional drug expenditures effectively. Most importantly, it would 
allow only the most cost-effective options to diffuse into the respective health care system. 
Such formulary among other things can better convince the prescribers whose compliance is 
essential to its success. A successful formulary in the long run can hope to contribute to 
lowering the overall system costs.  
 
4.2.2 Pharmacoeconomics: A tool to help in assessing ‘value’ in formulary decision 
Appropriate application of pharmacoeconomic evaluation facilitates systematic quantification 
of the ‘value’ of pharmaceutical products and services. From the available literature it seems 
that the role of pharmacoeconomics in formulary decision-making is being increasingly 
recognized and so pharmacoeconomic assessments of formulary actions are becoming 
increasingly common and standardized part of formulary decision-making at local, national 
and international levels.77, 83, 84, 85, 86,87 
Apart from knowing extra costs incurred for certain extra benefits obtained from new drug 
treatments, decision-makers increasingly want to know by how much their annual budget is 
likely to increase or decrease if a specific drug is added to or deleted from the formulary and 
what annual health benefits are likely to be associated with this budget increase or decrease. 88 
This can be achieved only through a systematic and conscious effort to integrate 
pharmacoeconomic concepts into decisions. 
Some researchers propose that formularies may actually lose importance over time as 
pharmacoeconomic results increasingly guide practice and management. 77, 85 However in the 
researcher’s opinion, the “formulary” is “a scientific and comprehensive listing” of drugs 
while pharmacoeconomics is a “science”. Pharmacoeconomics cannot actually “substitute” 
for the formulary. Rather by acting as a research tool, pharmacoeconomics will increasingly 
inform formulary decision-making.89, 90, 91, 92, 92 
 
4.3 Evolving role of the formulary especially at the Institutional Level in the changing 
context of health care delivery 
A discussion about the evolving role of formulary remains incomplete without a discussion of 
the new concept of disease management and the role of the ‘Formulary’ in the light of the 
changing circumstances. 
In today’s world, health care delivery in a piecemeal fashion is simply not affordable. It has 
been seen that most health care dollars are spent on small numbers of persons requiring 
multiple episodes of care often in the last stages of chronic diseases.94 Prompted by the 
mounting financial pressures, a paradigm shift in providing health care – from ‘treating’ or 
‘curing’ individual patients to ‘managing’ whole disease conditions, has taken place. This 
new evolving model of disease management is a systematic population-based approach to 
certain disease conditions that can deliver equal or even better outcomes at lower costs than 
the conventional approaches. It offers population-based, disease-focussed solutions that will 
redefine the organisational approach to diseases.81 Along the way, the existing roles of key 
players such as hospitals, physicians and pharmaceutical companies will change. Specially, 
the hospital, being a cost centre and a place for extreme intervention, is drawing increasing 
attention.   
 Disease management aims at cost-effective strategies whereby more resources are allocated 
to disease conditions that are more serious and widespread (i.e. where they are more needed) 
and less to less important areas.81 
A well-built formulary (based on pharmacoeconomics) can assist decision-makers by 
identifying the most efficient use of pharmaceuticals (or even allied services) in a disease 
state management program and therefore act as a concise guide to prevalent treatment patterns 
thereby ensuring that drug management is being placed in the framework of total health care 
management. Health care organizations that incorporate the tenets of economic analysis into 
their decision making are likely to build more efficient disease management programs leading 
to improved patient outcomes and lower costs.81 
With health care organizations increasingly moving towards the more holistic disease 
management programs the expectations from a formulary are changing. It is expected that a 
formulary would typically include only those drugs or interventions, which can demonstrate a 
‘net increase’ in ‘value’ to the disease management programs. In order to live up to these 
changing expectations, the formulary decision process has to have a changed approach.  
 
4.4 The Formulary: what should be its changed approach  
First and foremost, the formulary should have certain clear-cut objectives that it intends to 
achieve in the current context of integrated healthcare delivery. Its most important objective 
should be to help the hospital in reducing the burden of illness as efficiently as possible. For 
this, the hospital must first identify the major areas of illness treated at the institution. Then it 
must calculate the costs incurred for treating those illnesses per budget period. The next step 
would be to set optimum and achievable targets in terms of outcomes of therapy that would 
enable reduction in the burden of illness. The formulary must now aim to include such drugs 
and interventions, which are more efficient in helping attain those targets. 
Pharmacoeconomics can help in deciding which drugs to stock by telling the efficiency of the 
drug in achieving an outcomes target under a given level of resource usage. 
Pharmacoeconomics generates and/ or synthesizes and interprets available evidence to give 
useful information on efficiency of various interventions in helping achieve particular 
outcome targets of therapy.  Therefore, a good formulary including decisions based on 
pharmacoeconomic principles can contribute to the wider societal goal of reducing the burden 
of illness by ensuring judicious management of healthcare, and thereby societal resources. 
But, one of the first things formulary-framing bodies should do is to convince prescribers that 
it is evidence-based so that it becomes more acceptable. This is because it is the doctor who 
takes the day-to-day decisions about drugs and prescriber compliance to the recommendations 
made by the formulary is an essential pre-requisite to its success.   
Cost-control is an important objective of the formulary. But sheer cost-control aimed simply 
at containing costs without evidence of cost-effectiveness of drugs or other health care 
interventions may not just fail to improve efficiency in prescribing or health care delivery, 
they may deprive the patient population of the benefits of good drugs that may be worth the 
additional cost.  
A rationally built formulary can go a long way in actually assuring prescribers that it is 
offering the ‘best’ of interventions for their patients and thus ensure compliance while also 




SECTION 5.  EXPLORATORY STUDIES CONDUCTED TO IDENTIFY ‘NEED’ 
FOR PHARMACOECONOMICS IN FORMULARY DECISIONS 
The premise of our current argument runs as follows:  
If the expectation is “A formulary must help control drug costs but not just promote ‘cheap’ 
drugs (i.e. compromise on quality of care)”, there clearly exists a ‘need’ for 
Pharmacoeconomics in formulary decision-making.  
To understand if such an “expectation” and “need” exist in Singapore, and how confident 
pharmacists would be if asked to use pharmacoeconomics to aid in formulary decision-
making, an exploratory study was conducted.  The purpose was to identify the need (if any) 
and once done, to demonstrate the role that pharmacoeconomics could play in formulary 
decision-making, in one major public hospital, the National University Hospital in Singapore. 
The reason why pharmacists were chosen was that, pharmacists are the ones who are 
supposed to have the most information about drugs and they are the ones who dispense these 
drugs to the patients.  
 
5.1 METHODOLOGY  
Data were gathered through a survey questionnaire administered in 1998-99. The sample 
consisted of all practising pharmacists (except the DIS pharmacist and the pharmacy 
manager) in five major public hospitals in Singapore. These hospitals were identified as study 
centres. In view of the structure, financing and administration of the health care system in 
Singapore, public hospitals were chosen over private hospitals, as the latter do not operate 
under as stringent budget controls as the former. 
Consent to participate in the survey was obtained from the respective pharmacy managers at 
the above hospitals either over telephone or in person. 
Hard copies of the survey questionnaire∗ were circulated to all practising pharmacists in these 
hospitals. 
Questions addressed respondent background information, which included demographic 
information like age, race, gender and professional history like experience, current and 
previous area of experience and experience in the P&T committee. Questions in the main 
body were framed to draw out broadly the following information: 
 Whether practicing pharmacists (in the institutional settings) in Singapore have any idea 
regarding the expenditure incurred for drugs in their respective hospitals 
 Are aware of the concern globally regarding increasing drug expenditures 
 Know about and have any suggestions regarding how to control these increasing costs,  
 Know anything about the formulary, its role and decision-making process for the 
formulary,  
 Whether they are aware of the potentially useful role of pharmacoeconomics in the 
formulary decision-making process and if required to use pharmacoeconomics how 
confident they would be. 
The various statements expressing different opinions about the formulary, its functions and 
decision criteria of the formulary were based on our own judgment formed from a reading of 
the literature. The questionnaire was not pre-tested on any pharmacist. First the respondents 
were asked to identify which factors they considered important for decision-making of the 
formulary and then asked to rank the same in order of importance, 1 being for most important 
and 5 for least important. The other questions did not involve any ranking and usually 
required answers in the affirmative or the negative. 
                                                
∗
 See Appendix 1 – Survey Questionnaire - Pharmacists 
If after 2-4 weeks, the response rate was lower than 50%, a reminder (via e-mail) and a 
second circulation of the questionnaire was made. This was done to maximise responses 
without unduly offending the respondents. 
All respondents were administered the same questionnaire – without any personal explanation 
to the extent. Every query was uniformly handled over telephone to ensure no bias was 
created in the response. If any clarification or completeness follow up was required, the 
respondent was contacted over telephone and his/ her response was recorded ad verbatim.  
Analysis of all responses was done using Microsoft Excel. Raw data were entered into sheets, 
which were linked back through a custom-made analytical model to cross-tabulate and 
accumulate data individually and across all hospitals.    
Results were analyzed by individual hospitals and as a cumulative picture of all 5 hospitals. 
These were further analysed into various segments based on demographics, educational 
background, type and length of professional experience. Each of these segments was analysed 
to understand their level of familiarity and comfort with formulary and related cost control 
processes as well as their awareness with respect to potential contribution of 
pharmacoeconomics in management of the same. 
 
5.2 RESULTS ∗ 
With a response rate that ranged from 50% to 85% in the individual hospitals and an overall 
average of ~ 64% (70 of 110 identified pharmacists responded) our findings delineated the 
following picture in Singapore. Majority of the respondents fell into the 25-35 age group 
(60%) and were predominantly Chinese (96%) with a female preponderance (78%).  Most of 
the respondents graduated within less than 5 years (57%) and were less than 5 years in 
practice (64%).  Thirty-nine percent (39 %) of the respondents’ current area of practice was 
outpatient while 29% had previously worked for retail. Only one member had previous P&T 
Committee experience.  
 
5.2.1 Idea about average annual expenditure 
An overwhelming 84% of the respondents did not have any idea of the average annual drug 
expenditure in their respective institutions and as expected, 74% could not say whether the 
expenditure was ‘too high’.  
 
5.2.2 Acquaintance with different terms of cost containments in drug use 
84% and 77% of the respondents were acquainted with the terms ‘formulary restriction’ and 
‘DRG’ respectively. ‘Prescription restriction’ happened to occupy the third slot (67%) in 
order of awareness of cost containment methods. However, only 19% and 27% respondents 
were acquainted with the terms ‘Fund Holding’ and ‘Capitation’. None of the respondents 





Table 10: Pharmacists’ acquaintance of ‘tested’ terminology 
 
Response Terms  
Yes No 
Supply restriction 67% 33% 
Formulary restriction 84% 16% 
Reference pricing 36% 64% 
Prescription regulation/monitoring 61% 39% 
DRG 77% 23% 
Fund holding 19% 81% 
Capitation 27% 73% 
 
                                                                                                                                       
∗
 See Appendix 2 – Pharmacist responses 
However, no effort was made to evaluate the actual level of understanding of each term 
specifically except that a question was asked to rate the methods in order of importance with 
respect to methods of cost control.  
 
 
5.2.3 Perceived best method of controlling drug costs 
Chart 1.   Pharmacists’ perception of ‘best method’ of cost control  
 
 ‘Formulary restriction’ was ranked the best method for controlling drug costs by 57% of the 
respondents whereas ‘DRG’ was ranked as the no. 2 method by 32% of the respondents. 
A question was included asking for explanation for choosing the method. Major reasons cited 
for choosing the above method, were ‘Forces prescribers to adhere to guidelines’ (51%), 
‘Forces prescribers to work within a limited/pre-assigned budget’ (47%) and ‘Limits choice 










Reference pricing DRG Fund holding Capitation Supply restriction
of drugs’ (41%). Though this did not clarify if the respondent understood each term 
specifically, the explanations given do indicate that at least ‘formulary restriction’ and ‘DRG’ 
are well understood. 
 
5.2.4 Opinion about ‘the formulary’ and its ideal purpose 
Nearly all of the respondents (99%) claimed that their institution had a ‘formulary’ or ‘drug 
list’.  
In the response to their opinion of what is a formulary (Chart 2), 77% of the respondents 
called the formulary ‘a list of most essential drugs’, 31% opined it was a ‘list of most used 
drugs’ with only 10% calling it ‘a list of the cheapest alternatives’.  
Chart 2: Pharmacists’ opinion on Formulary 
As to the ideal formulary (Chart 3),  ‘the ideal formulary’ was considered by most 
respondents to serve ‘In promoting the use of the "best" drug/intervention’ (71%), ‘In 
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controlling the hospital budget’ (57%), ‘In subsidising life-saving medicines’ (47%) followed 
by ‘In restricting the use of drugs’ (34%).   
Therefore, it may be reasonably inferred most pharmacists considered ‘a formulary’ should 
ideally promote the use of the best drug or intervention while simultaneously controlling the 
hospital budget.   
 
Chart 3: Pharmacists’ opinion on purpose of an ideal formulary 
But when the pharmacists were asked whether they considered their hospital served the 
“ideal” purpose to their satisfaction, only a minority (35%) considered it to be so.  Most of the 
respondents either had the negative view (30%) or could not opine on this (35%). The reasons 
stated involved ‘No knowledge of the decision-making process’ (24%), ‘Formulary is too 
open’ (19%), ‘Drugs included solely on cost-basis’ (16%) and ‘No consideration of drug 
quality’ (10%). This was quite understandable in view of the negative and uncertain 
responses.  The breakdown of the response is shown in Table 10. More than one answer was 
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allowed on some questions. Therefore, percentages on some questions may add up to more 
than 100. 
 
Table 11. Pharmacists’ opinion on why ‘their formulary’ is not ‘ideal’ 
Reasons  % of Response 
Formulary is too open 19 
Drugs included solely on cost-basis’ 16 
No consideration of drug quality 10 






5.2.5.  Formulary Decision Process 
Although, nearly half of the respondents (49%) have no knowledge of the factors considered 
in the formulary decision-making process, most of them considered the P & T committee to 
be final decision maker for their hospital formulary (Chart 4).  However, when asked what 
factors would be most important if the respondents had to make formulary decisions 
themselves the factors they would consider (in order of importance) for formulary decision-
making would be drug effectiveness, safety and acquisition cost. 64% of them would consider 
drug effectiveness as the most important factor followed by safety (34%) and then acquisition 
cost as the next important factor (33%). The factors that they would consider as least 
important would be politics and hospital budget followed by drug/pharmacy budget. 
Chart 4: Pharmacists’ opinion on decision makers for ‘their formulary’ 
 
5.2.6.   Confidence of Using Pharmacoeconomics 
On being asked how confident pharmacists would be if asked to use pharmacoeconomics, 
‘not confident’ was the response given by 49% while 21% of the respondents felt they knew 
nothing about the subject.  However, 1% felt very confident about being able to use 
pharmacoeconomics to aid their decision-making, if asked to do so (Chart 5). 
Chart 5: Pharmacists’ confidence on usefulness of Pharmacoeconomics 
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 There is therefore, a definite but unstated need for use of pharmacoeconomics in the 
formulary setting; however, there is clearly a lack of capability to fulfil the need.  
Sorting pharmacist responses with respect to years in practice, we observed that 11% of 
respondents less than 5 years in practice, 9% of those between 5 and 10 years in practice, 33% 
of those between 10-20 years in practice and 50% of those over 20 years in practice, had an 
idea about the average annual expenditure on drugs. Therefore, to test whether years in 
practice and knowledge were independent of each other, or whether there was any statistically 
significant association between years in practice and knowledge of drug expenditure, the chi-
squared test was used. 
The results obtained from the survey of the pharmacists were further analysed to search for 
trends in the response obtained.  The results of these analyses are shown in Tables 12 – 16. 
Table 12: Chi-Squared test of ‘Years in practice’ vs. ‘Knowledge of Drug Expenditure’ 
 
The test clearly shows that there is no statistically significant association between 
knowledge of drug expenditure in their respective institutions and years of practice.  
Sorting pharmacist responses with respect to age we observed that 8% of respondents aged 
less than 25, 12% of those between 25 and 35, 29% of those between 35 and 45 and 50% of 
Table 1
H0 = Having information on drug expenditure is independent of years in practice
Experience Total Total
Has info on exp No info on exp Has info on exp No info on exp
Less than 5 yrs 5 40 45 7 38 45
5 - 10 yrs 1 10 11 2 9 11
10 - 20 yrs 4 8 12 2 10 12
More than 20 yrs 1 1 2 0 2 2
Total 11 59 70 11 59 70
X2 = 5.67
p = >.10 with 3 degrees of freedom
Observed Counts Expected Counts
those over 45 had an idea about the average annual expenditure on drugs. Therefore, to test 
whether age and knowledge were independent of each other, or whether there was any 
statistically significant association between age and knowledge of drug expenditure, the chi-
squared test was used.  







No association could therefore be found between age and knowledge about drug expenditure. 
Similarly, to examine the association between age and knowledge of factors involved in the 
formulary decision-making process, the following chi-squared test was performed. 








H0 = Having information on drug expenditure is independent of age
Experience Total Total
Has knowledge No knowledge Has knowledge No knowledge
Less than 25 yrs 1 11 12 2 10 12
25 - 35 yrs 5 37 42 7 35 42
35 - 45 yrs 4 10 14 2 12 14
More than 45 1 1 2 0 2 2
Total 11 59 70 11 59 70
X2 = 4.48
p = >.20 with 3 degrees of freedom
Observed Counts Expected Counts
Table 3
H0 = Knowledge of factors considered for formulary decision making is independent of age
Experience Total Total
Has knowledge No knowledge Has knowledge No knowledge
Less than 25 yrs 6 6 12 6 6 12
25 - 35 yrs 19 23 42 22 20 42
35 - 45 yrs 9 5 14 7 7 14
More than 45 2 0 2 1 1 2
Total 36 34 70 36 34 70
X2 = 3.47
p = >.20 with 3 degrees of freedom
Observed Counts Expected Counts
The test clearly demonstrated that no association could be found. Therefore we accept the null 
hypothesis that knowledge of factors considered for formulary decision-making is 
independent of age. 
To test the association between knowledge of factors considered for formulary decision-
making and years in practice a chi-squared test was performed. 






The results clearly show that there was no statistically significant association between 
knowledge of factors considered for formulary decision-making and years in practice. 
Therefore we accept the null hypothesis.  
Similarly, a chi-squared test was performed to test the association between knowledge of 
factors considered for formulary decision-making and area of practice. 






H0 = Knowledge of factors considered for formulary decision making is independent of yrs of practice
Experience Total Total
Has knowledge No knowledge Has knowledge No knowledge
Less than 5 yrs 22 23 45 23 23 45
5 - 10 yrs 4 7 11 6 6 11
10 - 20 yrs 7 5 12 6 6 12
More than 20 yrs 2 0 2 1 1 2
Total 35 35 70 35 35 70
X2 = 3.17
p = >.20 with 3 degrees of freedom
Observed Counts Expected Counts
Table 5
H0 = Knowledge of factors considered for formulary decision making is independent of area of practice
Experience Total Total
Has knowledge No knowledge Has knowledge No knowledge
Inpatient 4 10 14 7 7 14
Outpatient 18 16 34 16 18 34
Clinic 5 5 10 5 5 10
Laboratory 2 1 3 1 2 3
Purchase 1 3 4 2 2 4
Others 5.5 5.5 11 5 6 11
Total 35.5 40.5 76 36 41 76
X2 = 3.71
p = >.50 with 5 degrees of freedom
Observed Counts Expected Counts
The results showed there was no statistical significance. Therefore we accept the null 
hypothesis that knowledge of factors considered for formulary decision-making is 
independent of area of practice. 
Thus, all conceivable associations were tested for any significance. But none of the 
associations was statistically significant. Therefore we can safely say that all the pharmacists’ 
views were independent of their demographic background and years of professional 
experience.  
 
5.3 SURVEY OF PHARMACY MANAGERS 
A similar survey (with some structurally similar questions) was carried out among the 
pharmacy managers (and other P&T Committee members belonging to the Pharmacy 
Departments of the individual hospitals). This was designed to understand their views on the 
formulary, its decision-making process and whether there was any understanding and interest 
in pharmacoeconomics at the institutional formulary level. 
 
5.3.1 METHODOLOGY 
The instrument used for the survey was a semi-structured questionnaire comprising primarily 
of closed-ended questions. However, there were some open-ended questions where deemed 
necessary. The questionnaire∗ was sent by e-mail or faxed over and no personal explanation 
given to any of the respondents.  
Thirteen hospitals including the NUH were identified as major hospitals in Singapore of 
which one (National Skin Center) was left out as it was considered a Specialty Hospital. Of 
the remaining twelve, six are private hospitals and six public hospitals. The pharmacy 
managers of the various hospitals were identified and contacted over phone to seek their 
cooperation in the survey by answering a particular questionnaire. The manager of one public 
hospital declined to participate in the survey. Eleven hospitals agreed to answer but number of 
respondents was identified as thirteen.  This was because in two hospitals the Drug 
Information Service Pharmacists (members of the P&T Committees in their respective 
institutions) were also surveyed. 
Major information areas the questions addressed were: 
 the type of institution,  
 number of beds,  
 pharmacy budget of the respective institution,  
 presence of a formulary,  
 opinion about what a formulary is and what its function is,  
 major factors taken into account for drug decisions,  
 perceived impact of DRG on drug decisions,  
 whether the formulary in their institution achieved the aims that they thought it was 
supposed to and  
 suggestions to make the formulary achieve its designated aims.  
Respondent background was known. All were ‘formulary committee’ members and were 
either DIS pharmacists or managers. Therefore no demographic or personal information was 
sought in the questionnaire. 
                                                                                                                                       
∗
 See Appendix 3 – Survey Questionnaire – Pharmacy Managers 
Eleven of the identified 13 respondents sent their replies and two did not. Responses came in 
from eight hospitals. Therefore, of a target population of 13 respondents 11 pharmacy 
managers responded. This could be considered to represent the views of a majority of the 
target population and not just the responses from a small sample of the population. 
 
5.3.2 RESULTS∗  
With a response rate of 85% (11 out of 13 identified respondents), the following results were 
obtained.  
5.3.2.1 Drug budgets 
Of the respondents, 18% (n=2) had no idea about the drug budgets in their respective 
institutions. While 9% (n=1) mentioned a budget over 30 million dollars, 54% (n=6) claimed 
to have a budget of less than 20 million dollars. Another 9% (n=1) mentioned a budget of 21-
30 million dollars.  
 
5.3.2.2 Opinion about the ‘formulary’ 
Most respondents (64%, n=7) felt that the ‘formulary’ is a ‘list of most essential drugs’ while 
18% (n=2) noted it is a ‘list of most used drugs’.  
5.3.2.3 Functions of ‘the formulary’ 
‘The formulary’ was considered by most to serve ‘In controlling the hospital budget’ (91%, 
n=10), followed by ‘In promoting cost-effectiveness in drug treatment’ (73%, n=8) and ‘In 
promoting the use of the "best" drug/intervention’ (64%, n=7). Only 55% (n=6) considered it 
as performing a role ‘In restricting the use of drugs’. 
5.3.2.4 Factors considered important for the formulary decision-making process 
 If respondents were to consider factors in order of importance for formulary decision-
making, 82% (n=9) of them would consider drug effectiveness as the most important factor 
followed by available alternative (64%, n=7), acquisition cost (55%, n=6) and then safety 
(45%, n=5).  The least important factors to be considered were drug/pharmacy budget (18%, 
n=2) followed by politics (9%, n=1) and hospital budget (9%, n=1).  
72% (n=8) of the respondents felt that their approach to the formulary was ‘scientific’ or 
‘evidence-based’.   
The most important results have been summarized in the following graphs. 
A. 91% (n=10) respondents noted their institution has a formulary 
B. A majority (91%, n=10) felt that ‘aim of the formulary was to control budget’ 
Chart 6: Pharmacy Managers’ opinion on aim of a formulary 
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C. 72% (n=8) of the respondents felt the P & T Committee was the final decision-maker 
with respect to inclusion or exclusion of drugs 
D. More than half (82%, n=9, and 645, n=7) of the respondents opined that ‘efficacy’ and 
‘alternatives’ were the two important factors taken into consideration while selecting a 
drug for inclusion in the formulary. 
Chart 7: Pharmacy Managers’ opinion factors considered in drug selection to formulary 
E. Majority (64%, n=7) of respondents felt a ‘Formulary’ was a list of the most essential 
drugs 






































































Chart 8: Pharmacy Managers’ opinion of what a formulary is 
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Chart 11: Pharmacy Managers’ opinion on whether ‘their’ formulary achieves its aim 



















72% (n=8)of the respondents also felt that their formulary achieved the aims of a formulary as 
designated by each of them. 18% (n=2) of the respondents felt that it did not and among the 
reasons cited for why it did not, none of the respondents chose any of the statements provided 
in the questionnaire.  
Among different additional approaches cited to help the formulary attain its aims as 
designated by each one of them, pharmacoeconomics and /or cost-effective featured in 3 
responses. Various other institution-specific approaches were mentioned. Different reasons 
were cited for not being able to implement the additional approach. Most were related to the 
specific institutional settings. Only 18% (n=2) noted lack of expertise as one reason followed 
by lack of time (9%, n=1). 
 
Important Differences between The Responses Of The Pharmacists And The Pharmacy 
Managers and possible causes 
Both the pharmacists and the pharmacy managers agreed that a ‘formulary’ was a ‘list of most 
essential drugs’. However, the major point of difference lay in their view with regard to the 
function of the formulary. Whereas, a majority of the pharmacy managers (91%) felt that the 
most important function of a formulary was to control the hospital budget, the pharmacists 
(71%) opined that a formulary was supposed to promote the use of the best drug or 
intervention. This disparity in their idea about what the formulary was supposed to do was 
again evident when only 35% of the pharmacists felt that their formulary satisfactorily 
performed its function as opposed to 70% of the managers who felt the formulary achieved its 
aim. Given their preoccupation with managing budgets it seems that the managers considered 
the formulary as another budget management tool. ‘Drug effectiveness’ figured topmost in the 
list of factors that would be considered by both general pharmacists and P&T committee 
members if they were to decide on the formulary. However pharmacists felt that drug 
effectiveness though the most important, acquisition cost was the least important factor for 
consideration to them. To the pharmacy managers acquisition cost ranked third in order of 
importance after drug effectiveness and available alternative. 
 
Pharmacoeconomics and Pharmacists 
Promoting the health of patients is a role to which the pharmacists commit themselves when 
they join the profession. However, today “health” is not just considered the absence of disease 
or infirmity. Rather, a comprehensive approach to health is being embraced. Under this 
scenario, helping other healthcare professionals ensure positive outcomes has become the 
responsibility of the pharmacists. Good patient care lies in helping patients achieve positive 
outcomes that the patients and health care professionals mutually define, in the most cost-
effective manner. The principal aim of pharmacoeconomics is to elaborate and analyze the 
outcomes that are achieved or expected to be achieved versus the costs for that care. In order 
for pharmacists to discharge their duties effectively and efficiently in the current therapeutic 
milieu, therefore, it is important that pharmacists understand pharmacoeconomics. Focusing 
on the patient as a whole person is a completely new orientation. In this changed scenario, 
pharmacists as members of the healthcare team, must be able to evaluate the relationships 
between process, outcomes and costs to help reproduce the best or the most cost-effective 
outcomes (including patient satisfaction) and thereby help improve the physical, mental and 
social well-being of the patient.   
However, though pharmacoeconomics and pharmaceutical care are interrelated, the real world 
use of pharmacoeconomics by pharmacists seems to be confined to formulary decisions 
primarily. In fact, a conference held in Boston in September 1994, on applying 
pharmacoeconomics in patient care revealed that whatever was being used was mainly for 
making drug formulary decisions.95,96,97  In several countries, formal requirements and 
guidelines to assist in decisions about including and subsidizing specific drugs on formularies 
at a national or provincial governmental level have been established. In the United States, 
pharmacoeconomic studies are required on a less formal basis by P&T committees of 
institutions for drug inclusion on formularies.99 Other than these, based on the literature it 
seems that the use of pharmacoeconomic data by pharmacists is limited.  
 
Significant points from the survey 
Based on the results of the surveys a few significant points emerged: 
• The background of the respondents had no bearing on the individual’s responses to 
questions pertaining to opinion about the formulary and its decision-making process 
or idea about average annual expenditure on drugs. Ideally, one would have expected 
some difference, more particularly, people with greater experience or at least those 
between 25-45 years of age (those likely to have more active interest in professional 
matters) to differ significantly in some views. That did not happen. Therefore, there 
seems to be a general lack of interest in the “formulary” and how it operates or how it 
is expected to operate. Moreover, there also seems to be no awareness about the 
problems of increasing costs. However, as is being increasingly realized, the future 
with an ever-increasing elderly population and increasing expectations of better 
quality will definitely pose challenges. If governments are to live up to these 
challenges ‘cost-effectiveness’ in health care is an important consideration. However, 
in Singapore, the idea of cost-effectiveness in health care is only beginning to 
emerge.  
• Few hospitals have open formularies, with the exception of private hospitals, where 
patients pay in full stock all medicines.  
• The final decision to stock or not stock a particular medication rests on the medical 
board or the P&T Committee (the chairperson of which is usually a doctor). 
Thus, one can strongly argue that there is a covert need for a more complete evaluation of 
pharmaceuticals. Given the potential benefits of pharmacoeconomics, we would suggest that 
the subject has a definite role to play in formulary decision-making which would involve 
more comprehensive evaluation of pharmaceuticals. Therefore, it is being proposed that the 
















SECTION 6.  THE METHODOLOGY OF THE PROJECT 
4.1 Introduction 
The project endeavours to establish that pharmacoeconomics can play a potentially useful role 
in formulary decision-making at the institutional level in Singapore. For this purpose, the 
National University Hospital (Singapore), a tertiary institution was chosen as the centre of the 
study.   
However, if pharmacoeconomics is to contribute to a more rational allocation of health care 
resources at the hospital level (through a more comprehensive and scientific formulary 
decision-making process), P & T Committees must appreciate the potential role of that 
discipline in formulary decisions. This is because, in most practice settings, formularies are 
established and managed by this committee. At the same time, pharmacoeconomists must 
demonstrate that their analyses can lead to a more efficient allocation of limited resources in 
the purchase of drugs without compromising the quality of health care.75, 99  
Therefore, the first steps the researcher did was to write up a proposal explaining clearly to 
the P&T Committee chairperson, the following points: 
• Background as to why the researcher hypothesised that pharmacoeconomics could 
potentially be useful in formulary decisions in hospital practice settings 
• Why the researcher considers it useful in the Singapore scenario (incorporating the results 
of a survey of hospital pharmacy managers that clearly revealed the need for such an 
approach) 
• Time-tested benefits of incorporating pharmacoeconomics in formulary decisions by 
drawing on examples of countries, especially Australia. Examples of National and State 
level formularies were cited to demonstrate our hypothesis that similar activity at the 
institutional level would help improve the technical efficiency of the formulary process.  
• How the researcher intended to establish the role of pharmacoeconomics in formulary 
decisions (the exact modus operandii of the project)  
Starting from the approval date, for the following 3-4 P&T Committee meetings the 
researcher would evaluate any one to two of the 7-8 formulary submissions in each 
meeting and prepare a report suggesting what impact it would have (on both clinical and 
economic fronts) if included in the hospital formulary. This report along with all other 
reports prepared by the DIS pharmacist was to be circulated one week in advance of the 
meeting to all the 13 members to enable them go through the reports and ready 
themselves for the discussion. Next, the actual review process was observed first hand by 
the researcher to facilitate better understanding of their standard procedure and enable the 
researcher to help sharpen the approach. The letter and the proposal attached together as 
Appendix 5.∗   
The researcher, after having obtained the hospital’s consent attended four P&T Committee 
meetings from January 2001 through to April 2001. A total of 7 products (Basiliximab/ 
Daclizumab, Zanamivir/Oseltamivir, Gatifloxacin, Synercid and Linezolid) were reviewed 
with full and comprehensive pharmacoeconomic reports prepared for each. Each report on an 
average consisted of 15-18 pages and would take up to 2-3 hours to read carefully. The 
evaluations are all attached as appendices 6a-6e.+ Due to the researcher’s inexperience in 
performing evaluations, the first evaluation was substantially performed by the supervisor 
with some inputs from the researcher. In the interest of being truthful it was deemed more 
appropriate to put the supervisor’s name in that evaluation when submitting for discussion 
with the NUH P&T Committee. Thereafter, the other evaluations were substantially 
performed by the researcher with inputs and corrections by the supervisor. 
                                                
∗
 See Appendix 5 – Letter and Proposal 
+
 See Appendix 6a-6e - Evaluations 
Until June 2000 the frequency of the P&T Committee meetings was once every two months. 
However there was no rigid rule in this regard. But, from 2000 July onward, the meetings 
were conducted once every month.  
 
4.2 Process of Evaluating Formulary submissions at NUH 
For the appraisal a drug “topiramate” evaluated before June 2000 and “zafirlukast” evaluated 
after June 2000 were chosen. Attachedσ are the evaluations performed by the NUH DIS 
pharmacist and the decisions based on those evaluations. Additionally, the drug evaluations 
performed by the DIS pharmacist for the 7 products for which the researcher also performed 
evaluations were also reviewed. Following is a critical appraisal and comparison of the 
evaluations performed by the DIS pharmacist and later reviewed during the P&T committee 
meeting for decisions.  
 
4.3 Review of Existing Evaluation Process 
There seemed to be little effort at “synthesizing” findings from numerous similar and smaller 
trials to obtain what could be called an overall picture. The concept of meta-analysis while 
being understood was hardly ever performed. There was no attempt at evaluating clinical 
literature critically and arriving at information crucial for the decision-situation at hand. 
Information was derived from standard databases or journals and the conclusions reported ad 
verbatim with little attempt at finding out what the findings truly signified in the context of 
the NUH practice setting and formulary decisions. This may be quite understandable in view 
of the fact that most peer-reviewed journals are considered to produce bona fide information. 
There would seem to be little need to review clinical literature critically. No attempt at 
                                                
σ
 See Appendix 7 - NUH Evaluation Process 
finding out the impact on Quality of life outcomes was seen. Finally there was no reference to 
any economic evaluation or literature.  
  
4.4  Process of review until June 2000 
A drug company or a doctor was required to fill the request form∗ to incorporate a new drug 
in the formulary. This form was then sent to the NUH Pharmacy Department where the Drug 
Information Services (DIS) pharmacist evaluated the drug for its merits. The DIS pharmacist 
searched for relevant papers to carry out this evaluation process. Papers or studies submitted 
by the pharmaceutical companies were generally regarded as having a bias in favour of the 
company’s interests. Hence, the DIS pharmacist looked for his/her own references.  
The databases looked up for reference, were usually FDA web site databases and Medline. 
PubMed was the search engine most frequently used. Based on information available from the 
relevant clinical papers, the drug was compared to an alternative with respect to efficacy, side 
effects and cost. It was not clear, how this alternative was chosen. However, from the 
information available in the drug request form (which is to be filled in when a doctor requests 
for inclusion of a new drug), the alternatives chosen appeared to be drugs of the same class 
and/or drugs with the same therapeutic use in the NUH.     
For efficacy, a direct head to head comparison was made when such studies are available. 
Otherwise, both the drugs were compared to a placebo.  
Adverse effects included an evaluation of the drug based on the routine adverse effects. The 
FDA runs a very detailed account of adverse effects on its website and the DIS pharmacist 
made sure she got information from it. Therefore, there seemed a very strong inclination 
towards ensuring safety of the patients. 
                                                
∗
 See Appendix 8 – Request Form 
No references were provided for the studies based on which all the information was derived. 
Cost considerations included unit cost and acquisition cost for the hospital. Cost of treatment 
per day as well as, total treatment cost wais only sometimes considered.  
Any drug approved by the committee was considered a ‘Formulary Drug’. However, if it was 
approved as a non-standard category drug, a ‘subsidised’ patient would pay in part for that 
drug whereas, for a standard drug the patient has to pay a subsidized rate. For a ‘private full 
paying’ patient, however, full payment for both standard and non-standard drugs is required. 
Three weeks before the P & T Committee meeting, the review∗ along with relevant clinical 
papers, was sent to doctors of the relevant specialty. Expert clinical opinion of the reviewers 
was sought on a specified form+ after which the drug review report was finalised and then 
presented in the P&T committee meeting. Every round of a P&T meeting normally reviewed 
eight new requests.  
 
4.5   Major changes made after June 2000 
The major changes made after June 2000 were with respect to the frequency of meetings 
(once every month instead of once in two months) and the incorporation of references by the 
DIS pharmacist when doing the review. In addition, every round of meeting (because it was 
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 See Appendix 9 - Review 
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 See Appendix 10 – Expert Opinion 
SECTION 7.  WHY WERE THE AUSTRALIAN GUIDELINES FOR THE 
PHARMACEUTICAL INDUSTRY ON PREPARATION OF SUBMISSIONS TO THE 
PBAC CHOSEN AS THE REFERENCE POINT FOR THE WHOLE PROCESS?  
 
Starting through January 2001 to April 2001, approximately 3 weeks before each P&T 
Committee meeting the DIS pharmacist was approached by the researcher and asked to 
allocate one, or at most two, “difficult-to-evaluate” (usually due to high price and/or recent 
introduction into the market) product (s), to be evaluated by the researcher. Such a procedure 
resulted in the researcher performing the evaluation for the specified product and submitting 
the evaluation report approximately one week before the scheduled P&T Committee meeting.  
Evaluations and recommendations made for include monoclonal antibodies like basiliximab, 
daclizumab, antivirals like zanamivir and oseltamivir and antibacterials like gatifloxacin, 
quinupristin/dalfopristin, linezolid and synercid.∗ 
In addition to safety and efficacy, these evaluations assessed the cost-effectiveness of these 
high-priced drugs in the hospital setting. The above cost-effectiveness evaluations were based 
on a uniform method of interpretation, compilation and presentation of the ‘best’ evidence 
that could be generated from the available clinical literature. The model of “Guidelines for the 
Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits 
Advisory Committee (PBAC): including major submissions involving economic analyses” 
framed by the Commonwealth Department of Health and Aged Care in Australia was 
followed for the whole process. 
These guidelines require pharmaceutical companies, seeking recommendation for national 
formulary listing and subsidisation, to provide a detailed economic analysis to support their 
case. Australia is the first country to mandate such a requirement.100  
                                                
∗
 See Appendix 6 - Evaluations 
Any assessment of the contribution of the Australian Guidelines as, a model for formulary 
committee evaluation of drug applications must note the nature and jurisdiction of the PBAC 
as the formulary committee. In Australia, the PBAC serves a national body responsible for 
recommending listing of drugs prescribed through community pharmacies. Due to the 
universial pharmaceutical cover provided, without such a listing, it is less likely that a drug 
would be marketed in Australia. The PBAC plays, therefore, a pivotal role in the entry of 
drugs to the Australian market. In this context, it might be expected that the PBAC would 
take as its principal focus, a societal perspective in the evaluation of drug applications.101, 102  
However, while appreciating the role of the guidelines it has been cautioned that their 
usefulness in formulary settings at the institutional level must be reassessed before adopting 
them as a model because, health care institutions as drug purchasers have a different 
perspective compared to government regulating agencies. They are concerned with their long-
term survival in a highly competitive cost and outcomes conscious environment.101 In spite of 
various criticisms hurled against them, 100,102,74 the Australian guidelines may be taken as a 
reference point for formulary committees who wish to incorporate economic analyses as a 
part of their decision-making. These guidelines do stand out, because of certain distinctive 
features. 
 
How Elements of the Australian Guidelines can help NUH in their formulary decision-
making process 
The objective of the P&T Committee at the NUH should be to rationalise the inclusion of 
drugs on the formulary from both clinical and economic perspective thereby ensuring 
judicious allocation of health care resources and ultimately facilitating the development of 
disease management approach to treating different health conditions. In this context, the 
objective of the researcher was to develop a standard procedure for evaluation of 
pharmaceuticals that would include - 
• A sound clinical evidence  
• An assessment of the economic impact of the decisions  
• The financial impact of the decisions to include or withdraw drugs to / from the formulary 
For developing the aforementioned standard procedure, the intent was to borrow from the 
various guidelines, concepts that considered most appropriate for the purposes of the research. 
In the opinion of the researcher certain salient features make the Australian guidelines 
important source for the aforementioned borrowing. These are: 
 The Australian Guidelines were the first to force decision-makers to evaluate drugs by 
going beyond mere clinical considerations to consider in a consistent manner the impact 
on both economic and HRQoL outcomes of the treatment.   
 Australia by following the above process has been able to keep its drug prices at a 
fraction of the prices in other developed countries while providing standards of care at par 
with those countries. In the fiscal year 1997-98, approximately 125 million prescriptions 
were written for a population of 18 million, at a cost of A$2.8 billion (US $1.75 billion), 
or about A$13 per person per month.74 In contrast, the spending on prescription drugs by 
the elderly alone, in the United States was approximately US $30 billion in 1998 and was 
growing at an estimated 15% per year.103  
 It is true that the guidelines have drawn criticism from some quarters for focussing too 
intensely on clinical implications and relying on clinical trials for pharmacoeconomic 
information. This could be because of two reasons: (1) because of the lack of an agreed 
upon methodology for deriving economic information, the use of clinical trials is 
preferred, (2) modelling relies too much on assumptions that may sometimes not have a 
basis in real life.104, 105,106,107 Moreover, modelling could be tailor-made in a way to reach a 
desired or pre-selected result. Therefore, modelling is sometimes an unconvincing and 
unreliable approach for decision-makers. Until economists could prove to the contrary (at 
least where health care is concerned), the Australian approach rooted in evidence 
obtained from well-designed and scientific trials, does seem to be quite acceptable. 
 The Australian guidelines have been criticised for representing the traditional ‘clinical 
paradigm’ of drug-impact assessment.108 However the role of outcomes assessment is to 
evaluate the anticipated impact of the proposed drug or therapy on the clinical. Outcomes 
can be expressed in clinical terms or in terms of a disease – specific health status 
measure, a HRQOL profile or preference –based instrument score. The choice of outcome 
measures or instrument needs to be justified and acceptable in the context of disease or 
therapeutic area and in terms of the usual criteria of validity and reliability. Only few 
instruments have been assessed within treating populations (as opposed to trial 
environments). 54,110 Therefore, until the time that some “pragmatic trials” or naturalised 
studies110 that capture real-world effectiveness of drugs are done routinely and get 
accepted as well as scientifically designed randomised clinical trials, the latter will need 
to be used for deriving maximum information.  This the researcher feels, in no way 
belittles the economists but rather provides them with a challenge to design ‘more 
practically informative’ studies that would also come to be accepted as well as or even 
better than the current ‘gold standard’ of the double-blind, randomized, clinical trials. 
Therefore, the current ‘clinical paradigm’ seems acceptable to the researcher. 
 As a health system, it is understandable that NUH is particularly concerned with the 
direct cost impacts of new therapies; costs which have to be met by the health system. 
The hospital is primarily concerned with being able to assess the anticipated impact of 
introducing the product on the patterns of resource utilisation, estimated costs of 
treatment and the outcomes profile of patients in the therapeutic area. Such an approach 
to assessing interventions is very clearly explained in the Australian Guidelines. 
 Moreover, the guidelines framed by different countries are largely similar to the ones in 
Australia. 100, 54 There are some subtle differences 54 accounted for by the difference in 
purpose of the guidelines, the particular health care systems of the respective countries 
and the extent of government intervention in health care. 100, 101, 110 
Australia has been the only country, (other than Canada to some extent), to have 
rigorously and strictly enforced the guidelines (for proper conduct of pharmacoeconomic 
studies) at a national level.101 The acceptance of new chemical entities on the national 
formulary in Australia and the ten provincial formularies in Canada depends on the 
results of these pharmacoeconomic studies.111 Only those products which are proved cost-
effective based on these studies are allowed entry into the market. 
 The relatively lower price levels of major pharmaceutical products (multinational brands) 
in Australia 112 as compared to other developed countries and the overall efficiency of 
health care expenditure (reflected in similar standards of care achieved at a fraction of the 











SECTION 8. A CRITICAL APPRAISAL OF THE FORMULARY DECISION-
MAKING PROCESS ON THE BASIS OF FIRST HAND OBSERVATION OF FOUR 
P&T COMMITTEE MEETINGS ATTENDED BY THE RESEARCHER  
Traditionally, P&T committees have been responsible for overseeing the drug use process, 
and using formulary systems to control drug costs. By means of this method, P&T members 
evaluate and select from the commercially available drug products, those that are most useful 
for patient care and thus help in promoting rational drug therapy. In many health care 
systems, the P&T committee of the 1990s functions as an advisory committee and policy 
recommending body to the medical and administrative staff, for the purpose of promoting 
rational drug therapy.113 
 
8.1 The P & T Committee of the National University Hospital (NUH), Singapore  
The National University Hospital (NUH) is an autonomous hospital managed by its own 
governing body. The P & T Committee at NUH takes decisions on admission of new drugs to 
the hospital formulary. 
Members of the P & T Committee – The membership of the committee comprises primarily of 
doctors from the departments of Pharmacology, Pediatrics, Medicine, Obstetrics and 
Gynecology, Anesthesiology, Surgery, Medical Oncology etc. The pharmacy manager is the 
only voting non-medical member. The DIS pharmacist is a non-voting member. There is also 
the finance secretary of the hospital who serves as a financial consultant.  
Membership is not permanent and changes are made regularly keeping the total number of 
members at around ten at any time. When the project was conducted there were 13 members 
in the committee.   
 8.1.1 Roles and Responsibilities∗  
The primary roles of the P&T Committee are:  
• To recommend policies to the medical and nursing staff and the Hospital Administration 
on all matters relating to the use of drugs in patients, including drugs in the treatment and 
prevention of disease and drugs for clinical investigation and research. 
• To advice the Pharmacy Manager on the selection of drugs for specified diseases; on 
selection of drugs to be stocked in patient care areas; on the distribution and 
administration of medications, including errors in the prescribing, preparation, drawing 
up and administration of drugs.   
• To evaluate pharmacological and clinical data from all appropriate sources on new drugs 
or formulations offered or requested for use in the hospital. In particular, the Committee 
will from time to time, conduct drug utilization reviews to measure the usage of certain 
drugs with regard to their safety, cost and prevention or therapeutic efficacy.  
• To maintain and continually upgrade through revision a formulary of drugs accepted for 
use in the Hospital. The selection of items to be included in the formulary will depend on 
the evaluation of their efficacy, safety and cost. The Committee will attempt to minimise 
the duplication of similar drug types, drug entities and drug products (formulations) in 
order to reduce unnecessary expense.  
• To monitor and review unwanted (adverse) drug reactions which occur in the hospital and 
relate them to similar information from other appropriate sources. 
• To establish and organise appropriate educational programmes for the hospital 
professional staff on matters relating to drug use, including a drug information bulletin. 
To advise the National Health care Group Management as to whether the standard drug 
list requires modification. 
In the opinion of the pharmacy manager (one of the members of the P & T Committee), a 
‘Formulary’ is “a list of the most essential drugs as these drugs must be made available for 
treating a variety of conditions. If drugs can be shown to be ‘really needed (essential for 
treatment of patients)’, cost is not a critical deciding factor. 
 
8.1.2 Major approach of the P&T Committee Meeting  
• With the exception of the finance secretary all members of the committee were 
required to attend the meeting. However, full attendance was not seen in any of the 
four meetings attended by the researcher.  If attendance were to be considered an 
indicator of participant interest, then the indicator definitely showed lukewarm 
interest, at best. 
• The members served as representatives of their individual departments and were 
consulted for their department’s specific needs, their perception about the usefulness 
of the product in their respective practice settings and their estimation of the volume 
of actual or potential use by members of their specialty. Any other opinion relevant to 
the decision about the product was also welcome. 
• Comments on each drug submitted for inclusion / exclusion, were invited by the 
chairperson. A part of this process was carried out even before the meeting was 
conducted, by soliciting expert opinion on certain products (usually the newer ones) 
from consultants considered “knowledgeable” about such and related products and 
who could be the most likely users of such products.  
                                                                                                                                       
∗
 See Appendix 11 – Terms of Reference of the P&T Committee 
• The “expert” opinions were usually based most often on FDA web site reports rather 
than what could be termed compilation of the best (or all) available evidence derived 
from different sources, especially reports of clinical trials published in peer reviewed 
literature. A major drawback with such an approach to evaluating pharmaceuticals 
was a conspicuous overlook of the fact that the FDA needs just enough proof of the 
new agent being generally safer and more efficacious than placebo to grant approval 
for marketing a new drug. FDA approvals are not incumbent on the comparison of the 
new agent with other drugs available for treating that indication. Such comparison 
however, is almost indispensable for making good formulary decisions. 
• In an attempt to put a consensus decision approach into practice active participation 
with respect to expressing views was encouraged.  
• Attention to numbers (volume and money value of use) was also paid and causes for 
over use or deviation from the normal standard of other hospitals (especially the 
Singapore General Hospital, comparable in size, pharmacy drug budget and volume 
of business) were considered.  
• There seemed to be an attempt by the P&T Committee to not make the physicians 
feel restricted in their practice due to “cost-cutting” or “budget-control”. However, 
there was a general consensus that unwarranted and unbridled usage of expensive 
drugs had to be curtailed. Some acceptable “rules” to bring an element of 
accountability and responsibility when using expensive drugs were trying to be 
brought in. However, a system that encouraged prior approval of emergency use 
drugs did not seem acceptable. Doctor education (in the line of practice guidelines) 
was an idea being considered to facilitate more standardization in treatment practices.   
• An inclination to make the decisions more rational was evident from the suggestion 
of members to change the format of the form (to be filled up when requesting 
formulary inclusions of drugs) to suit the requirements of a good evaluation. It was 
agreed upon that more space for incorporating enough reasons to justify inclusion 
was required.  
• Distinct eagerness to make the formulary selection process more transparent was 
evident from the suggestion that declaration of any interests in the pharmaceutical 
company (by the requesting doctor) be made mandatory.  
• It was being felt that the evaluation process would do well to be ‘a bit more 
scientific’. Though the term was yet to be clearly defined, the researcher felt that this 
could mean “more information that would facilitate better decisions”. However, the 
members, given their tight schedules also opined that while the form should help 
establish proven safety and efficacy facts and quote references, it should be 
“concise”.  
• A need for differently formatting forms filled out by drug companies for requesting 
inclusion of their products was expressed. Simple declaration of interests, the number 
of company products available on the formulary and the volume of business with the 
NUH were suggested for inclusion in the proposed format. This may have been the 
result of an inclination to see if any particular company was getting unduly favoured 
due to vested interests of the medical specialists (who most often proposed new 
inclusions). 
• When a consensus was difficult to arrive at, an expert in that subject was consulted. 
This seemed justified as not all specialties can be represented in the committee. 
• A protocol requiring a check of head-to-head clinical trials or a meta-analysis of 
smaller trials was trying to be instituted for incorporation of expensive drugs. A 
definite need to check whether individual experience was borne out in well-controlled 
clinical trials was being expressed.  
Discussion 
Although during the four meetings attended by the researcher the discussion centred on the 
formulary, it would be inappropriate in that sense to conclude that the P&T committee in the 
NUH served primarily as the ‘formulary committee’. Clearly, the approach of the committee 
had all the ingredients of a progressive decision-making body. The tactical issues involved 
were recognized correctly and action was being solicited. Attempts to make the information 
requirements more rigorous and comprehensive before acting on drug inclusion requests 
could be seen as a step in this direction. Mandating expert evaluations of newer (more 
expensive) drugs before deciding on their inclusion could definitely be interpreted as an 
attempt to make “more robust” decisions. Benchmarking costs and performance with other 
comparable hospitals could also be a case in point. Needs for more “depth” and transparency 
were clearly evident. For instance, doctors are usually not trained in assessing financial 
information. However, an attempt to evaluate financial impacts of decisions was seen. The 
concept of “cream off”, by which excess of revenues (over a particular amount) generated in 
the hospital are ploughed back by the government are usually financial matters. This was also 
paid attention to in the meeting.  Attention was drawn to the “pricing” of pharmaceuticals. For 
example, surprise at 50mg and 100mg tablets of a certain drug having the same price was 
expressed. An increasing concern about the ‘true worth’ or the actual value of the products 
being paid for was evident. Attempt to correct loopholes in the system were evident when 
attention to the usage of 746 vials of a particular drug for one patient was drawn. Thus, it 
could be said that the approach was all geared towards incorporation of pharmacoeconomics. 
However, a probable unfamiliarity with the subject and its use (as evident from the surveys of 
pharmacy managers) may have been the reason why pharmacoeconomics was not being 
actively used. However, as discussed subsequently, the researcher’s contribution (using 
pharmacoeconomics for drug evaluations) was amply recognized and a definite desire to 
increase use of pharmacoeconomic approach to decision-making was expressed. Therefore, it 
was only a matter of correctly understanding and appreciating the true usefulness of the 
subject before it would be accepted by the committee.   
SECTION 9.   EVALUATION OF THE RESEARCHER’S CONTRIBUTION TO THE 
FORMULARY DECSION-MAKING PROCESS AT THE NUH 
9.1 The researcher believes that pharmacoeconomic assessments of formulary decision would 
help to ensure that only those drugs or interventions, which yield the highest outcome per 
dollar spent, diffuse into the healthcare systems. The researcher endeavored to test this 
hypothesis in the setting of the university hospital through a means deemed appropriate 
by her. This was to evaluate one or two products for each P&T Committee meeting 
through 3-4 meetings and submit the evaluations for facilitating P&T Committee 
decision-making. An objective measure of the success of the process would be an 
assessment of the percentage change in the number of P&T approvals and potential cost 
savings to the organization as a result of pharmacoeconomic assessments. However, due 
to the inherent nature of the project (such information may not be forthcoming due to the 
time constraint of the project) it was not possible to consider them as primary outcome 
measures. 
9.2 Ideally, economic evaluations (as proposed and demonstrated by the researcher), in 
addition to the primarily pharmacotherapeutic (efficacy and safety) based considerations 
currently taken into account by the P&T Committee at the NUH would entail a more 
comprehensive or in-depth evaluation of formulary actions (addition or deletion) leading 
to increased user satisfaction. Hence, the primary outcome measure ‘user satisfaction’ 
was measured or gauged by a questionnaire at the end of 4 P&T committee meetings. 
9.3 A questionnaire∗ was prepared and circulated to 12 P&T Committee members. The 
questionnaire was drawn up by the researcher based on what the researcher felt would be the 
most useful questions to ask about the formulary decision-making process and how to 
improve that process. The questionnaire was drawn based on an idea of general perceptions 
about the process. However, this questionnaire was not pre-tested. Instead a set of questions 
from the pool of questions written by the researcher was finalized by the supervisor. Of the P 
& T Committee members, 10 had replied and 2 in spite of repeated reminders did not. Hence, 
the responses represent the views of the majority of the target population i.e. (P&T 
Committee members of the NUH) and not just those of a very small sample of the population. 
Following are the most important (relevant) responses ∗ in tabular form: 




	 Yes No Not sure 
Indispensable in every hospital 100% 0% 0% 
Essential though not indispensable 0% 100% 0% 
Is ‘nice’ to have 0% 100% 0% 
Is not very important 0% 100% 0% 
Is just a “show” 0% 90% 10% 
 
The results clearly show that all members feel that a P&T Committee is ‘indispensable’ for 
every hospital and a majority (90%, n=9) of the respondents do not think that it is just a 
‘show’.  
Table 18: P&T Committee members’ opinion of the most important objectives of the committee 










Yes No Not sure 
To control the hospital budget 40% 50% 10% 
                                                                                                                                       
∗
 See Appendix 12 – P&T Member Questionnaire 
∗
 See Appendix 13 – P&T Committee member responses 
To facilitate efficient management of 
the hospital as a “health care portfolio” 
80% 20% 0% 
To control doctors’ prescription habits 40% 50% 10% 
Management of the hospital inventory 70% 30% 0% 
 
A substantial number of members in the NUH P&T Committee feel that the most important 
objective (s) is (are) ‘To facilitate efficient management of the hospital as a “health care 
portfolio” (80%, n=8), ‘Management of the hospital inventory (70%, n=7)’, followed by ‘To 
control doctors’ prescription habits (40%, n=4)’ and ‘To control the hospital budget (40%, 
n=4)’. 
Table 19: P&T Committee members’ opinion of the required constitution of the Committee         
(n = 10) 
‘Must’ be members of the Pharmacy and Therapeutics Committee 
  Y N Not Sure 
Physicians  100% 0% 0% 
Pharmacists  100% 0% 0% 
Financial analysts  50% 40% 10% 
Hospital administrators  60% 20% 20% 
Nurses  30% 50% 20% 
Health economists  60% 10% 30% 
 
All the respondents consider physicians and pharmacists as ‘must be’ members of the P&T 
Committee unanimously and without ambiguity. However, a substantial proportion (60%, 
n=6) feels that health economists should be considered as ‘must be’ members. Though 30% 
(n=3) have not unambiguously declared that health economists ‘must be’ members, they 
remain unsure about the issue. Only 10% (or 1 respondent) feels that health economists 
should not be “must-be” members of the committee.  
Table 20: P&T Committee members’ opinion of value adding viewpoints (n = 10) 
Viewpoints considered to add value to P&T decisions 
  Y N Not Sure 
Financial analysis  60% 40% 0% 
Health care administration  60% 40% 0% 
Pharmacoeconomic analysis  90% 0% 10% 
 
However, pharmacoeconomic analysis is considered to ‘add value’ to their decisions by 90% 
(n=9) of the respondents. Only 1 respondent (10%) though not sure about whether such an 
analysis adds value has also not ruled out pharmacoeconomics completely. 
Table 21: P&T Committee members’ opinion on desirable frequency of committee meetings 
(n = 10) 
Frequency of meeting to achieve a meaningful purpose 
  Y N Not Sure 
Once every month  87% 13% 0% 
Once in three months  0% 100% 0% 
Once in two months  50% 33% 17% 
More often  0% 75% 25% 
 
A considerable proportion of the respondents, feels that the P&T meeting should be 
conducted every month to achieve a meaningful purpose. Though some (50%) would like it to 
be conducted every two months, 75% certainly do not want it conducted more often than once 




Table 22: P&T Committee members’ opinion on decisions made by the committee (n = 10) 
Kind of decisions made most often by the P&T Committee 
  Y N Not Sure 
Patient management decisions  43% 29% 29% 
Budget management decisions  43% 29% 29% 
Formulary drug decisions  100% 0% 0% 




This question was asked with the intention of finding out how their approach related to their 
work.   
All the respondents feel that the P&T Committee makes formulary drug decisions. However, 
43% of the respondents feel that the committee also makes patient management and budget 
management decisions. However, none of the respondents feels that the committee makes 
diagnostic and screening procedures decisions.  
Table 23: P&T Committee members’ opinion on ideal formulary (n = 10) 
A formulary should ideally be     
  Y N NS 
An essential drug list  89% 11% 0% 
A list of life-saving drugs meant 
for subsidy 
71% 29% 0% 
A list of drugs most frequently 
used 
63% 25% 13% 
A comprehensive list of drugs 
avoiding generic duplication 
63% 13% 25% 
Others  0% 0% 0% 
 
Opinions about what the formulary should ideally be, ranged from ‘an essential drug list 
(89%, n=9), ‘a list of life-saving drugs meant for subsidy (71%, n=7)’, ‘a list of drugs most 
frequently used (63%), to ‘a comprehensive list of drugs avoiding generic duplication (63%, 
n=6)’.  The pharmacists opined that the purpose of an ideal formulary was “to promote the 
use of the “best” drug/intervention.  
Table 24: P&T Committee members’ opinion on ‘idealness’ of NUH formulary (n = 10) 
How close is NUH formulary to the aforesaid choice 
Not at all  0% 
very slightly close  0% 
somewhat close  20% 
close  60% 
very close  10% 
 
A substantial proportion (60%, n=6) of the respondents think that the NUH formulary is close 
to their choice of ‘ideal’ formulary while only 20% (n=2) feels that it is ‘somewhat close’ to 
their choice. However, only 1 respondent feels it is ‘very close’ to the aforesaid choice. 
 
Table 25: P&T Committee members’ opinion on factors for formulary decisions (n = 10) 
Factor (s) to be considered when including/ deleting drugs from a formulary 
  Y N NS 
Cost 90% 10% 0% 
Only clinico-therapeutic properties of drug and 
alternatives 
56% 44% 0% 
Institutional Budget 67% 33% 0% 
Economic impact of drug on the therapeutic area 89% 11% 0% 
Safety 100% 0% 0% 
Cost-effectiveness  100% 0% 0% 
Brand equity  11% 67% 22% 
Other Quality of Life factors  89% 0% 11% 
 
Factors cited as the ones to be considered when including/deleting drugs to and from the 
formulary included safety (100%, n=10), cost-effectiveness (100%, n=10), cost (90%, n=9), 
economic impact of the drug on the therapeutic area (89%, n=9), other quality of life factors 
(89%, n=9), institutional budget (67%, n=7) and brand equity (11%, n=1). An attempt was 
made to clarify their concepts of ‘cost’ and ‘cost-effectiveness’ in a later question.  
Table 26: P&T Committee members’ opinion on NUH formulary drug decision process (n = 10) 
Does NUH approval process consider all 
factors 
Not at all  0% 
only little  0% 
considers partially  0% 
considers  60% 
considers completely  20% 
A substantial proportion of the respondents felt that the NUH approval process ‘considers’ 
(60%, n=6) as opposed to ‘completely considers’ (20%, n=2) all the aforementioned factors in 
the approval process. 
Table 27: P&T Committee members’ opinion on ‘cost’ (n = 10) 
Connotation of the term “cost”     
  Y N Not Sure 
Acquisition cost  57% 43% 0% 
Total cost of treatment  100% 0% 0% 
Budget impact  100% 0% 0% 
Cost to the patient  89% 11% 0% 
 
The term ‘cost’ denoted ‘total cost of treatment’ and ‘budget impact’ to 100% (n=10) of the 
respondents; whereas it meant ‘cost to the patient’ to 89% (n=9) and ‘acquisition cost’ to 57% 
(n=6) of the respondents respectively. Therefore there seems to be some non-uniformity in 
their understanding of the term ‘cost’. 
Table 28: P&T Committee members’ opinion on ‘cost-effectiveness’ (n = 10) 
Connotation of the term “cost-effectiveness” 
  Y N Not Sure 
Cheap  0% 86% 14% 
Value for money  89% 0% 11% 
Optimising the clinical efficacy, 
economic impact and patient 
quality of life 
100% 0% 0% 
Effective control of the 
institutional budget for drugs 
50% 38% 13% 
 The term ‘cost-effectiveness’ stood for ‘optimizing the clinical efficacy, economic impact and 
patient quality of life’ to 100% of the respondents, followed by ‘value for money (89%, n=9)’ 
and ‘effective control of the institutional budget for drugs’ to 50% (n=5) of the respondents. 
However to none of the respondents did the term stand for ‘cheap’; though there was some 
ambiguity about the decision, because 14% (n=1) of the respondents were not sure if the term 
meant ‘cheap’. 
 
Table 29: P&T Committee members’ opinion on prerequisites for good product review (n = 10) 
The prerequisite (s) for good review of a product 
  Y N Not Sure 
Extensive literature search  100% 0% 0% 
Proper interpretation of clinical data 100% 0% 0% 
Compilation of evidence most relevant 
to the decision 
100% 0% 0% 
Good presentation of available 
information about the product 
100% 0% 0% 
All of the above  89% 0% 11% 
 
The prerequisite (s) for good review of a product were considered to be all the following by 
100% of the respondents: 
Extensive literature search, proper interpretation of clinical data, compilation of evidence 
most relevant to the decision and good presentation of available information about the 
product. 
Table 30: P&T Committee members’ opinion on comprehensiveness of medical literature (n = 
10) 
Extent to which literature search for review of formulary inclusions 
is comprehensive 
50%  20% 
60%  0% 
70%  20% 
80%  20% 
90% and more  40% 
 
40% of the respondents felt that the literature search conducted in the hospital for evaluation 
purposes was comprehensive to the extent of 90% (n=9) and more, however, 20% (n=2) felt it 
was only 50% complete. 
Table 31: P&T Committee members’ opinion on decision criteria (n = 10) 
Kind of evidence formulary decisions are usually based on 
  Y N Not Sure 
Local clinical (and/or marketing) trials of the 
product (s) conducted for registration purposes 
78% 22% 0% 
Experience of senior colleagues with that 
product either in Singapore, or elsewhere 
56% 44% 0% 
International and multicenter clinical trials 100% 0% 0% 
Own experience with the same product and/or a 
member of the same and/or similar class 
67% 33% 0% 
"Expert opinion" (of senior consultants) in NUH 67% 22% 11% 
Review of all or/most of the available literature 100% 0% 0% 
 
All the respondents unanimously agreed that ‘international and multicenter clinical trials’ and 
‘review of all or most of the available literature’ provided the ‘evidence’ on which formulary 
decisions are usually based. ‘Own experience with the same product and/or a member of the 
same and/or similar class’ and ‘Expert opinion (of senior consultants) in NUH’ were cited as 
a source for evidence by 67% of the respondents.  There was some ambiguity about the issue 
of expert opinion because 11% of the respondents were not sure whether such 'expert opinion’ 
was used. ‘Local clinical (and/or marketing) trials of the product (s) conducted for registration 
purposes’ and ‘Experience of senior colleagues with that product either in Singapore, or 
elsewhere’ were also mentioned as being used as evidence by 78% and 56% of the 
respondents respectively. Therefore there seems to be certain confusion regarding the 
‘evidence’ used for evaluations in P&T committee decisions. 
Table 32: P&T Committee members’ opinion drug decision ‘questions’  
Response Questions asked before making decisions 
Yes No Not sure 
completely revolutionary or  other members of the 
same class and/or a different class for the same 
indication 
100% 0% 0% 
How new drug compares with other drugs / 
treatment w.r.t. safety, efficacy and cost 
100% 0% 0% 
Is new drug more "cost-effective" compared to 
others for same indication 
100% 0% 0% 
Does new drug radically alter quality of life 
experienced by patients 
80% 10% 10% 
 
Although 100% of the respondents agreed to asking about the relative efficacy, safety and 
cost-effectiveness of a new agent as compared to the available drugs, only 80% of the 
respondents agreed to asking a question about the impact of the drug on quality of life of the 
patient. This probably reflects the relative unfamiliarity with HRQoL as one of the outcomes 
in patient management. 
 
Table 33: P&T Committee members’ satisfaction with literature search 
Satisfaction with literature search of evaluator 
Very satisfactory  10% 
Good  80% 
Okay but not good  10% 
Unsatisfactory  0% 
 
90% of the respondents felt that the literature search of the evaluator was ‘good’ to “very 
satisfactory”. However, one respondent (10%) felt that it was ‘okay but not good’. 
Table 34: P&T Committee members’ opinion on relevance of evidence presented by evaluator      
Relevance of evidence presented by the evaluator 
90% relevance and above  30% 
80-90% relevance  50% 
less than 80% relevance  10% 
 
While 80% (n=8) of respondents felt that relevant evidence was presented in the evaluation, 
one respondent felt that it had less than 80% relevance. 
 
P&T Committee members’ opinion of new approach to drug evaluation  
The new approach to drug evaluation presented by the evaluator was rated ‘useful’, ‘quite 
useful’ and ‘very useful’ by 20% (n=2), 50% (n=5) and 10% (n=1) of the respondents 
respectively. No respondent felt that it was ‘little useful’.  However, one respondent (10%) 
rated it as ‘not at all useful’. 
Table 35: P&T Committee members’ opinion on extensiveness of new approach (n = 10) 
Whether the new method considers more comprehensive gamut of factors 
Considers completely  0% 
Considers  50% 
Somewhat  40% 
Not at all  10% 
 
To the question about whether the new method considers a more comprehensive gamut of 
factors 50% (n=5) felt it ‘considers’ whereas 10% (n=1) felt it ‘does not consider at all’.   
Table 36: P&T Committee members’ satisfaction with new approach (n = 10) 
The approach is  Response 
Fully satisfactory  10% 
Somewhat satisfactory  30% 
Satisfactory  40% 
Fairly satisfactory  10% 
Not at all satisfactory  10% 
 
The majority of the respondents (80%, n=8) rated the new approach as satisfactory to fully 
satisfactory.  
 
Advantages and Disadvantages of Proposed Approach 
The major advantages of the approach as perceived by the committee members are tabulated 
in Table 37.  
 
 
Table 37: P&T Committee members’ opinion on major advantages of new approach (n = 10) 
Response Major Advantages 
Yes No Not Sure 
Comprehensive 70% 10% 20% 
Objectively attends decision at hand 80% 0% 20% 
Raises pertinent issues for a wider 
perspective to decision 
90% 10% 0% 
Conducts sensitivity analysis for more robust 
decision 
50% 20% 30% 
Quantifies in economic terms the impact of a 
particular decision 
70% 10% 20% 
All of the above 80% 0% 20% 
 
Overall, most of the committee members were very positive about the many advantages that 
the approach can bring to the formulary decision-making process. 
As to the major disadvantages perceived with the approach used by the researcher (Table 38), 
50% of the committee members felt that the current lack of technical expertise would be the 
major impedance in applying the approach in the current environment. 
Table 38: P&T Committee members’ opinion on major disadvantages of new approach  
 Response Disadvantages 
 Yes No Not Sure 
Approach is too roundabout  10% 70% 10% 
The report is far too long  30% 40% 30% 
Leaves no room for personal experience  30% 50% 20% 
Requires special expertise that may be lacking 
at the moment 
50% 40% 10% 
 
Half of the respondents would recommend that the approach recommended by the researcher 
be followed for all drug evaluations. Of the 20% (n=2) who felt otherwise, 10% (n=1) felt that 
it should be reserved for ‘some difficult to evaluate’ products and not be used for all the 
evaluations. However, 30% (n=3) of the respondents are not sure if such a process needs to be 
followed for all drug evaluations.  
 
Conclusions 
From the above results it may be reasonably concluded that all the members consider a P&T 
Committee indispensable. However, there seemed to be no unanimity regarding the most 
important objective of the committee. Formulary decisions appeared to be the decisions made 
most often by the committee but there seemed to be no agreement on what a ‘formulary’ 
meant to them. Majority of respondents however, considered it to be an “essential drug list”. 
Pharmacoeconomic viewpoint was considered to add value to P&T Committee decisions by 
the majority of the members. This is congruent with the finding that a majority of the P & T 
Committee members at NUH felt that health economists had to be ‘must be’ members of the 
P&T Committee though there was some amount of non-surety about the idea. Three factors 
cited as being most important to be considered when including/deleting drugs to and from the 
formulary included safety, cost-effectiveness and cost. However, only one-fifth of the 
respondents felt that the NUH approval process considered all the factors. An attempt was 
made to clarify their concepts of ‘cost’ and ‘cost-effectiveness’ in a later question. There did 
not seem to be an agreement on what the terms should mean. Most respondents felt that each 
term meant more than one thing. However, everyone agreed on what the prerequisites for 
good review of a product should be. Generally, a majority of the respondents felt that the 
literature search of the evaluator was ‘good’ and majority opined that the evidence presented 
by the evaluator was of 80-90% relevance. The approach presented by the evaluator was rated 
from ‘useful’ to ‘very useful’ by 80% of the respondents. Again, the approach presented by 
the evaluator was rated from ‘satisfactory’ to ‘fully satisfactory’ by 80% of the respondents. 
A good majority of the respondents felt that the approach used by the evaluator offered all the 
advantages listed in the questionnaire. These advantages included, ‘Comprehensive’, 
‘Objectively attends decision at hand’, ‘Raises pertinent issues for a wider perspective to 
decision’, ‘Conducts sensitivity analysis for more robust decision’, and ‘Quantifies in 
economic terms the impact of a particular decision’. A major disadvantage perceived by half 
of the respondents was, that the new approach required special expertise that may be lacking 
at the moment. Only one respondent felt that this approach was not to be followed for drug 
evaluations at all. However, a majority of respondents felt that it must be followed for all or at 
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Comparison of the traditional role of the P&T Committee as published in the literature 
and the role of the P&T Committee at the NUH 
Though the specific objectives of P&T Committees vary from one institution to another, the 
broad goals based on the literature, seem to be to ensure high-quality drug therapy for hospital 
patients, provide advice to the medical staff on the most safe and appropriate therapy for 
disease conditions treated at the hospital, provide liaison between the medical staff and the 
pharmacy services. To meet these responsibilities, the P&T Committee maintains a formulary 
of medications approved for routine patient care, reviews drug use and adverse drug reactions, 
and establishes procedures for prescribing, dispensing and administering drugs in the hospital. 
Traditionally, P&T committees have focused on drug safety, efficacy and acquisition costs 
when considering a request for formulary addition. In times of economic constraint, the 
primary objectives of a P&T Committee are usually seen to be to appropriately select 
medications and promote their rational use while attempting to minimize institutional 
expenditures.  
The P&T committee at the NUH also seems to be catering to similar objectives. The 
formulary minimizes duplication of therapeutic agents by including selected medications that 
are representative and superior or equivalent to other available agents, according to the 
assessment of the committee members after consultation with the medical staff. Physicians 
are guided in their prescribing by the formulary, which, tries to include a broad but minimally 
duplicative list of therapeutic agents.  To be responsive to the needs of the medical staff, the 
committee welcomes new drug additions but tries to carefully base its evidence on what it 
considers sound clinical reports or data from reliable sources. Since it is not the intent of the 
P&T Committee to prevent the use of drugs uniquely important for the care of a particular 
patient such drug may be obtained on a non-formulary basis. A proposed drug is not admitted 
to the formulary if the committee judges that meaningful therapeutic, pharmaceutical, or 
“cost” advantage over similar agents already available on the formulary is lacking. However, 
these “cost” considerations are increasingly being replaced by “economic” considerations in 
an increasing number of P&T committees in major developed nations across the world. 
Increasingly pharmacoeconomic assessments when evaluating formulary requests are being 
taken into consideration. This is where the NUH P&T committee seems to lag behind. It 
would definitely do better to incorporate pharmacoeconomics more routinely into its 
















SECTION 10.  CONCLUSIONS  
In order for getting towards an overall conclusion about the research objective to evaluate the 
role of pharmacoeconomics in formulary decision-making – the researcher would suggest a 
three-step review of the findings through the duration of the project: 
10.1 The exploratory surveys conducted among pharmacists and pharmacy managers – this 
step served to identify and analyse the status quo perception and utility of the formulary 
(whether a list of cheapest drugs or otherwise) among decision-makers and other 
involved parties. These surveys established what the respondents felt the formulary was 
and whether there was any need for decision support   
10.2 The attendance of the researcher at the NUH P&T Committee meetings – with the 
baseline practice for formulary decision-making established through the surveys, this 
step served to validate and further build on the survey findings with first hand 
observation of the process, influence, motivations, logic and strategic and tactical 
approach used in selection of drugs in a real hospital setting in Singapore. The 
researcher observed the proceedings at a few official meetings and built an 
understanding of the current process and further identified areas where 
pharmacoeconomics would significantly add value to the quality of the decision made.  
10.3 Evaluation of the researcher’s contribution done by the NUH P&T Committee members 
– building further on the findings from the two earlier steps this feedback established 
the degree of perceived benefits and willingness for adoption of pharmacoeconomic 
principles and methods, at least in the NUH. 
 
Almost all the institutions had a ‘formulary’ or ‘drug list’ of some kind. With a clear mandate 
against the formulary being a list of cheapest alternatives it was evident that the formulary 
was perceived to be much more than a mere instrument for cost-control. The ideal formulary 
was expected to promote the use of the “best” drug or ‘cost-effectiveness’ in treatment’ while 
also attaining the objective of controlling the hospital budget.  
Therefore, the fact that the formulary was perceived as an instrument for promoting effective 
drug use while also considering the issue of cost-control clearly showed that there was a need 
for pharmacoeconomics in formulary decisions. However, such a need was not explicitly 
stated. This could most possibly be attributed to the fact that P&T Committee members are 
probably not very familiar with this relatively new and evolving discipline. However, no 
study was made in this respect (i.e. familiarity of the NUH P&T Committee members with the 
discipline of ‘pharmacoeconomics’). Formulary restriction, nevertheless, was ranked to be the 
most effective method for cost-control. However, in the survey of the pharmacist, no 
association/ correlation could be found between years and area of practice of the respondents 
and their knowledge about factors considered for formulary decision-making.  
The researcher observed a series of P&T Committee meetings at the NUH which varied in the 
degree of attendance but were generally directed towards a consensus oriented systematic 
approach towards a significant number of issues related to health care delivery and costs at 
the hospital. The drug evaluation process for inclusion into or exclusion from the formulary 
starts with a search of relevant literature and expert views and recommendations for drugs to 
be used in specialist setups. However, the researcher observed that though the literature 
search covered most widely accepted medical databases – there is no critical review of 
clinical information in comparative trials and no meta-analysis of data from several smaller 
trials. 
The researcher keenly observed the initial effort and willingness of the committee members to 
further strengthen the process of decision-making with more comprehensive approach 
balancing clinical efficacy and safety benefits with cost to the hospital or payers. The 
approach to the final decisions took the form of a consensus representing as far as possible the 
major departments of the hospital. Instead of coercing doctors to restrict usage the committee 
felt it was better to educate them on that front. Formulary inclusions were trying to be 
rationalized from both clinical and budget impact point of view (though this was a bit crude) 
and requests for such inclusions also needed to be justified. The need for a more thorough 
evaluation of requests for formulary inclusion was clearly expressed, at least in so far as the 
expensive products were concerned. In fact, treatment (especially drug use) guidelines were 
already in place for certain conditions. Though these were rough instructions on which drugs 
to use in certain conditions and in what manner and were solely based on practice of experts 
in the respective areas, at least they signified some interest in the direction of framing 
appropriate clinical practice guidelines. Hence there definitely is an important role that 
pharmacoeconomics can play in this setup. 
P & T committees in the hospitals surveyed were by far believed to be the final decision 
makers for drug inclusion/ exclusion in the formulary. Different questions posed to the NUH 
P&T Committee members revealed that a majority of respondents considers it the duty of the 
committee to facilitate efficient management of the hospital as an investment portfolio and 
not simply review the formulary at intervals. In addition, the willingness to accept 
pharmacoeconomic principles for a more informed and effective decision-making process 
was further ratified by the recommendation of a substantial majority of members that ‘health 
economists’ should be  “must-be” members of the P&T Committee, together with 90% 
claiming that pharmacoeconomic analyses add value to their decisions. 
The most important factors for drug inclusions so far as the committee members were 
concerned were safety and cost-effectiveness. The term cost-effectiveness to them signified 
either “an optimizing of clinical efficacy, economic impact and patient rated health related 
quality of life’ or “value for money”. To none of them did the term imply “cheap”. The most 
important bases for their decisions were a review of clinical literature and expert opinion. 
Everyone agreed that the prerequisites to a good review were extensive literature search, 
proper interpretation of trial data, compilation of relevant evidence and good presentation. 
The researcher’s approach was considered ‘useful’ to ‘very useful’ and the literature search 
‘satisfactory’ to ‘fully satisfactory’. The most important advantages of the approach followed 
by the researcher, in the view of the members, were that the approach raises pertinent issues 
for a wider perspective to the decision and objectively attends the decision at hand. However, 
a majority felt that such an approach required special expertise that may be lacking at the 
moment.  In fact, most of the members felt that this approach could be followed for all or at 
least the difficult-to-evaluate drugs. 
Based on such findings it may be reasonably inferred that the researcher was successful in 
adequately demonstrating to the relevant decision-makers the role of pharmacoeconomics in 
formulary decisions. They would even be willing to adopt such an approach but for the lack 
of appropriate expertise.  
Therefore, it can be concluded from these findings that there exist a desire and demand, if not 
explicitly, but certainly covertly for the application of PE in the formulary decision process. 
 
SECTION 11. RECOMMENDATIONS TO FURTHER STRENGTHEN THE 
FORMULARY DECISION-MAKING PROCESS AT THE NUH 
 
It is increasingly important that P&T Committees base their decisions not only on the usual 
clinical considerations and acquisition costs but other outcome measures such as quality of 
life. This is because the future role of the P&T Committee may be quite different from its past 
and present. Future roles may include assessment of clinical outcomes information for various 
treatment alternatives, prospective continuous quality improvement (CQI) for current 
therapeutic recommendations and the establishment of policies governing the use of drugs at 
all levels and in all types of care.113  
As such, the NUH P&T Committee may also have a substantially different role to perform in 
the future, in the context of the changing demography of the health care sector. In order that 
the formulary decision-making process may be more responsive to changing needs of health 
care delivery in general and the institutional operation in particular. Therefore, it is 
recommended that the NUH consider taking some necessary steps. These are: 
1. Standard guidelines for effectively managing the formulary in particular should be 
drawn. These guidelines must look beyond efficacy by incorporating both economic 
and financial analyses for drug evaluation and approval. 
2. Based on the above guidelines development of appropriate models to consistently 
evaluate cost-effectiveness of drugs or therapeutic interventions is urgently needed 
3. The P&T Committee should explicitly base formulary decisions on cost-effectiveness 
information obtained from such models. This would ensure active usage of cost-
effectiveness information. 
It is quite unlikely that the NUH with its limited buying power could ever require mandatory 
pharmacoeconomic evaluations to be submitted by pharmaceutical manufacturers (as in 
Australia) for all products submitted for formulary listing. The best the committee could do is 
to draw certain guidelines that would formalise information requirements for anyone making 
requests for formulary inclusions and set methodological standards for evaluating those 
formulary submissions. In particular, such guidelines should try to encourage consideration of 
a ‘value’ dimension when evaluating pharmaceutical interventions for listing. The pursuit of 
effectiveness alone, regardless of cost, can deprive other patients of care from which they 
would benefit more. Such care may be clinically effective but is inefficient and unethical.111 
Health care systems as drug purchasers should link evidence of cost-effectiveness to potential 
formulary inclusions. In an increasingly fiscally conscious milieu, unless such a stance is 
adopted, issues such as technical and economic efficiency in health care delivery cannot be 
addressed. A rational heath care system is one that finances expensive alternatives to existing 
therapeutic interventions only if such alternatives bring in additional benefits worth the extra 
costs. Not ensuring that such an approach is strictly followed will increase inefficiencies in 
the system.  
The purpose should be to rationalise the inclusion of drugs on the formulary from both 
clinical and economic perspectives thereby ensuring judicious allocation of health care 
resources and ultimately facilitating the development of disease management approach to 
treating different health conditions. In this context, a standard procedure for evaluation of 
pharmaceuticals should include - 
• A sound clinical evidence  
• Economic impact of decisions  
• The financial impact of decisions to include or withdraw drugs to / from the 
formulary 
For developing the aforementioned standard procedure, the NUH may borrow from the 
various guidelines (e.g. Australian and Canadian Guidelines). In addition, the Formulary 
Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada may also be 
consulted.111 These guidelines framed from the perspective of a health system concerned with 
its survival in an increasingly competitive environment might provide some valuable input to 
the framing of the NUH formulary submission evaluation procedure.  
The NUH being uninitiated in the conduct and use of economic analyses, the researcher 
suggests that they first get used to identifying outcomes (both intermediate and final) and 
linking these outcomes obtained to the expenditure incurred. This process would enable an 
understanding of outcomes obtained for money spent (cost-effectiveness) or more 
appropriately incremental benefits (in the form of improved and/or more outcomes) for 
additional expenditure. These outcomes may be derived from reports of well-controlled 
randomised clinical trials or a meta-analysis of several small trials. This, the researcher 
recommends even while realising that randomised clinical trials do not give any idea of the 
effectiveness of products when used in practice but only give us a picture of efficacy (how the 
drug behaves under optimal conditions).   This is because, reports of clinical trials are the 
easiest to obtain and are more readily accepted by medical professionals.  Once the approach 
falls into place, the researcher recommends that adjustments to the clinical trial data be made 
in order to replicate the effect of actual practice conditions.  
Comparing the drug to be evaluated with the range of comparators used normally in practice 
is another point worth remembering. 
A point that seems noteworthy is, simply presenting cost-outcome ratios and judging cost-
effectiveness not anchored to treatment targets and budget allocations within treatment areas 
will not be sufficient.118 It is important to track and monitor patient outcomes. This would 
help the development of treatment guidelines for the optimal use of drugs and set into place 
procedures for the managed introduction of expensive new medicines. 
A budget may be set aside to conduct institution-specific pragmatic outcome studies for 
certain critical drugs on a limited number of patients. These studies must aim to verify 
sufficient cost-effectiveness for the new products to justify subsequent spending. Such studies 
can be very expensive and must be restricted to those drugs for which costs of such studies 
can be justified, i.e. for which costs of such studies are far less than the costs of unrestricted 
entry into the formulary.  
Consideration of economic consequences of decisions on drug treatment would help meet the 
health needs of the population treated by the hospital, more efficiently and ensure good 
justification of the hospital pharmacy budget. This consideration would mean using of 
pharmacoeconomics to arrive at various treatment and service use decisions. A particularly 
useful step in this regard could be to set up and maintain a drug evaluation unit (employing 
one or more pharmacoeconomists) that would aid and augment the services of the Drug 
Information Services currently in operation at the hospital especially with respect to 
formulary decisions.  
A rational health care system is one that finances expensive alternative to existing therapeutic 
interventions only if such alternatives bring in additional benefits commensurate with the 
additional expenditure and if these benefits are really ‘needed’. Not ensuring that such an 
approach is strictly followed will increase inefficiencies in the system. In order that the NUH 
may successfully run as an efficient health care delivery centre, adoption of the 







SECTION 12.  LIMITATIONS OF THE CURRENT STUDY AND SUGGESTIONS 
FOR FURTHER RESEARCH  
As with most other pioneering exploration, this research study also has had limitations that 
leave significant opportunities for further exploration in the determination and establishment 
of the critical role pharmacoeconomics could play in formulary decision-making. 
12.1 Direct budgetary and fiscal impact: An objective measure of the success of the 
project would have been an assessment of the impact of the formulary decisions based on 
pharmacoeconomic evaluations on the potential and/or actual cost savings to the 
organization. However, such information being contingent on the evaluations being 
performed consistently for at least one fiscal year could not be gathered. Hence lack of 
time permitted little objective analysis of the impact on direct cost and healthcare delivery 
efficiency. Furthermore, trend evaluations and chronological comparisons could not be 
performed. 
12.2 Benchmarking: Again owing primarily to the time schedule of the project, the 
researcher was unable to establish a nationwide perspective for the practicing hospitals 
with respect to the impact of pharmacoeconomics in formulary decision-making. Practice 
comparisons could not be made in-depth across all major healthcare providers in 
Singapore and hence a national picture could not be established.  
12.3 Best practices in a healthcare hub:  With Singapore aspiring to become a hub for 
the life sciences for the Asia Pacific region – the researcher believes it could have been an 
interesting value-add to the research findings if benchmarking information with formulary 
decision making practices from other similar or more developed economies could have 
been obtained and incorporated. Such information would likely contribute significantly in 
establishing best practices for Singapore for utilizing pharmacoeconomics in a better 
justification of use of public healthcare dollars. 
12.4 Pharmacoeconomic principle based guidelines – another potential scope for 
research is offered by the lack of clinical guidelines for treatment (drug use) based on 
pharmacoeconomic principles.  
12.5 Lack of awareness of the principles and the potential benefits offered by 
pharmacoeconomics left room for significant skepticism and hence posed as a barrier to 
the early start of the project and therefore to even more extensive research findings to 
some extent. With some convincing demonstration of the role of pharmacoeconomics to 
the NUH P&T Committee at least further research may take off from where this 
researcher left. By following the same procedure for a longer period of time, tangible 
impact on the budget or the number of formulary approvals in the hospital may be 
demonstrated. Helping make effective drug decisions and thereby pruning the formulary 
may achieve more efficient use of the hospital budget and better inventory control. 
12.6 Standard guidelines and operating procedures for drug evaluation and approval 
set forth, explicit criteria for admission of new products and thereby ensure uniformity in 
drug selection. By requiring justification of a new product on both clinical and economic 
grounds by a comprehensive assessment of the therapy’s benefits to patients and its costs 
to the health care system, the guidelines incorporate an extra ‘value’ dimension when 
considering pharmaceutical interventions for subsidization.  
12.6.1. Scope for further research is offered in the area of development of such 
guidelines for evaluating formulary submissions at the NUH. Such guidelines 
apart from contributing to developing a standard procedure for evaluation of 
pharmaceuticals for formulary decisions at the NUH would also serve to set an 
example for other health care institutions in Singapore. 
It is the hope of the researcher that this research would be continued further to add to 
and/or improve upon the findings of the current project and also that tangible action 
would be taken based on the available data to contribute to the efficient management of 
the formulary resulting in more cost-effective treatments for patients and better 
management of the hospital budget. If this research could contribute to improving the 
formulary decision-making process at least in the institution the researcher will consider 










1. Schieber GJ. Financing and Delivering Health care - A Comparative Analysis of 
OECD Countries. OECD Social Policy Studies No. 4, OECD, Paris, 1987. 
2. Gillion C, Schieber G, Poullier J. Measuring Health Care 1960 – 1982 – Expenditure, 
Costs and Performance. OCED Social Policy Studies No. 2, OECD, Paris, 1985. 
3. Working Party No 2 (Economic Policy Committee). Public Expenditure on Health. 
OCED Studies in Resource Allocation No. 4, OECD, Paris, 1977. 
4. Directorate for Social Affairs, Manpower and Education. Health Care Systems in 
Transition – The Search for Efficiency. OECD Social Policy Studies No. 7, OECD, 
Paris, 1990. 
5. Hurst J. The reform of Health Care – A comparative Analysis of Seven OECD 
Countries. OECD: Health Policy Studies No. 2, OECD, Paris, 1992. 
6. Abel-Smith B. The reform of Health Care Systems – A Review of Seventeen OECD 
Countries. OECD Health Policy Studies No. 5, OECD, Paris, 1994. 
7. Report of Conference Agenda (Nos. 1994), Health Care Reform – The Will to 
Change. OECD Health Policy Studies No. 8, OECD, Paris, 1996. 
8. Looney W. Labour/ Management Programme – Financing Innovation in Health Care 
(including Biotechnology). OECD Working Papers Vol. V: No. 25, OECD, Paris, 
1997. 
9. Kalisch DW, Aman T, Buchele LA. Social and Health Policy in OECD Countries: A 
survey of current programmes and recent developments. OECD Working Papers 
Vol VI, No 53, OECD, Paris, 1998. 
10. Jee M, Or Z. Health Outcomes in OECD countries: A framework of health indicators 
for outcome-oriented policy making. OECD Working Papers Vol. VII, No. 3, 
OECD, Paris, 1999. 
11. Feldbaum E, Hughesman M. Healthcare Systems – Cost containment versus Quality.  
Financial Times Business Information, London, 1993; 3-20 
12. Rowlatt P, Lloyd A. Projections of Health Care Need and Funding. In: UK 
Hoffmeyer, TR McCarthy, eds. Financing Health Care vol I. Dordrecht: Kluwer 
Academic, 1994; 63-88 
13. Dorothy M. Gilford (editor). Social, economic and demographic changes among the 
elderly. In “The Aging Population in the twenty-first Century – Statistics for Health 
policy.” National Academy Press, Washington DC 1988; pp.52-64  
14. Malek M. Pharmacoeconomics: what’s in a name? In Sam Salek (editor). 
Pharmacoeconomics and Outcome Assessment: A Global Issue. Euromed 
Communications, Haslemere, 1999. pp.19-20 
15. Malek M. Pharmacoeconomics. The Pharmaceutical Journal 1996; 256,  759-761 
16. Eddy DM. From Theory to Practice: Health System Reform: Will Controlling Costs 
Require Rationing Services? JAMA.1994; 272 (4): 324-28. 
17. Grumbach K, Bodenheimer T. Painful versus Painless Cost Control. JAMA 1994. 
272 (18): 1458-64. 
18. Freemantle N, Bloor K. Lessons from international experience in controlling 
pharmaceutical expenditure. I: influencing patients. BMJ 1996; 312: 1469-1471. 
19. Bloor K, Maynard A, Freemantle N. Lessons from International experience in 
controlling pharmaceutical expenditure. III: regulating industry. BMJ 1996; 313: 
33-35. 
20. Soumerai SB, Ross-Degnan D. Inadequate Prescription – Drug Coverage for 
Medicare Enrolees – A Call to Action. NEJM 1999; 340(9): 722-28. 
21. Fugelli P, Heath I. The nature of general practice: Yes to traditional values must 
mean no to fundholding and managerial ambitions. BMJ 1996; 312 (7029): 456-57. 
22. Dixon J, Glennerster H. What do we know about fundholding in general practice? 
BMJ 1995; 311 (7007): 727-30. 
23. Sloan F, Grabowski H. The impact of cost-effectiveness on public and private 
policies in health care: an international perspective. Introduction and Overview. Soc 
Sci Med. 1997; 45(4): 505-510. 
24. Dixon J. France seeks to curb health costs by fining doctors: Heavy handed and 
expensive. BMJ 1997; 315 (7113): 895-896. 
25. Freemantle N, Bloor K. Lessons from international experience in controlling 
pharmaceutical expenditure. II: influencing doctors. BMJ 1996; 312: 1525-1527. 
26. Maling TJB. The New Zealand Preferred Medicines Concept. Pharmacoeconomics 
1994; 6: 5-14. 
27. Hutton J, Borowitz M, Olesky I, Luce BR. The pharmaceutical industry and reform: 
lessons from Europe. Health Aff (Millwood) 1994; 13: 98-111. 
28. Narine L, Senathirajah M, Smith T. Evaluating reference-based pricing: initial 
findings and prospects. CMAJ 1999; 161(3): 286-88. 
29. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health 
Policy 1998; 44: 73-85. 
30. Menkes D. New Zealand’s pharmaceutical reference-pricing strategy may backfire. 
Lancet 2000; 355(9203):558. 
31. Gross DJ, Ratner J, Perez J, Glavin SL. International pharmaaceutical spending 
controls: France Germany, Sweden and the United Kingdom. Health Care financing 
Review 1994; 15:127-141.  
32. Jonsson B. Pricing and reimbursement of pharmaceuticals in Sweden. 
PharmacoEconomics 1994; 6(S1): 51-60. 
33. Iglehart JK. The American Health Care System. NEJM 1999; 340 (1): 70-76. 
34. Grund J. The Societal Value of Pharmaceuticals: Balancing industrial and Health care 
Policy. Pharmacoeconomics 1996; 10(1): 14-22. 
35. DeMonaco H. Impact of Health Outcomes on Clinical Practice: Focus on Infectious 
Disease. Infect Med 1996; (suppl 13B): 36-42. 
36. Levit K, Cowan C, Braden B, Stiller J, Sensenig A, Lazenby H. National health 
expenditures in 1997: more slow growth. Health Aff (Millwood) 1998; 17(6):99-
110. 
37. Schwartz WB. The inevitable failure of current cost-containment strategies: why they 
can provide only temporary relief. JAMA 1987; 257: 22024. 
38. Greenberg PE, Almudena A, Birnbaum HG, Cremieux P, Lelorier J, Ouellette P, 
Slavin MB. Pharmacoeconomics and Health Policy. Current applications and 
Prospects for the Future. Pharmacoeconomics 1999;16 (5Pt1): 425-32 
39. Evans RG. Manufacturing Consensus, Marketing Truth: Guidelines for Economic 
Evaluation. Ann Intern Med 1995; 123 (1): 59-60. 
40. Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics, Second 
Edition: Introduction to Pharmacoeconomics. Harvey Whitney Books Company; 
Cincinnati, Ohio. 1991; 1: 5-8 
41. Revicki DA.  Relationship of Pharmacoeconomics and health related quality of life: 
In Spilker B. Quality of Life and Pharmacoeconomics in clinical trials. – 
Philadelphia: Lippincott-Raven; 1996; pp.1077. 
42. What is the Difference between Pharmacoeconomics and Outcomes Research? In 
Basskin LE. Practical Pharmacoeconomics: How to design, perform and analyse 
outcomes research. Advanstar Communications Inc. Ohio, 1998. pp.2-3  
43. Grossman JH. The outcomes movement and healthcare reform. Am J Health-Syst 
Pharm 1995; 52 (Suppl 3): S6 – 11. 
44. Gouveia WA, Chapman MA. The outcomes of patient care.  Am J Health-Syst Pharm 
1995; 52 (Suppl 3), S11 – 15. 
45. Marwick C. Pharmacoeconomics: is a drug worth its cost? JAMA 1994; 272:1395 . 
46. Task Force on Principles for Economic Analysis of Health Care Technology. 
Economic analysis of health care technology. A Report on Principles. Ann Intern 
Med 1995; 123(1): 61-70. 
47. Walley T, Haycox A. Pharmacoeconomics:basic concepts and terminology. Br J Clin 
Pharmacol 1997; 43:343-348. 
48. Lilas B. How to calculate indirect costs in economic evaluations. 
Pharmacoeconomics 1998; 13(1 Pt 1): 1-7. 
49. Minshall ME, Kody MC, Mosbacher F. Pharmacoeconomics Research Credibility: A 
Controversial and Recurring theme in Health Outcomes Research. Medical Care 
1999; 37 (4): AS12-19. 
50. Drummond MF, Brandt A, Luce B, Rovira J. Standardising economic evaluations in 
health care: practice, problems and potential. Int J Technol Assess Health Care 
1993; 9: 26-36 
51. Drummond MF. Issues in the conduct of economic evaluations of pharmaceutical 
products. Pharmacoeconomics 1994; 6: 405-11. 
52. Drummond MF. Guidelines for Pharmacoeconomic Studies: The ways Forward. 
Pharmacoeconomics 1994; 6 (6): 493-497.   
53. Revicki DA, Frank L. Pharmacoeconomic Evaluation in the Real World: 
Effectiveness versus Efficacy Studies. Pharmacoeconomics 1999; 15(5): 423-434.  
54. Genduso LA, Kotsanos JG. Review of health economic guidelines in the form of 
regulations, principles, policies, and positions. Drug Inf J 1996; 30: 1003-1016 
55. US Food and Drug Administration. Principles for the review of pharmacoeconomic 
promotion (draft). Food and Drug Administration, Rockville, MD, 1995. 
56. US Centers for Disease Control. A practical guide to prevention effectiveness: 
Decision and economic analysis. US Department of Health and Human Services, 
Centers for Disease Control (CDC), Atlanta, GA, 1995.  
57. Gold M, Siegel J, Russell L, Weinstein MC, eds. Cost-effectiveness in health and 
medicine. New York: Oxford University Press, 1996. 
58. PhRMA Task Force on the Economic Evaluation of Pharmaceuticals. Methodological 
and conduct principles for pharmacoeconomic research.. Pharmaceutical Research 
and Manufacturers of America, Washington, DC, January, 1995.  
59. Commonwealth Department of Health and Aged Care. Guidelines for the 
Pharmaceutical Industry on preparation of submissions to the Pharmaceutical 
Benefits Advisory Committee Including submissions involving economic analyses. 
Commonwealth of Australia, Canberra:, 1995.  
60. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 
Guidelines for the economic evaluation of pharmaceuticals. CCOHTA, Ottawa, 
1994.  
61. Ontario Ministry of Health. Ontario Guidelines for Economic Analysis of 
Pharmaceutical Products. Ontario Ministry of Health, Toronto, 1994. 
62. Glennie JL, Torrance GW, Baladi JF, Berka C, Hubbard E, Menon D, Otten N, 
Riviere M. The Revised Canadian guidelines for the economic evaluation of 
pharmaceuticals. Pharmacoeconomics 1999; 15 (5): 459-682. 
63. Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in 
pharmacoeconomics. PharmacoEconomics 1995; 7(1): 1-6.  
64. ABPI – Government Strategic Working Group. Guidelines on good practice in the 
conduct of economic evaluations of medicines. London, United Kingdom, May, 
1994.  
65. Singapore Ministry of Health. Statistics: Health Facts 2002. Government of the 
Republic of Singapore, Singapore, 2002. (http://app.moh.gov.sg/sta/sta01.asp). 
66. Chen R, Thong JL. Singapore Healthcare System: Success and Challenges into the                    
New Millennium: American Risk and Insurance Association, 2001 
(www.aria.org/1999program/singapore_healthcare.htm). 
67. World Health Organization: Countries 2001 Statistics. World Health Organization, 
Geneva, 2003. (http://www.who.int/country/en/) 
68. Commonwealth Department of Human Services and Health.  Casemix Development 
Program: Report on the Development of AN_DRG Version 3 Cost Weights. 
Commonwealth Department of Human Services and Health.  Canberra, Australia, 
1995. 
69. Siow JK. Casemix in Singapore – A Clinician’s Perspective. Ann Acad Med 
Singapore 2001 Jul;30(4 Suppl):1-2. 
70. LePen C, Berdeaux G. Diagnosis Related Group Costs in a Regulated environment A 
note About Their Economic Interpretation.  Pharmacoeconomics 2000; 17(2): 115-
120. 
71. Research and Policy Committee. Adopting market incentive in public sector policy: 
pp. 82-88. In: Committee for Economic Development, ed. Reforming Health Care: 
A Market Prescription. Committee for Economic Development, New York: 1987.  
72. Drummond MF. The Future of Pharmacoeconomics: Bridging Science and Practice. 
Clin Ther 1996; 18 (5):  969-78.  
73. Henry D, Lopert R. Pharmacoeconomics and Policy Decisions: The Australian Health 
Care System. Clin Ther 1999; 21 (5): 909-915. 
74. Greenberg PE, Arcelus A, Birnbaum H, Cremieux PY, LeLorier J, Ouellette P, Slavin 
MB. Pharmacoeconomics and Health Policy: Current Applications and Prospects 
for the Future. Pharmacoeconomics 1999; 16 (5 Pt1): 425-432. 
75. Langley PC. Pharmacoeconomics and the quality of decision-making by pharmacy 
and therapeutics committees. Am J Health-Syst Pharm. 1995; 52(Suppl3): S24-26. 
76. Hill SR, Mitchell AS and Henry DA. Problems with the Interpretation of 
Pharmacoeconomic Analyses: A review of Submissions to the Australian 
Pharmaceutical benefits Scheme. JAMA 2000; 283 (16): 2116-2121. 
77. SanchezLA. Pharmacoeconomics and Formulary Decision-making. 
Pharmacoeconomics 1996: 9 (suppl 1): 16-25.    
78. Franic D. Pharmacoeconomics of key importance in formulary decision-making.  
Pharmacoresources 1994; 15: 8. 
79. Sanchez LA. Expanding Pharmacists’ Role in Pharmacoeconomics: how and why? 
Pharmacoeconomics 1994; 5 (5): 67-75.  
80. Nash DB, Catalano ML, Wordell CJ. The formulary decision-making process in a US 
academic medical center. Pharmacoeconomics 1993; 3(1): 22-35. 
81. Kozma C, Reeder CE. Pharmacoeconomics: Where does it fit into Disease 
management? In “Disease Management Primer: A Review of the Principles of 
Disease Management”, Adis International, Auckland, New Zealand, pp.37-46. 
82. McCain J. System helps P&T Committees get pharmacoeconomic data they need. 
Manag Care, April 2001, 24C-J.  
83. Stergachis A, Sullivan S, Penna P. The application of pharmacoeconomics in 
managed health care settings.  In Bootman LJ, Townsend RJ and McGhan WF 
(eds.) Principles of Pharmacoeconomics. (2nd edition) Harvey Whitney Books, 
Cincinnati, 1996; pp. 243-256 
84. Jones AJ, Sanchez LA. Pharmacoeconomic evaluations: Applications in managed 
Health care formualry decision-making. Drug Benefit Trends 1995; 7:12-34. 
85. Lyles A. Managed Care Pharmacy, Socioeconomic Assessments and Drug Adoption 
Decisions. Soc Sci Med 1997; 45 (4): 511-21.   
86. Hatoum HT, Freeman RA. The use of pharmacoecopnomic data in formulary 
selection. Top Hosp Pharm Manage 1994; 13(4): 47-53. 
87. SanchezLA. Pharmacoeconomic principles and methods: including 
pharmacoeconomics into hospital pharmacy practice. Hosp Pharm 1994; 29 (11): 
1035-40 
88. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact 
analysis. Pharmacoeconomics 2001;19(6):609-21. 
89. Nash DB, Schrogie JR. Relationship between practice guidelines, formulary 
management and pharmacoeconomic studies. Top Hosp Pharm Manage 1994; 
13(4): 38-46. 
90. American Society of Hospital Pharmacists (ASHP). Practice Standards of ASHP 
1991-92. American Society of Hospital Pharmacists, Bethesda (MD), 1991. 
91. Lipman AG.A new formulary statement and formulary service. Hosp Formul 1983; 
18: 771. 
92. Ekedahl A, Petersson B, Eklund P, Rametsteiner G, Melander A. Prescribing patterns 
and drug costs: effects of formulary recommendations on community pharmacy 
campaigns. Int J Pharm Pract 1994; 2: 194-98. 
93. Shepherd MD, Falzman RD. The formulary decision-making process in a health 
maintenance organization setting. Pharmacoeconomics 1994; 5(1): 29-38. 
94. Harris JM Jr. Disease Management: Why Do It? In “Disease Management Primer: A 
Review of the Principles of Disease Management” Adis International, Auckland, 
New Zealand, pp: 9-14. 
95. Gouveia WA, Carmichael JM. Applying patient outcomes and pharmacoeconomics in 
patient care. Am J Health-Syst Pharm. 1995; 52(Suppl 3):S3-5 
96. Gouveia WA, Carmichael JM. The outcomes of patient care. Am J Health-Syst 
Pharm. 1995; 52(Suppl 3):S11-15 
97. Gouveia WA, Carmichael JM. Introduction to pharmacist participation in measuring 
and monitoring patients’ health-related quality of life. Am J Health-Syst Pharm. 
1995; 52(Suppl 3):S19-23 
98. Johnson JA, Bootman JL. Pharmacoeconomic analysis in formulary decisions: An 
international perspective. Am J Hosp Pharm. 1994; 51:2593-98 
99. Langley PC. The role of Pharmacoeconomic Guidelines for Formulary Approval: The 
Australian Experience. Clin Ther 1993; 15: 1154-76.  
100. Jacobs P, Bachynsky J, Baladi JF. A Comparative Review of Pharmacoeconomic 
Guidelines. Pharmacoeconomics 1995; 8(3): 182-189.  
101. Langley PC. The November 1995 Revised Australian Guidelines for the Economic 
Evaluation of Pharmaceuticals. Pharmacoeconomics 1996; 9(4): 341-352. 
102.  Grobler MP, Macarounas-Kirchmann K, Pearce GA, Stafford M. Industry 
comment on the 1995 revised Australian pharmacoeconomic guidelines. 
Pharmacoeconomics 1996; 9: 353-356.  
103. Mehl B, Santell JP. Projecting Future Drug Expenditures – 2000. Am J Health-Syst 
Pharm 2000; 57:129-138.  
104. Sheldon TA. Problems of using modelling in the economic evaluation of health 
care. Health Econ. 1996; 5: 1-11. 
105. Kassirer JP, Angell M. The journal’s policy on cost-effectiveness analysis. NEJM 
1994; 331: 660-670.  
106. Drummond MF, Jefferson TO. Guidelines for researchers and peer reviewers of 
economic submissions to the BMJ. BMJ 1996; 313: 275-283. 
107. Khan ZM, Miller DW. Modelling Economic Evaluation of Pharmaceuticals: 
Manipulation or Valuable Tool? Clin Ther 1999; 21 (5): 896-908.  
108. Langley PC. Meeting the Information Needs of Drug Purchasers: The Evolution of 
Formulary Submission Guidelines. Clin Ther 1999, 21 (4): 768-787. 
109. Baltussen R, Leidl R, Ament A. Real World Designs in Economic Evaluation: 
Bridging the Gap Between Clinical Research and Policy-Making. 
PharmacoEconomics 1999; 16 (5 Pt 1): 449-458. 
110. Hayes RD, Sherbourne CD, Bizzette SA. Pharmacoeconomics and quality of life 
research beyond randomised clinical trials. In Spilker B (ed). Quality of Life and 
Pharmacoeconomics in clinical trials. (second edition)  Lippincott-Raven; 
Philadelphia, 1996; pp. 155-58. 
111. Minshall ME, Kody MC, Mosbacher F. Pharmacoeconomics Research Credibility: 
A Controversial and Recurring theme in Health Outcomes Research. Medical Care 
1999; 37 (4): AS12-19. 
112. Freund DA. Initial Development of the Australian Guidelines. Medical Care 1996; 
34 (12): DS 211-215.  
113. Wade WE, Spruill WJ, Taylor AF, Longe RL, Hawkins DH. The Expanding role of 
Pharmacy and Therapeutics Committees: The 1990s and Beyond. 
Pharmacoeconomics 1996; 10(2): 123-28. 
114. Langley PC. Formulary Submission Guidelines for Blue Cross and Blue Shield of 
Colorado and Nevada: Structure, application and manufacturer responsibilities. 

































































 Dear Sir/Madam, 
 
Subject: Survey of pharmacists working in public hospitals in Singapore 
 
One of my post-graduate research students Ms.Anuja Nidumolu Roy (Pharmacy) 
is conducting a research project to study the scope and application potential of 
pharmacoeconomics in hospitals in Singapore, under my guidance at the National 
University of Singapore. 
  
The study methodology requires opinion of pharmacists working in different 
hospitals on issues addressed by the questions. The study is purely for academic 
purposes and has in no way any business interests associated with it. The co-
operation of each of you would help in the successful completion of the research 
project, thereby also leading to the attainment of a higher degree by Ms.Roy. In 
addition, it would also provide useful background information for policy makers to 
decide on training of pharmacists. 
 
It is in the aforesaid interests therefore, that I seek some of your valuable time to 
complete the questionnaire as soon as possible. If you need any clarification on 
the project, please do not hesitate to contact Ms.Roy on 8743120. All information 
provided by you will be treated confidentially. Any results, if published, will not 



























 Survey of hospital pharmacists in Singapore 
 
 






Name                                                                                Contact no.     
(For clarifications, if any) 
 
Age        <25  25-35  35-45    >45
       
 




Sex            Male €  Female € 
 
 
No. Of years in practice         <5 5-10  11-20  >20 
  
 
No. Of years since graduation       <5  5-10  11-20  >20 
 
 
Areas of practice  Outpatient    Purchase management 
                                                            
                                                             Clinical specialist     Other(s), please specify 
 
 
Previous area of practice (if applicable) 




Are you a member of the P&T committee of your institution? 
Yes       No    
 
 
Have you ever been a member of any P&T committee before? 
Yes       No    
 
          
                
               Questionnaire 
 
 
1) How many beds does your hospital have?                              
 
    <100     100-199     200-499     500-999     >999     No idea 
 
 
2) How would you classify your institution? 
 
Primary/Community hospital    Secondary Referral Hospital   
 
Tertiary Hospital      Specialist Hospital    
                  
 
3) Do you have any idea regarding the average annual expenditure on drugs 
in your institution?  
 
Yes       No    
 
  
4) Do you think the expenditure is too high?  
 




5) If your answer to Qs.4 is no, what would your answer be in the light of 
increasing proportion of ageing population and rising drug costs?  
 




6) Have you heard of the following terms? 
 
Supply Restriction     Yes     No    
 
Formulary Restriction   Yes     No    
 
Reference Pricing    Yes     No    
 
Prescription regulation/monitoring Yes     No    
                                                                                                        
(continued)      
 
DRG      Yes     No    
 
Fund holding     Yes     No     




7) Which of the following ways would you consider important in helping to 
control drug costs? Please rank them (if you have chosen more than one). 
 
Y  N    Rank 
 
 
• Formulary Restriction                       
     
• Prescription regulation/monitoring                       
  
 
• Reference pricing                          
  
 
• DRG                                        
  
• Fund Holding                                      
 
• Capitation                                       
  
• Supply Restriction                                     
  
 




8) Why would you recommend the aforementioned method? 
 
 Forces prescribers to adhere to authority guidelines 
   
 Forces prescribers to work within a limited /pre-assigned budget 
  
 A scientifically determined price 
 
 Confers responsibility on the fund-holder to manage funds more 
effectively 
 
 Limits choice of drugs  
 




9) Does your institution have a ‘formulary of drugs’ or a “drug list”?  
 
Yes       No      Cannot say    
 
 
10) In your opinion, a formulary (or a drug list) is  
 
 A list of the most essential drugs 
 
 A list of the most expensive drugs 
 
 A list of the most used drugs 
 
 A list of the cheapest alternatives 
 




11) In your opinion which of the following functions should an “ideal” 
formulary serve (maybe more than one)? 
 
 In subsidizing life-saving medicines 
 
 In promoting the use of the best drug or intervention 
 
 In restricting the use of drugs 
 
 In controlling the hospital budget 
 




12) Does your hospital formulary serve the aforementioned purpose(s) to 
your satisfaction?    
 `  




13) What reasons would you assign to your choice of answer to Qs.12? 
 
 The formulary is too open 
 
 It includes drugs solely on the basis of costs 
 
 It does not consider the quality of drugs included in it  
 
 Do not know how the decisions are made 




14) Who makes the final decisions with respect to inclusion/exclusion of drugs 
in the formulary? 
 
Hospital administration Medical specialist(s)   Pharmacy 
 




15) Do you know what factors are considered in the above approval process? 
 





16) Which of the following factors would you consider in the formulary 
decision-making process? Please rank them in order of importance.  
    
Y  N    Rank 
 
 
Effectiveness of the drug         €               €             -----    
 
Acquisition cost          €              €      ----- 
  
 
Available alternative          €               €      ----- 
                 
Politics            €               €            -----      
 
Pharmacy/Drug budget                            €               €            ----- 
                                                                                                   (continued)      
 
Hospital budget           €                €          -----         
 
Safety              €               €          -----     
 




17) If you were asked to use pharmacoeconomics to assist in formulary 
decision-making how confident are you 
 
Not confident     € 
 
Somewhat confident    € 
 
Very confident    € 
 











































































































No of responses 8
Respondent code: CGH 1 CGH 2 CGH 3 CGH 4 CGH 5 CGH 6 CGH 7 CGH 8
Parameters
25 25-35 35-45 45
Age 25 25-35 35-45 35-45 25 35-45 25-35 25-35 25% 38% 38% 0%
C O
Race C C C C C C C 100% 0%
M F
Sex F F M F F F F 14% 86%
5 5-10 11-20 20
No. of yrs. in practice 5 5 5-10 11-20 5 5-10 5 5 63% 25% 13% 0%
5 5-10 11-20 20
No. of yrs. Since graduation 5 5-10 5-10 11-20 5 11-20 5 5 50% 25% 25% 0%
OP IP *Cli* *Lab*
Area of practice OP Aseptic dispensin
IP,OP, 
Purchase OP OP Other IP IP 38% 25% 0% 0%
**Ret** Hosp** **Whole** O
Previous area of practice NA NA Retail Retail NA Retail NA NA 38% 0% 0% 0%
Y N
Member of the P&T committee N N N N N N N N 0% 100%
Y N
Any previous experience in the P&T N N N N N N N N 0% 100%
100 100-199 200-499 500-999
Knowledge about no. of beds 500-999 500-999 500-999 500-999 500-999 500-999 500-999 500-999 0% 0% 0% 100%
Primary Secondary Tertiary Specialist
Knowledge about type of institution Secondary Tertiary Secondary Specialist Tertiary Secondary Tertiary 0% 43% 43% 14%
*Y* *N*
Idea of Average annual drug 
expenditure N N N Y N N N N 13% 88% 100%
Y N Can't say
Whether exp. is too high Can't say N Can't say Can't say Can't say Y Can't say 14% 14% 71% 100%
Y N Can't say NA
Idea about annual exp. (too high/not) 
given the facts of ageing population and 
rising drug costs
Can't say Can't say NA 0% 0% 67% 33%
Acquaintance of the following terms;
*Y* *N*
Supply restriction Y N Y Y Y Y Y 86% 14% 100%
*Y* *N*
Formulary restriction N Y Y Y Y Y Y Y 88% 13% 100%
*Y* *N*
Reference pricing N N Y Y Y N N 43% 57% 100%
*Y* *N*
Prescription regulation/monitoring Y N Y Y Y Y Y Y 88% 13% 100%
*Y* *N*
DRG Y Y Y Y Y Y Y Y 100% 0% 100%
*Y* *N*
Fund holding N N N Y Y N N 29% 71% 100%
*Y* *N*
Capitation N N N N Y N Y N 25% 75% 100%
Which approach cosidered important 
for controlling drug costs
1 2 3 4
Formulary restriction 3 1 1 1 NR 2 1 57% 14% 14% 0%
1 2 3 4
Prescription regulation/monitoring 1 4 3 2 25% 25% 25% 25%
1 2 3 4
Reference pricing 2 5 3 0% 33% 33% 0%
















No of responses 13
Respondent code: KKH 1 KKH 2 KKH 3 KKH 4 KKH 5 KKH 6 KKH 7 KKH8 KKH9 KKH10 KKH11 KKH12 KKH13
Parameters
Age 25-35 35-45 25-35 25-35 25-35 25-35 35-45 25-35 45 25 25-35 25-35 25
Race C C C C C C C C C C C C C 
Sex F F F M F F F F M F M F F
No. of yrs. in practice 5 5 5 5 5-10 5 5 5 20 5 5-10 5 5
No. of yrs. Since graduation 5 5 5 5 5-10 5 11-20 5 20 5 11-20 5 5
Area of practice Info mgmt Cli Spe Cli Spe O(DIS) OP OP OP IP Purchase OP,IP Cli Spe IP OP
Previous area of practice O NA NA NA Retail NA Retail NA Wholesale Retail Retail
Member of the P&T committee N N N Y N N N N N N N N N
Any previous experience in the P&T Y N N Y Y N N N N N N N N
Knowledge about no. of beds 500-999 500-999 No Idea 500-999 500-999 500-999 500-999 500-999 >999 >999 500-999 500-999 No idea
Knowledge about type of institution Specialist Specialist Specialist Tertiary Specialist Specialist Specialist Specialist Specialist Specialist Specialist Specialist Specialist
Idea of Average annual drug 
expenditure Y N N Y N N N N Y N N N N
Whether exp. is too high Can't say Can't say Can't say Y Can't say Can't say Y Can't say N Can't say Can't say Can't say Can't say
Idea about annual exp. (too high/not) 
given the facts of ageing population and 
rising drug costs
Y Can't say NA Can't say Can't say NA Can't say Can't say Can't say Y N
Acquaintance of the following terms;
Supply restriction Y N Y N N N N Y Y N Y N N
Formulary restriction Y Y Y Y Y N N Y Y N Y Y Y
Reference pricing Y Y Y Y N N N N N Y Y N N
Prescription regulation/monitoring Y Y Y Y Y N N Y Y Y Y Y Y
DRG Y Y Y Y Y Y N Y Y Y Y Y Y
Fund holding N Y N N N N N N N N Y N N
Capitation Y Y N N N N N N Y N N Y Y
Which approach cosidered important 
for controlling drug costs
Formulary restriction 1 2 1 3 2 1 2 1 3 2 2 3
Prescription regulation/monitoring 1 3 2 3 1 2 1 4 2 1 1















No of responses 11
Respondent code: NUH 1 NUH 2 NUH 3 NUH 4 NUH 5 NUH 6 NUH 7 NUH 8 NUH 9 NUH 10 NUH 11
Parameters
25 25-35
Age 25-35 25-35 25-35 35-45 25-35 25 25-35 25-35 35-45 25-35 25-35 9% 73%
C O
Race C O C C C C C C C C C 91% 9%
M F
Sex F M F M F F F F M F F 27% 73%
5 5-10
No. of yrs. in practice 5 11-20 5 11-20 5 5 5 5-10 11-20 5-10 5 55% 18%
5 5-10
No. of yrs. Since graduation 5 11-20 5 20 5-10 5 5 5-10 11-20 5-10 5 45% 27%
OP IP
Area of practice IP Cli Spe IP OP CTU OP Cli Spe Purchase Cli Spe Lab OP 27% 18%
**Ret** Hosp**
Previous area of practice NA NA Retail O O NA NA Retail Retail Retail, IP NA 36% 0%
Y N
Member of the P&T committee N N N N N N N N N N N 0% 100%
Y N
Any previous experience in the P&T N Y N N N N N N Y N N 18% 82%
100 100-199
Knowledge about no. of beds 999 500-999 500-999 999 500-999 500-999 500-999 500-999 500-999 999 500-999 0% 0%
Primary Secondary
Knowledge about type of institution Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary 0% 0%
*Y* *N*
Idea of Average annual drug 
expenditure N N N Y N N N Y Y N N 27% 73%
Y N
Whether exp. is too high NA Y Can't say N Can't say Y Can't say N Can't say Can't say 20% 20%
Y N
Idea about annual exp. (too high/not) 
given the facts of ageing population and 
rising drug costs
Y NA N NA NA Can't say Y 29% 14%
Acquaintance of the following terms;
*Y* *N*
Supply restriction N N N N N Y Y N Y N Y 36% 64%
*Y* *N*
Formulary restriction Y Y Y N Y Y Y Y Y Y Y 91% 9%
*Y* *N*
Reference pricing N Y N N N Y N Y Y N N 36% 64%
*Y* *N*
Prescription regulation/monitoring N Y Y N N Y N N Y N Y 45% 55%
*Y* *N*
DRG Y Y Y Y Y Y Y Y Y Y Y 100% 0%
*Y* *N*
Fund holding N N N N N N N N N Y N 9% 91%
*Y* *N*
Capitation N Y N N N N N N Y Y N 27% 73%
Which approach cosidered important 
for controlling drug costs
1 2
Formulary restriction NR 2 NR 1 1 2 1 4 2 4 30% 30%
1 2
Prescription regulation/monitoring 1 NR 4 3 2 3 2 14% 29%
1 2

















No of responses 29
Respondent code: SGH 1 SGH 2 SGH 3 SGH 4 SGH 5 SGH 6 SGH 7 SGH 8 SGH 9 SGH 10 SGH 11 SGH 12 SGH 13 SGH 14 SGH 15
Parameters
Age 25-35 35-45 25-35 35-45 35-45 25-35 25-35 25-35 25-35 45 25-35 35-45 25-35 25 25-35
Race C C O C C C C C C C C C C C C
Sex F F M M F M F F M F F M F F F
No. of yrs. in practice 5-10 11-20 5-10 11-20 11-20 5-10 5 5 5-10 20 5 11-20 5 5 5
No. of yrs. Since graduation 5-10 11-20 5-10 11-20 11-20 5-10 5 5 5-10 20 5-10 11-20 5 5 5
Area of practice Lab OP IP Purchase OP OP, Cli Spe OP, Lab Hosp IP Ret IP OP OP OP OP
Previous area of practice O O Retail NA Retail NA NA NA NA Hosp pharmacy NA O NA O O
Member of the P&T committee N N N N N N N N N N N N N N N
Any previous experience in the P&T N N N Y N N N N N Y N N N N N
Knowledge about no. of beds 999 999 999 999 999 100-199 999 999 999 999 999 999 999 999
Knowledge about type of institution Tertiary Tertiary Tertiary Specialist Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary
Idea of Average annual drug 
expenditure N N N Y N N Y N N N N N N N N
Whether exp. is too high Can't say Y Can't say N Can't say Y Y Can't say Can't say Can't say Can't say N Can't say Can't say Can't say
Idea about annual exp. (too high/not) 
given the facts of ageing population and 
rising drug costs
Y NA Can't say Y NA NA NA Can't say NA Can't say Can't say Y Can't say NA Can't say
Acquaintance of the following terms;
Supply restriction N Y N Y Y Y Y N Y Y N Y Y Y Y
Formulary restriction Y Y Y Y N Y Y Y Y Y Y Y Y N N
Reference pricing Y N Y Y N N N N N N N Y N N N
Prescription regulation/monitoring N Y Y Y N Y Y N Y Y Y Y Y N Y
DRG Y Y N Y Y N Y Y Y N Y Y Y Y N
Fund holding N N N Y N N N N N Y N Y Y N N
Capitation Y Y N Y N N N N N N Y Y Y N N
Which approach cosidered important 
for controlling drug costs
Formulary restriction 1 1 1 3 1 1 1 NR 1 1 4
Prescription regulation/monitoring 2 3 2 3 3 NR 2 NR 3

















No of responses 9
Respondent code: TTSH 1 TTSH 2 TTSH 3 TTSH 4 TTSH 5 TTSH 6 TTSH 7 TTSH 8 TTSH 9
Parameters
25 25-35 35-45 45
Age 25-35 25 25 25 25-35 25-35 25 25-35 25-36 44% 44% 0% 0% 89%
C O
Race C C C C C C C C C 100% 0% 100%
M F
Sex F F F F F F F F F 0% 100% 100%
5 5-10 11-20 20
No. of yrs. in practice 5 5 5 5 5 5 5 5 5 100% 0% 0% 0% 100%
5 5-10 11-20 20
No. of yrs. Since graduation 5 5 5 5 5 5 5 5 5 100% 0% 0% 0% 100%
OP IP *Cli* *Lab* *Pur**
Area of practice IP Satellite OP OP OP OP Satellite Cli Spec Satellite 44% 11% 11% 0% 0%
**Ret** Hosp** **Whole** O NA
Previous area of practice Retail NA Retail NA NA NA NA NA NA 22% 0% 0% 0% 78%
Y N
Member of the P&T committee N N N N N N N N N 0% 100%
Y N
Any previous experience in the P&T N N N N N N N N N 0% 100%
100 100-199 200-499 500-999 999
Knowledge about no. of beds 999 999 500 - 999 999 999 999 999 No idea 0% 0% 0% 0% 75%
Primary Secondary Tertiary Specialist





ry referral Tertiary Tertiary Primary 11% 0% 67% 0% 78%
*Y* *N*
Idea of Average annual drug 
expenditure N N N Y N N N N N 11% 89% 100%
Y N Can't say
Whether exp. is too high Can't say Can't say N Can't say Can't say Can't say Can't say Can't say Can't say 0% 11% 89% 100%
Y N Can't say NA
Idea about annual exp. (too high/not) 
given the facts of ageing population and 
rising drug costs
Can't say N Y Can't say Can't say Can't say Y 29% 14% 57% 0% 100%
Acquaintance of the following terms;
*Y* *N*
Supply restriction Y Y Y Y Y N Y Y Y 89% 11% 100%
*Y* *N*
Formulary restriction Y Y Y Y Y Y Y Y Y 100% 0% 100%
*Y* *N*
Reference pricing N N N N N N N N N 0% 100% 100%
*Y* *N*
Prescription regulation/monitoring Y Y N N N N N N N 22% 78% 100%
*Y* *N*
DRG N Y Y N N N Y Y N 44% 56% 100%
*Y* *N*
Fund holding N N N N N N N N N 0% 100% 100%
*Y* *N*
Capitation N Y N Y N N N N N 22% 78% 100%
Which approach cosidered important 
for controlling drug costs
1 2 3 4 5
Formulary restriction 1 1 1 1 2 1 1 86% 14% 0% 0% 0%
1 2 3 4 5










No of responses 70
Respondent code:
Parameters
25 25-35 35-45 45
Age 17% 59% 20% 3% 99%
C O
Race 96% 3% 99%
M F
Sex 22% 78% 100%
5 5-10 11-20 20 5 = <5, 20= 
>20
No. of yrs. in practice 64% 16% 17% 3% 100%
5 5-10 11-20 20 5 = <5, 20= 
>20
No. of yrs. Since graduation 57% 19% 20% 4% 100%
OP IP *Cli* *Lab* *Pur** Others
Area of practice 39% 17% 14% 4% 7% 19% 100%
**Ret** Hosp** **Whole** O NA
Previous area of practice 29% 1% 1% 12% 56% 100%
Y N
Member of the P&T committee 1% 99%
Y N
Any previous experience in the P&T 11% 89%
100 100-199 200-499 500-999 999 No idea
Knowledge about no. of beds 0% 2% 0% 39% 47% 8% 95%
Primary Secondary Tertiary Specialist
Knowledge about type of institution 3% 5% 68% 22% 97%
*Y* *N*
Idea of Average annual drug 
expenditure 16% 84% 100%
Y N Can't say
Whether exp. is too high 15% 10% 74% 99%
Y N Can't say NA
Idea about annual exp. (too high/not) 
given the facts of ageing population and 
rising drug costs
18% 5% 44% 33% 100%
Acquaintance of the following terms;
*Y* *N*
Supply restriction 67% 33% 100%
*Y* *N*
Formulary restriction 84% 16% 100%
*Y* *N*
Reference pricing 36% 64% 100%
*Y* *N*
Prescription regulation/monitoring 61% 39% 100%
*Y* *N*
DRG 77% 23% 100%
*Y* *N*
Fund holding 19% 81% 100%
*Y* *N*
Capitation 27% 73% 100%
Which approach cosidered important 
for controlling drug costs
1 2 3 4 5 6 7 NR
Formulary restriction 57% 19% 10% 7% 0% 0% 0% 7% 100%
1 2 3 4 5 6 7 NR
Prescription regulation/monitoring 20% 34% 27% 12% 0% 0% 0% 7% 100%
1 2 3 4 5 6 7 NR
Reference pricing 25% 10% 30% 20% 10% 0% 0% 5% 100%
1 2 3 4 5 6 7 NR




















































SECTION 1 : 
  
Information about the Institution 
 
 
1) How many beds does your institution possess? 
  <100     100-199     200-499     500-999     >1000 
2) How big is the pharmacy budget of your institution? 
<10M     10-20M     21-30M     >30M 
3) How would you classify your institution? 
Primary/community Hospital     Secondary Referral Hospital     
Tertiary Referral Hospital      Specialist Hospital  
 
 
SECTION  2:  
 
Information about formulary in the institution  
 
1) Does your institution have a formulary of drugs?  
Yes/No  
2) If the answer to Qs.1 is yes, how long has the formulary been in existence? 
3) If the answer to Qs. 1 is no how does your institution decide on what drugs to 
stock in the pharmacy? 
4) In your opinion a formulary is:  
a) a list of the most essential drugs 
b) a list of the most expensive drugs 
c) a list of the most used drugs 
d) a list of the cheapest alternatives 
e) others, please specify 
 
5) In your opinion a formulary can serve which of the following functions 
(maybe more than one)  
a) in controlling the hospital budget  
b) in subsidizing life-saving medicines 
c) in promoting the use of the best drug or intervention  
d) In restricting the use of drugs  
e) To promote cost-effectiveness in drug treatment 
f) Any others please specify  
 
6) If your institution has a formulary, the proposal for inclusion of a new drug 
is made by: 
P&T Committee     Pharmacy administration   Medical Specialist     
Hospital Administration     Others please specify  
 
7) For the above proposal, the final decision is made by  
P&T Committee     Pharmacy     Medical Specialist     Hospital 
Administration  
Other, please specify  
 
8) In case it is made by the P&T Committee what is the membership of this 
committee? 
 
9) How often are these decisions made?   
 
10) In making the decision, what are the major factors being taken into 
consideration?  
Effectiveness of the drug    Acquisition cost   Available alternative    Politics   
Pharmacy Budget   Hospital budget  Others, please specify   
 
11) What do you think would be the impact of introduction of DRG case-mix 
funding on inclusion of drugs into the formulary?   
 
12) Do you consider the approach used in formulary decision in your institution 




13) Can you elaborate your reason for your choice of answer to Qs.12?  
 
14) Do you consider that the method used for formulary decision in your 
institution can achieve the aims of a formulary nominated in  Qs.5?    
Yes/ No  
 
15) Can you give reasons for your answer to Qs. 14?  
 
16) If your answer is no, what additional approach do you consider necessary to 
achieve those aims?  
 
17) Can you give reasons for your answer to Qs.16   
 
18) Why is your additional approach not implemented in your formulary 
decision process?  
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20.0% 19.4% 18.4% 17.3% 16.7%
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EVALUATION REPORT  
ON 
 
 BASILIXIMAB INJECTION  
FOR  








DR. LI SHU CHUEN  
B.Pharm, Cert. Health Econ.,Grad.Dip.Bus.(Tech Mgt), M.App.Sc.,MBA, PhD 
DEPARTMENT OF PHARMACY 







FOR SOLID ORGAN TRANSPLANT 
 
APPLICATION FOR INCLUSION IN NATIONAL UNIVERSITY HOSPITAL (NUH) 
DRUG LIST AS A NON STANDARD DRUG 
SEPTEMBER 2000 
 
Preamble: The purpose of this document is to evaluate the cost-effectiveness of basiliximab 
as compared to daclizumab as ant-rejection therapy in solid organ transplantation (see section 
on comparator).   
Although the indications applied for included renal transplant as well as liver transplant, the 
lack of information regarding liver transplant precludes any formal evaluation to be 
performed.  The evaluation will focus mainly on the comparative cost-effective of basiliximab 
and daclizumab as routine immunosuppression for renal allograft patients 
Comparator(s):  Daclizumab injection as per request from the NUH P & T Committee.  
However, in theory if the request is really an evaluation for inclusion as a non Standard Drug, 
then standard immunosuppressive therapy of cyclosporin and corticosteroids, with or without 
azathioprine would be the appropriate comparator. 
Part A. For Renal Allograft 
Clinical Summary:  The clinical evaluation was based on four large multi-centre randomized 
clinical trials, two of which compared basiliximab with standard therapy, and two compared 
daclizumab with standard therapy (Nashan et al, 1997; Kahan et al, 1999; Vincenti, et al. 
1998; Nashan et al, 1999). The trials by Nashan et al and Kahan et al compared basiliximab 
with standard double immunosuppressive therapy of cyclosporin and corticosteroids, while 
the trials by Nashan et al and Vincenti et al compared daclizumab with standard double 
immunosuppressive therapy of cyclosporin and corticosteroids, and triple immunosuppressive 
therapy that included cyclosporin and corticosteroid as well as azathioprine. 
The clinically relevant outcomes used in all trials included acute rejection during the 1st 6 
months after transplant, graft and patient survival at one year after transplant, safety and 
tolerability over 12 months. 
By pooling the data, it would appear that basiliximab and daclizumab when added to standard 
immunosuppressive therapy produced the same trend but different magnitude in all the 
important outcome indicators. The results of these trials were summarized in the following 
table.  However, the results should be interpreted with caution given the caveats associated 
















rejection (6 months) 
32.6% 47.3% -14.7%* 
 
25.1% 41% -15.9%* 
Steroid resistant  
rejection 
14.6% 26.2% -11.6%* 
 
7.9% 15.3% -7.4%* 
Patient survival (12 
months) 
96.1% 96.7% -0.6% 
 
98.5% 95.1% 3.4%*  
Graft survival (12 
months) 
91.2% 89.7% 1.5% 91.4% 86.6% 4.8% 
Any infection (12 
months) 
80.2% 79.9% 0.3% 69% 72% -3% 
Footnote: * denotes statistically significant  
 
Costs per course of treatment:  A course of basiliximab costs around S$5,922 to the 
hospital irrespective of patient body weight whereas the cost of daclizumab therapy would be 
between S$6,225 and S$9,337.50 for patient weight range from 50 –70 kg.  
Economic Summary: Depending the interpretation of the clinical data, the evaluation can 
take the approach of either a Cost-Minimization Analysis (i.e. assuming no clinical difference 
between basiliximab and daclizumab) or a Cost-Effectiveness Analysis (i.e. assuming there 
are clinical differences between the two drugs). 
CMA:  A course of basiliximab for any adult would cost S$5922 
A course of daclizumab for any adult would cost S$9337.50 (based on a body weight 
of between 55-70kg) 
CEA:  
Outcome Indicator Used ICER (Cost per extra outcome achieved) 
Biopsy-proven rejection (6 months) $ 284,625 
Steroid-resistant rejection Daclizumab is more costly & less 
effective. 
Patient survival (12 months) $83,637 
Graft survival (12 months) $103,500 
Any infection (12 months) Daclizumab is more costly & less 
effective. 
Recommendations: 
Based on the results from the CMA, basiliximab is the cheaper alternative that can achieve 
the same clinical outcomes as daclizumab. 
If it is decided to use the results from the CEA, the use of daclizumab over basiliximab is 
either inferior (more costly and less effective), or gives very high ICERs in all the clinical 
outcome indicators.  Therefore, it would appear that basiliximab is a reasonable alternative for 
daclizumab as an inductive immunosuppressive agent in combination with cyclosporin and 
corticosteroid.   
Other Issues to be considered: 
• Basiliximab is approved in Singapore for pediatric usage whereas daclizumab has not 
been approved for use in pediatric patients 
• Exact role and cost-effectiveness of basiliximab and daclizumab in immunosuppressant 
therapy needs to be further evaluated  
 
Part B.   For Liver Transplant  
 
Neither basiliximab, nor daclizumab, has yet been approved for use in liver transplantation in 
pediatrics and adults by Ministry of Health in Singapore.  
 
Evidence used in the Evaluation  
 
The main evidence for basiliximab was in the form of an abstract (Neuhaus et al, 1999).  It 
was a randomized, double blind, placebo-control, multicentre study carried out in US, Canada 
and Europe. The results from this trial showed that patients treated with basiliximab had 
better clinical outcomes as measured by percentage of patients with biopsy-confirmed acute 
rejection at 6 months, severe rejection at 6 months, and patent and graft survival at 12 months.  
 
Two studies were available for daclizumab in liver transplant (Eckhoff et al, 2000; Hirose et 
al, 2000). Hirose et al’s study was a case series reporting the use of daclizumab, while 
Eckhoff et al’s study was a retrospective evaluation of the use of daclizumab in 39 patients 
who had received daclizumab plus conventional immunosuppressants against 58 patients who 
did not receive daclizumab as case controls.  The results showed that patients treated with 
daclizumab experienced an improved clinical outcome of reduction in the incidence of acute 
rejection at 6 months (18% vs. 40%, p=0.02), and similar outcomes in terms of patient 
survival at one, three and six months after transplant. However, the first dose of daclizumab at 
2mg/kg was twice that used in renal transplant.  
 
The evaluator did not attempt to compare the clinical efficacy of basiliximab and 
daclizumab through the common comparator approach as for renal transplant due to: 
1.  It is problematic to compare the results of randomized clinical trial with that of 
non-randomized trial. 
2.  It is meaningless to compare the efficacy of the two drugs when it is unclear 




The first consideration is that basiliximab is not yet approved for the indication of 
liver transplant.  Coupled with the fact that very limited data on the long-term 
beneficial and adverse effects are available, it might not be appropriate to consider its 
inclusion as a non- standard drug in the formulary. 
 
However, from the scanty data available, it would appear that there was a trend in 
favor of patients treated with basiliximab.  Therefore, it would be advisable that the P 
& T Committee considers basiliximab to be used as an investigational drug for liver 















DETAILS OF DRUG AND ITS PROPOSED USE 
 
Pharmacological class and its action 
 
Basiliximab (Simulect) is a chimeric monoclonal antibody that binds with high affinity and 
specificity to the IL-2 receptor alpha chain on the surface of activated T-lymphocytes. This 
action competitively inhibits IL-2 mediated activation of lymphocytes, a critical pathway in 




Basiliximab is approved as part of the prophylactic immunosuppression regimen in renal 
transplant patients by the FDA. However, Basiliximab has not been approved for liver 
transplant patients. In the United States, daclizumab was introduced in December 1997 and 
basiliximab in May 1998.  
 
In Singapore, basiliximab has been approved for use in renal transplant in adult and pediatric 
patients.  Daclizumab has been approved for use in adult renal transplant patients only. 
 
The application is for the use of basiliximab as a non-standard drug for: 
(1) Prophylaxis against acute rejections in patients receiving renal transplantation when 
used as part of an immunosuppressive regimen that includes cyclosporin and 
corticosteroids, and  
(2) Prophylaxis against acute rejections in liver transplant patients. 
 
The applicants who wish Basiliximab to be incorporated in the hospital Non-standard Drug 






Adult Dosage – 1st dose of 20 mg is to be diluted to 50mL with normal saline or dextrose and 
administered intravenously over 20 to 30 minutes.  The first dose is to be given within 2 hours 
prior to surgery and 2nd dose is administered on day 4 of transplantation.  
Pediatric dose is 12mg/m2, not exceeding a maximum of 20mg. The dose is to be injected 
twice, first within 2 hours prior to transplantation and the second on day 4 of transplantation. 
 
For Daclizumab 
Adult dosage – 1mg/kg body weight to be added to 60 mL of normal saline and administered 
IV over 15 minutes.  The first dose should be administered within 24 hours prior to surgery 
and subsequent doses at 14 days intervals for a total of 5 doses.  The subsequent doses should 
be given within a day before or after the scheduled administration. 
 
Co-administered and substituted therapies 
 
Basiliximab is used as part of an inductive immunosuppressive regimen that includes other 
immunosuppressants such as cyclosporin (calcineurin Inhibitor) and corticosteroids.  
 Main comparator   
 
 In theory either standard treatment without basiliximab should have been the main 
comparator for a formal pharmacoeconomic evaluation for inclusion into formulary.  
 
Daclizumab is a chemical analogue of basiliximab that is recommended for the same 
indication. Hence, the P&T Committee feels that daclizumab and basiliximab are almost the 
same for all practical purposes; and therefore whichever can be substantiated to be more cost-
effective for the indication(s) applied for, is the one to be incorporated in the hospital non-
standard drug list.  
 
The task at hand, therefore, is to evaluate basiliximab and daclizumab to decide which one 
would be a more “cost-effective” alternative given the perspective of the P&T Committee. 
The goal of this evaluation is limited to a comparison of daclizumab and basiliximab.  
 
DATA FROM COMPARATIVE RANDOMISED TRIALS FOR MAIN INDICATION 
 
Description of Search Strategies 
 
Databases searched were MEDLINE, and CORE BIOMEDICAL COLLECTION, using the 
key words  ‘Basiliximab’, ‘Daclizumab’, ‘Immunosuppression’, ‘Renal transplantation’, 
‘Monoclonal antibodies’.   The bibliography sections of the literature provided by NUH were 
also searched for relevant articles. 
 
Besides the literature provided by the NUH, the literature search by the evaluator retrieved a 
few other relevant papers. However, no head to head trials comparing basiliximab with 
daclizumab were found.  
 
Listing of all References   
 
See Appendix 1. 
 
Part A.  For Renal Allograft Transplant 
 
Evidence used in the Evaluation 
 
Of these articles, the primary evidence used in this evaluation was the 4 clinical trials (two 
trials for basiliximab - Nashan et al, 1997; Kahan et al, 1999; and two trials for daclizumab – 
Vincenti, et al. 1998; Nashan et al, 1999). Another article by Ekberg et al (2000) that pooled 
the results of the two trials for daclizumab (Vincenti, et al. 1998; Nashan et al, 1999) was also 
used. 
 
Due to the lack of direct head-to-head clinical trial comparing basiliximab and daclizumab, 
the evaluation will adopt a common comparator approach.  That is, basiliximab is compared 










Quality of the Evidence 
 
The primary evidence used in this evaluation was summarized in the following table. 
  
Basiliximab Trials 
Trial Study Design Patient randomized Follow-up 
Nashan et al, 1997* randomized, db, pc, mc 380 (placebo-187; basiliximab-193) 12 months 
Kahan et al, 1999** randomized, db, pc, mc 348 (placebo-174; basiliximab-174) 12 months 
Daclizumab Trials 
Vincenti, et al 1998+ randomized, db, pc, mc 260 (placebo-134; daclizumab-126) 12 months 
Nashan et al, 1999++ randomized, db, pc, mc 275 (placebo–134; Daclizumab-141) 12 months 
Ekberg et al (2000) Pooling of above 2 trials 535 (placebo-268; daclizumab-267) 12 months 
Footnote: db - double-blind; pc - placebo controlled; mc – multicentre;  * multinational study - Europe 
(including Belgium, France, Germany, Norway, Switzerland, and United Kingdom) and Canada;  ** 
US study; + multinational study – Canada, US and Sweden; ++multinational study –Australia, Canada 
and Europe (Austria, Belgium, France, Germany, Italy, Sweden, and UK). 
 
All the trials were randomized and double-blinded. The number of withdrawals and number 
of dropouts were all accounted for.    The length of follow-up was reasonable for measuring 
anti-rejection therapy and the trials were large enough for the indication.  The dosage 
regimens used for basiliximab and daclizumab were as per manufacturers’ product 
information.  
 
All the trials used the proportion of patients who experienced at least one acute rejection 
episode (biopsy confirmed) during the first 6 months after transplantation, with follow-up 
data for graft and patient survival at 12 months as the primary outcome variables.  Safety and 
acute tolerability up to 12 months were also measured.   
 
The standard therapy used in all trials except Vicenti et al (1998) was cyclosporin and 
cortcosteroid.  The standard therapy used in the trial by Vicenti et al (1998) was cyclosporin, 
cortcosteroid and azathioprine.  These are all acceptable standard immunosuppressive 
therapies. 
 
Generally, baseline characteristics were well matched between the trial drug-treated and 
placebo groups. In addition, the age ranges and baseline characteristics of the patients were 
comparable between the basiliximab and daclizumab trials.  Appropriate statistical tests were 
used in all the trials. 
 
Overall, the trials used in the evaluation were all of high quality according to the hierarchy of 
clinical evidence. 
 
Summary of  Results of the Trials 
 
For the basiliximab trials, the results of the trials by Nashan et al (1997) and Kahan et al 
(1999) were summarized in the following tables. All the clinical outcomes were based on ITT 
analysis. 
Patient randomization and follow-up 
 
Patient randomized Patients for ITT analysis Patients followed for 12 months 















 Clinical Outcomes 
Nashan et al (1997) 
Outcome Indicators Basiliximab Group Placebo Group P value 
Any rejection episode (6 months) 34.2% 52.2% < 0.001 
Biopsy-confirmed rejection (6 months) 29.8% 44% 0.012 
Steroid resistant 1st rejection 10% 23.1% <0.001 
Graft survival (12 months) 86.6% 87.9% 0.591 
Patient survival  (12 months) 97.3% 95.3% 0.293 
Infection (any type) 84.7% 86.6% NS 
Kahan et al (1999) 
Any rejection episode (6 months) 37.6% 54.9% 0.001 
Biopsy-confirmed rejection (6 months) 35.3% 49.1% 0.009 
Steroid resistant rejection 25.4% 41.6% 0.001 
Graft survival (12 months) 94.6% 93% NS 
Patient survival  (12 months) 97.1% 96% NS 
Infection (any type) 12 months 75% 73% NS 
  
No clinically meaningful differences in the mean daily dose of cyclosporin were observed 
between treatment groups throughout both trials. Hence, basiliximab addition does not reduce 
the dose of cyclosporin needed.  There was a trend toward faster improvement in renal 
function in the basiliximab group.  
  
For the daclizumab trials, the results of the trials by Vincenti et al (1998) and Nashan et al 
(1999) were summarized in the following tables. All the clinical outcomes were based on ITT 
analysis. 
 
Patient randomization and follow-up 
 
Patient randomized Patients for ITT analysis Patients followed for 12 months 



























Any rejection episode 
(6 months) 
34% 50% 0.006 25% 39% 0.04 
Biopsy-proven 
rejection at 6month 
28% 47% 0.001 22% 35% 0.03 
Steroid-resistant 
rejection 
8% 16% 0.02 8% 14% 0.09 
Graft survival at 12 
month 
88% 83% 0.3 95% 90% NS 
Patient survival at 12 
month 
99% 94% 0.01 98% 96% 0.19 
Infections (any type) 74% 72% NS No significant difference reported 
 
The results from pooling the data of the above-mentioned two trials of daclizumab and using 
the number of patients randomized were shown in the following table. 
 







One or more biopsy-proven acute rejection at 6 months 25.1% 41% <0.001 
One or more biopsy-proven acute rejection at 1 year  27.7% 43.3% <0.001 
Steroid resistant  rejection 7.9% 15.3% 0.005 
1 year patient survival 98.5% 95.1% 0.022 (log-rank) 
1 year graft survival 91.4% 86.6% NS 
1 year incidence of any infection 69% 72% NA 
  
Comparison between basiliximab and daclizumab 
 
The objective of this evaluation is to compare the cost-effectiveness of basiliximab and 
daclizumab. Before any economic evaluation can be performed, it is necessary to decide on 
the relative clinical efficacy of the two drugs.  A common comparator approach via standard 
therapy was used in lieu of head-to-head trial. 
 
In order to make this comparison, the evaluator had pooled the data from the two basiliximab 
trials (Nashan et al, 1997; Kahan et al, 1999) to perform a meta-analysis (see Appendix 2) and 






N = 363 
Placebo 
Group 












rejection (6 months) 
32.6% 47.3% -14.7%* 
 
25.1% 41% -15.9%* 
Steroid resistant  
rejection 
14.6% 26.2% -11.6%* 
 
7.9% 15.3% -7.4%* 
Patient survival (12 
months) 
96.1% 96.7% -0.6% 
 
98.5% 95.1% 3.4%*  
Graft survival (12 
months) 
91.2% 89.7% 1.5% 91.4% 86.6% 4.8% 
Any infection (12 
months) 
80.2% 79.9% 0.3% 69% 72% -3% 
Footnote: * denotes statistically significant  
 
From this comparison, it would appear that basiliximab and daclizumab when added to 
standard immunosuppressive therapy produced the same trend in all the important outcome 
indicators.  In addition, the pooled results showed that daclizumab treatment had a statistically 
significant beneficial effect on patient survival at 12 months.   
 
In all the other outcome indicators, the results were in favor of treatment with basiliximab or 
daclizumab.  However, there were differences in the magnitude in these effects.  In general, 
the magnitude of improvement in all clinical outcomes with the exception of steroid-resistant 
rejection appears to favor daclizumab.   
 
Nevertheless, it must be stressed that given the caveats of inferring the difference between 
basiliximab and daclizumab through a common comparator, the significance of these findings 




Dependent on the interpretation of the clinical data, two approaches can be adopted for the 
economic evaluation. 
1. Taking a more conservation and cautious approach in interpretation, the evaluation 
can assume that there is no significant clinical difference between the two drugs.  
Hence, the economic evaluation would become one of Cost-Minimization Analysis. 
2. Taking a more literal interpretation of the results as shown above, the evaluation 
would assume that there is some clinical difference between the two drugs and a Cost 
Effectiveness Analysis is used. 
 
Approach 1 – Cost Minimization Analysis 
The major consideration will be the cost of drug acquisition.  
Cost of daclizumab per vial (25 mg/5ml)= S$622.50 
Cost of basiliximab per vial (20mg/5ml)= S$2961 
 
Hence, a course of basiliximab for any adult as per the price in Singapore would cost: 
 (2 x $2961.00) = S$5922 
This is based on 2 doses of 20mg basiliximab for any adult patient irrespective of body 
weight as per manufacturer’s product information.  
 
On the other hand, the cost per course of treatment with daclizumab will be dependent on the 
body weight of the patient.  Daclizumab is to be administered at a dose level of 1mg/kg body 
weight for a total of 5 doses over a 10-week period, the first dose being given within 24 hours 
prior to surgery and subsequent doses at intervals of 2 weeks.  
 
Body weight Number of vials required 
per dose 
Calculation Treatment cost of 
daclizumab 
50 kg 2  10 x $622.50 $6225.00 
55-75 kg 3  15 x $622.50 $9337.50 
80-100 kg 4  20 x $622.50 $12450.00 
 
Taking the weight of an average Asian to be in the range of 55-75 kg, the treatment cost of 
daclizumab will cost $9337.50. 
 
In addition, there would be other cost, albeit small as compared to the drug cost, for visits to 
the outpatient clinic for further doses of the drug.  
 
Approach 2 – Cost Effectiveness Analysis 
The evaluation is based on the data from the clinical trials, the costs per course of treatment of 
daclizumab using a body weight of between 55 and 75 kg, and a time frame of 12 months 
(therefore no discounting of future costs). The incremental analysis of using daclizumab 






Outcome Indicator Used Calculation ICER (Cost per extra 
outcome achieved) 
Biopsy-proven rejection (6 months) ($9337.50 - $5922)/(0.159 – 0.147) $ 284,625 
Steroid-resistant rejection  Daclizumab is more 
costly & less effective. 
Patient survival (12 months) ($9337.50 - $5922)/(0.034 – [-0.006]) $83,637 
Graft survival (12 months) ($9337.50 - $5922)/(0.048 – 0.015) $103,500 
Any infection (12 months)  Daclizumab is more 
costly & less effective. 
 
Definitely, these ICERs can vary depending on the body weight of the patient.  By using a 
body weight of 50 kg and 80-100 kg, the following results are obtained.  
 
Outcome Indicator Used ICER (Cost per extra 
outcome achieved) based 
on body wt of 50kg 
ICER (Cost per extra 
outcome achieved) based on 
body wt of 80-100 kg 
Biopsy-proven rejection (6 months) $25,250 $ 544,000 
Steroid-resistant rejection Daclizumab is more costly & 
less effective. 
Daclizumab is more costly & 
less effective. 
Patient survival (12 months) $5,825 $163,200 
Graft survival (12 months) $9,182 $197,818 
Any infection (12 months) Daclizumab is more costly & 
less effective. 
Daclizumab is more costly & 
less effective. 
 
Definitely, the cost of treating acute rejection should also be included in the costs.  However, 
based on the small difference between the two drugs in this clinical outcome, it is unlikely to 
alter the ICERs substantially except in patients whose body weight are 50 kg or less. 
 
Recommendations 
Based on the results from the CMA, basiliximab is the cheaper alternative that can achieve 
the same clinical outcomes.   
If it is decided to use the results from the CEA, the use of daclizumab over basiliximab is 
either inferior (more costly and less effective), or gives very high ICERs in all the clinical 
outcome indicators.  Therefore, it would appear that basiliximab is a reasonable alternative for 
daclizumab as an inductive immunosuppressive agent in combination with cyclosporin and 
corticosteroid. 
 
Other issues pertinent to this evaluation 
 
1. A significant proportion of renal transplant patients (30-50%) experiences acute 
rejection episodes. Indeed, it has been shown that the occurrence of an acute rejection 
episode correlates with a poor long-term outcome despite initial clinical evidence of 
therapeutic reversal.  Both basiliximab and daclizumab treatments resulted in a 
reduction in acute rejection at 6 months as shown by the clinical trials.  However, in 
the absence of conclusive evidence of long-term (12 months in this case) beneficial 
effects on graft survival as compared to standard therapy, it is unclear how well 
reduction in acute rejection corresponds to prevention of chronic rejection and 
ultimately to graft survival. 
2. If basiliximab or daclizumab are simply more potent immunosuppressants instead of 
being more specific, they may lead to an unacceptable increase in long-term 
complications like neoplasia. These agents may help in increasing choice, thereby 
enabling greater flexibility in prescription for the individual patient; however, the 
way they can be combined to obtain maximum efficacy and to keep side effects to a 
minimum is an issue.  
 
 
Part B.   For Liver Transplant  
 
Neither basiliximab, nor daclizumab, has been approved by the FDA for use in liver 
transplantation in pediatrics and adults.  Likewise, the indication is also not yet approved by 
Ministry of Health in Singapore.  
 
Evidence used in the Evaluation  
 
The main evidence for basiliximab was in the form of an abstract (Neuhaus et al, 1999).  It 
was a randomized, double-blind, placebo-control, multicentre study carried out in US, Canada 
and Europe.  The number of patients involved was large – 188 in the basiliximab treatment 
arm and 193 in the placebo arm.  Due the fact that it was presented in the abstract form with 
scanty detail, it is impossible for the evaluator to comment on the quality of the study. 
 
The results from this trial showed that patients treated with basiliximab had better clinical 
outcomes as measured by percentage of patients with biopsy-confirmed acute rejection at 6 
months, severe rejection at 6 months, and patent and graft survival at 12 months.  
 
Two studies were available for daclizumab in liver transplant (Eckhoff et al, 2000; Hirose et 
al, 2000). The study by Hirose et al (2000) was a pilot study carried out in the US that 
involved a total of 32 patients. In fact, the study was a case series reporting the use of 
daclizumab. 
 
The study by Eckhoff et al (2000) was a retrospective evaluation of the use of 
daclizumab in liver transplant in a US hospital. It compared the outcomes of 39 
patients who had received daclizumab plus conventional immunosuppressants against 
58 patients who did not receive daclizumab as case controls.  The results showed that 
patients treated with daclizumab experienced an improved clinical outcome of 
reduction in the incidence of acute rejection at 6 months (18% vs. 40%, p=0.02), and 
similar outcomes in terms of patient survival at one, three and six months after 
transplant. However, the first dose of daclizumab at 2mg/kg was twice that used in 
renal transplant.  
 
In this case, the evaluator did not attempt to compare the clinical efficacy of 
basiliximab and daclizumab through the common comparator approach as for renal 
transplant.  This decision was based on two factors.   
 
Firstly, the study design of the two studies for daclizumab renders them lower in the 
hierarchy of evidence as they were more prone to bias as compared to randomized 
clinical trial. It is problematic to compare the results of randomized clinical trial with 
that of non-randomized trial. 
 
Secondly, both basiliximab and daclizumab are not yet approved for the indication of 
liver transplant.  Therefore, there are no accepted recommended doses for the two 
drugs for this indication. It is meaningless to compare the efficacy of the two drugs 
when it is unclear whether the maximal doses of basiliximab and daclizumab were 




The first consideration is that basiliximab is not yet approved for the indication of 
liver transplant.  Coupled with the fact that very limited data on the long-term 
beneficial and adverse effects are available, it might not be appropriate to consider its 
inclusion as a non- standard drug in the formulary. 
 
However, from the scanty data available, it would appear that there was a trend in 
favor of patients treated with basiliximab.  Therefore, it would be advisable that the P 
& T Committee considers basiliximab to be used as an investigational drug for liver 
transplant at NUH. 
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Appendix 2.  Results of Meta-analysis of the basiliximab renal transplant trials 
based on the random effects model (Der Simonian & Liard Method) 
 
1.  Any rejection episode (6 months) 
                             Basiliximab         Placebo         Rate     95% CI 
Trial       Year     Obs   Tot      Obs   Tot       Diff            Lo             Hi   
----------------------------------------------------------------------------------------------------------------------------
----- 
Nasah et al   1997       65     190     97      186     -0.1794      -0.2779       -0.0809  
Kahan et al           1999                     65     173              95     173    -0.1734       -0.2769      -0.0699  
Pooled Rate Difference and 95% CI                                              -0.1766       -0.2479      -0.1052 
 
2. Biopsy-confirmed rejection episode (6 months) 
                             Basiliximab         Placebo         Rate    95% CI 
Trial       Year     Obs   Tot      Obs   Tot       Diff            Lo            Hi   
----------------------------------------------------------------------------------------------------------------------------
----- 
Nasah et al   1997       51     171     73      161     -0.1415      -0.2435      -0.0395 
Kahan et al          1999                     61      173             85       173    -0.1387       -0.2418     -0.0357  
Pooled Rate Difference and 95% CI                                              -0.1401       -0.2126     -0.0676 
 
3.  Steroid-resistant rejection episode (6 months) 
                             Basiliximab         Placebo         Rate    95% CI 
Trial       Year     Obs   Tot      Obs   Tot       Diff            Lo            Hi   
----------------------------------------------------------------------------------------------------------------------------
----- 
Nasah et al   1997       19     190     43      186     -0.1312       -0.2053      -0.0571  
Kahan et al          1999                      34    173              51       173    -0.0983       -0.1884      -0.0081  
Pooled Rate Difference and 95% CI                                              -0.1179        -0.1751     -0.0607 
 
4.  Graft Survival (12 months) 
                             Basiliximab        Placebo          Rate    95% CI 
Trial       Year     Obs   Tot      Obs   Tot       Diff            Lo            Hi   
----------------------------------------------------------------------------------------------------------------------------
---- 
Nasah et al   1997       167     190     161     186     0.0134      -0.0541       0.0808 
Kahan et al          1999                     164      173           161     173     0.0173      -0.0329       0.0676  
Pooled Rate Difference and 95% CI                                               0.0159      -0.0244       0.0562 
 
5.  Patient Survival (12 months) 
                             Basiliximab         Placebo         Rate    95% CI 
Trial       Year     Obs   Tot      Obs   Tot       Diff            Lo            Hi   
----------------------------------------------------------------------------------------------------------------------------
---- 
Nasah et al   1997       181   190     181     186     -0.0205     -0.0586       0.0176  
Kahan et al          1999                     168   173              166     173      0.0116      -0.0270      0.0501  
Pooled Rate Difference and 95% CI                                               -0.0046      -0.0360      0.0268 
 
6.  Infection 
                             Basiliximab          Placebo        Rate    95% CI 
Trial       Year     Obs   Tot      Obs   Tot       Diff            Lo            Hi   
----------------------------------------------------------------------------------------------------------------------------
----- 
Nasah et al   1997       161     190     161    186     -0.0182      -0.0891      0.0526  
Kahan et al          1999                     130      173           126    173      0.0231       -0.0693      0.1155  
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APPLICATION FOR INCLUSION IN NATIONAL UNIVERSITY HOSPITAL 




Preamble: The purpose of this document is to evaluate whether Gatifloxacin 
is a worthwhile addition to the hospital formulary. No specific indication has 
been applied for. Therefore with the broadest approach Gatifloxacin should be 
evaluated for all approved indications mentioned in the package insert. 
However, based on available literature and the company’s focus -- CAP has 
been evaluated as the primary focus. 
 
Comparator:  
Using the Antibiotic Guidelines 2000, framed by the Department of Medicine 
consultants as the basis for the normal treatment pattern for CAP at the NUH  
1. Penicillin G iv 2MU every 4 hourly in young, healthy lobar pneumonia  
2. Cefuroxime iv 750mg 8-hourly or Ceftriaxone iv 1g 12-hourly for all 
other varieties, except suspect severe or PCP or aspiration or immuno-
compromised pneumonia 
 
Clinical Summary: The primary evidence used in the evaluation was based 
on two phase III head-to-head clinical trials comparing gatifloxacin with 
ceftriaxone IV in hospitalized patients and oral gatifloxacin with oral 
clarithromycin in outpatients. The results were summarized in the following 
table. 
   
































6% -2.5% to 
17.6% 
2 Ramire










2% -4.2% to 
9.1% 
 
In the trial with hospitalized patients the number of days of hospitalization was 
also not statistically different.  
 
No statistical difference in ADRs between the treatments in both trials. 
 
In summary, both trials show that gatifloxacin is not statistically different (both 
in terms of clinical cure and in terms of bacteriologic eradication) from the 
other two regimens used in the trials.  
 
Costs per day of treatment: see CMA section of economic summary 
 
Economic Summary:  Depending on the interpretation of the clinical data, 
the evaluation can take approach of either a Cost Minimization Analysis or a 
Cost-Effectiveness Analysis. 
 
CMA: The daily cost of the individual antibiotic treatment  (as shown in the 
following table) will be the determining factor of the choice. 
 
Drugs Treatment Cost per Day 
Gatifloxacin IV (400mg once daily) $82.19 
Gatifloxacin oral (400mg once daily) $5.40 
Ceftriaxone IV (1gm 12 hourly) $5.26 
Clarithromycin oral (500mg b.d.) $6.34 
  













($ per extra 
patient cured) 
Scenario 1 
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1. Based on the available evidence used in this evaluation, there is no 
indication that Gatifloxacin offers staistically significant advantages 
over the other antibiotics in the treatment of either Community 
Acquired Pneumonia or the other indications.  
2. However, the results from the economic evaluation show that oral 
gatifloxacin 400 mg o.d. is a cost-effective alternative to clarithromycin 
500 mg b.i.d when used in the outpatient setting. 
3. Because of concerns that resistance among pneumococci will rapidly 
emerge after widespread use of this class of antibacterial agents, it 
might be prudent to reserve the drug for selected patients with 






























INCLUSION IN NATIONAL UNIVERSITY HOSPITAL (NUH) DRUG LIST AS 
A NON-STANDARD DRUG 
JANUARY 2001 
 
DETAILS OF THE PROPOSED DRUG AND ITS PROPOSED USE 
 
Pharmacological class and mode of action 
 
Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone 
antibacterial agent for oral or intravenous administration. The oral form is 
available as 200 mg or 400 mg tablets and the intravenous form is available 
as 200mg/20 ml or 400-mg/40ml single-use vials intended for dilution prior to 
administration. The antibacterial action of gatifloxacin results from inhibition of 
DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that 
is involved in the replication, transcription and repair of bacterial DNA. 
Topoisomerase IV is an enzyme known to play a key role in the partitioning of 
the chromosomal DNA during bacterial cell division.  
 
Spectrum 
Gatifloxacin is an extended-spectrum fluoroquinolone with improved gram-
positive and anaerobe coverage compared with older agents such as 
ciprofloxacin. It is slightly less active against enterobacteriaceae and 




Gatifloxacin is indicated in patients greater than 18 years of age for the 
treatment of the following infections when caused by susceptible bacteria: 
Community acquired pneumonia 
Acute bacterial exacerbation of chronic bronchitis 
Acute sinusitis 
Uncomplicated skin and skin structure infections 
Uncomplicated urinary tract infections (cystitis) 
Complicated urinary tract infections 
Pyelonephritis 
Uncomplicated urethral gonorrhea in males  
Endocervical and rectal gonorrhea in females. 
 
Since no specific indication has been applied for gatifloxacin. Therefore with 
the broadest approach gatifloxacin should be evaluated for all approved 
indications mentioned in the package insert.    
 
However, based on the references and the clinical literature (both 
comparative and non-comparative) presented by the company, a strong 
implication can be drawn that the gatifloxacin is intended to be promoted for 
use in community-acquired pneumonia. An independent literature search by 
the evaluator also revealed that most published trials of gatifloxacin were for 
community-acquired pneumonia. 
 In addition, according to the recommendations in the IDSA Guidelines, “newer 
respiratory quinolones” (of which gatifloxacin belongs) are recommended for 
the treatment of community-acquired pneumonia (CAP). 
 
Based on these considerations, it would be reasonably to evaluate 
gatifloxacin with community-acquired pneumonia  (CAP) as the main 
indication. Gatifloxacin will also be evaluated briefly for other indications at the 




For both the oral and the intravenous routes of administration gatifloxacin is 
recommended once every 24 hours. When switching from IV to oral dose 
administration no dosage adjustment is necessary. 
 
Co-administered and substituted therapies 
 
Depending on the condition being treated, co-administered therapies could 
include other antibacterials like cephalosporins or other beta-lactams or 
macrolides.   
 
Gatifloxacin is expected to substitute for the antibiotics most commonly 





The objective of this evaluation is to evaluate whether gatifloxacin is a cost-
effective alternative as compared to standard practice in treating CAP at the 
NUH.   Therefore the main comparator should be the antibiotic(s) used for 
treating CAP at NUH. 
 
Using the Antibiotic Guidelines 2000, framed by the Department of Medicine 
consultants as the basis for the normal treatment pattern for CAP at the NUH, 
the following antibiotics should be the main comparators un the evaluation: 
 
1. Penicillin G iv 2MU every 4 hourly In young, healthy lobar 
pneumonia  
2. Cefuroxime iv 750mg 8-hourly or Ceftriaxone iv 1g 12-hourly for all 
other varieties, except suspect severe or PCP or aspiration or immuno-
compromised pneumonia  
 
With regard to OPD treatment, it is assumed that NUH being a tertiary 
hospital, cases of pneumonia would not be referred to the hospital unless 
hospitalization is needed. However, there is a clinical trial conducted for 
outpatients, which, has been used for outpatient treatment evaluation though 
very few cases are treated as outpatients at the NUH.  
 
However, due to the unavailability of published clinical trails comparing 
gatifloxacin with Penicillin G or Cefuroxime in the treatment of community 
acquired pneumonia, the present evaluation is limited to evaluation of the 
cost-effectiveness of gatifloxacin with other antibiotics that are used in NUH, 
in this case ceftriaxone for inpatient treatment and clarithromycin for 
outpatient treatment (see Evidence used in the Evaluation Section). 
 
 
DATA FROM COMPARATIVE RANDOMIZED TRIALS FOR MAIN 
INDICATION 
 
Description of Search Strategies 
 
Databases searched included MEDLINE (via Ovid and Pub Med), EMBASE, 
and CORE BIOMEDICAL COLLECTION using the keywords ‘gatifloxacin’ and 
‘clinical trial’ and their combination.  The bibliography sections provided by the 
NUH were also searched for relevant articles. Besides the literature provided 
by the NUH, the literature search by the evaluator retrieved a few other 
relevant papers (See Appendix 1).  However, the evaluator could not locate 
any published clinical trials comparing gatifloxacin with Penicillin G or 
Cefuroxime.   
 
Listing of all References 
 
See Appendix 1.  
 
Evidence used in the evaluation 
 
The search revealed three direct head-to-head phase III trials one comparing 
Gatifloxacin to standard treatment of ceftriaxone/clarithromycin (Fogarty et al, 
1999) one to oral clarithromycin (Ramirez et al, 1999), and the other to 
levofloxacin (Sullivan et al, 1999).   
 
The primary evidence used in the evaluation was however, based on two 
clinical trials comparing gatifloxacin with ceftriaxone/clarithromycin in 
hospitalized patients and gatifloxacin with clarithromycin in outpatients 
(Fogarty et al, 1999; Ramirez et al, 1999) This is because levofloxacin is not 
used in NUH. 
 
Quality of the Evidence 
 
Both trials were randomized, double-blinded, prospective and comparative 
and as such would rate very high in the hierarchy of evidence.  
 
The primary endpoint used was clinical cure rate. The term ‘clinical cure’ was 
unambiguously defined. The secondary efficacy assessment in both the 
studies assessed microbiologic responses in the microbiologically evaluable 
population. “Microbiologically evaluable” patients were clearly defined and the 
term ‘eradicated’ was precisely explained.  
 Adverse drug reactions were monitored in both trials as a measure of safety 
of the treatments. 
 
Generally baseline characteristics were well matched between the two drug-
treated groups in the trial. The most common reason for being considered 
clinically unevaluable was inadequate duration of therapy. Inclusion-exclusion 
criteria were clearly defined and stated unambiguously. However, the basis 
used for sample size calculation was not specified. 
 
A summary of the two trails is listed as follows. 
 








Fogarty C et al* 
 
Pros, ran, 
db, mc,  
283 205 7-14 days 
Ramirez J A ** Pros, ran, 
db, mc 
432 372 7-14 days 
* 
1Fogarty C et al , Treating Community-Acquired Pneumonia in Hospitalized Patients: Gatifloxacin vs. 
Ceftriaxone/Clarithromycin; J Respir Dis. 1999;20(11, suppl):S60-69 
** 2 Ramirez JA et al, Treating Community-Acquired Pneumonia in Hospitalized Patients: Gatifloxacin vs. 
Ceftriaxone/Clarithromycin; J Respir Dis. 1999;20(11, suppl):S40-48 
 
Results of the Trials 
 




All patients in the gatifloxacin arm received 400 mg IV +/- transition to 400 mg 
of gatifloxacin PO qd.  
 
In the ceftriaxone treatment group 96 patients received 1 g IV qd and 45 
received 2 g qd  (NB. The regimens used is slightly different from that 
recommended in the Antibiotics Guidelines at NUH.  The Guidelines 
recommend cefotriaxone to be used 1g bd). In addition, 56 ceftriaxone 
patients received concomitant intravenous erythromycin.  
 
Overall 85 received step down therapy to gatifloxacin, 400 mg qd, or 
clarithromycin, 500 mg bid. The median duration of therapy was 3 days in 
both treatment groups. 22 patients (12 in the gatifloxacin group and 10 in the 
ceftriaxone group) received more than 14 days of therapy.  
 
Summary of the Results of the Trial 
 
Clinical response, clinically evaluable patients 
                                         Number of patients (%) 
                                                                                
  Cure rate                                             Gatifloxacin                                            Ceftriaxone  
                                                                 (n=99)                                                      (n=106) 
  Total                                                   96/99 (97%)                                            96/106 (91%) 
  Severe pneumonia                              68/71 (96%)                                            72/80 (90%) 
  Mild to moderate pneumonia             28/28 (100%)                                          24/26 (92%) 
 
The cure rate among clinically evaluable patients was 97% for gatifloxacin 
and 91% for ceftriaxone (p=NS, 95% confidence interval, -2.5% to 17.6%).  
 
Overall bacteriologic eradication rates in microbiologically evaluable patients 
were 97% for gatifloxacin-treated patients and 92% for ceftriaxone-treated 
patients (not statistically significant).  
 
Safety and Tolerability 
 
The numbers of patients withdrawn from treatments due to ADRs were 
comparable between the two treatment arms, with 12 from ceftriaxone arm 
and 11 from the gatifloxacin arm.   
 
In addition, it was reported in the article that both the severity and frequency 
of ADRs were substantially comparable between the two treatment arms.  
 
 




All patients in the gatifloxacin arm received 400 mg oral gatifloxacin once 
daily. In the other group all patients received 500 mg oral clarithromycin twice 
daily. The median duration of therapy was 11days in both treatment groups. 
However, the modal value was 14 days, which means, most patients received 
therapy for 14 days. 
 
Summary of the Results of the Trial 
 
Clinical response, clinically evaluable patients 
                                                                               Number of patients (%)      
  Cure rate                                           Gatifloxacin                                            Clarithromycin 
                                                             (n=184)                                                      (n=188) 
  Total                                                   175/184(95%)                                         175/188 
(93%) 
  Severe pneumonia                              92%                                                         89% 
 
The cure rate among clinically evaluable patients was 95% for gatifloxacin 
and 93% for clarithromycin (p= NS, 95% confidence interval, -4.2% to 9.1%). 
Overall bacteriologic eradication rates in microbiologically evaluable patients 
were 98% for gatifloxacin-treated patients and 93% for clarithromycin-treated 
patients (not statistically significant).  
 There was no mention of any reduced incidence of hospitalization in the 
gatifloxacin treated group in the trial.  
 
Safety and Tolerability 
 
Adverse drug events and abnormal laboratory results led to discontinuation of 





Interpretation of Results from the Evidence 
 
Thus both the trials show that gatifloxacin is not any significantly different 
(both in terms of clinical cure and in terms of bacteriologic eradication) from 
the other two regimens used in the trials. In the trial with hospitalized patients 
the number of days of hospitalization was also not statistically different.  
 
[However, it should be noted that in another study of 212 patients CAP 
patients treated with gatifloxacin spent less time in the hospital and ICU than 
ceftriaxone +/- erythromycin group but not significantly so.3   Unfortunately, this 
was published only in the abstract form that makes the evaluation of the data 




Dependent on the interpretation of the clinical data, two approaches can be 
adopted for the economic evaluation.  
 
1. Based on the data as mentioned in the previous sections, the 
evaluation can assume that there is no statistically significant 
difference in clinical outcomes between the two drugs.  
 
In this case, it would be appropriate to conduct a cost-minimization 
analysis and whichever regimen would entail lesser costs, would be 
the better option for the NUH formulary listing. 
 
The duration of treatment in hospitalized patients ranges from a 
median of three days to a maximum duration of fourteen days for both 
Gatifloxacin and Ceftriaxone groups; and for OPD patients the duration 
of treatment ranges from a median of eleven days to a maximum of 
fourteen days for both Gatifloxacin and Clarithromycin groups.  
 
Thus there is no difference in duration of treatment between the two 
groups that therefore makes the Per Day Cost of Treatment more 
relevant -- both for hospitalized as well as OPD cases.     
 
2. Another approach is to assume that although the analysis of the data of 
the clinical trials did not show statistical significant difference, there is 
some clinical difference between the two drugs and a cost-
effectiveness analysis is conducted. 
 
 
Approach 1  
 
Costs incurred for treating a typical hospitalized patient at the NUH  
                                   
Condition  Treatment 
used 
Cost/day  







(including WFI @ $0.10 










 Penicillin iv 
2MU 4 hourly 
$0.57/MU  
6 




750 mg 8 
hourly 
$6/ 750 mg  
3 





1g 12 hourly 
$2.45/1g  
2 













The above table on an average assumes that there are only reconstitution 
costs over normal acquisition cost. However, there is also the cost of 
administration with a compatible intravenous solution, especially with 
gatifloxacin as it cannot be given as a bolus i.v injection.  
 
Costs incurred for treating a typical OPD patient at the NUH 
 
Drug Dosage Acquisition Cost Cost per day of 
treatment 
Clarithromycin 500mg b.d. $3.17/tablet $6.34 





Cost Effectiveness Analysis: for treating CAP in hospitalized patients 
 
Scenario 1:  3 days IV + 4 days oral 
The evaluation is based on the data form the clinical trials, the cost per course 
of treatment of Gatifloxacin and Ceftriaxone using the assumption that the 
median duration of IV therapy is 3 days in both treatment groups followed by 4 
days of oral therapy (based on total duration of therapy being between 7 – 14 
days). In the Ceftriaxone group it is assumed that only Ceftriaxone is used 
without the addition of erythromycin.  
The step-down therapies are: 
 Gatifloxacin group – 400mg oral Gatifloxacin o.d. 
 Ceftriaxone group – 500 mg oral Clarithromycin b.d.  
 
Based on these assumptions, the Incremental Cost-Effectiveness Ratio of 
gatifloxacin as compared against ceftriaxone is calculated as follows: 
 
($268.17 - $47.18) / 6% = $3,683/extra patient with clinical cure 
 
However, by testing the robustness in the sensitivity analysis by using the 
95%CI of the clinical cure, the ICER can be as follows: 
 
Difference in outcome Calculation ICER (cost per extra 
outcome achieved) 
-2.5 % ($268.17 - $47.18) / -2.5% Gatifloxacin is less 
effective and more costly 
17.6% ($268.17 - $47.18) / 17.6% $1,255 
 
Scenario 2: 3 days IV + 11 days oral 
The evaluation is based on the data form the clinical trials the assumption that 
the duration of IV therapy is 3 days in both treatment groups followed by 11 
days of oral therapy (based on total duration of therapy being between 7 – 14 
days). The other assumptions are the same as in Scenario 1.  
 
Based on these assumptions, the Incremental Cost-Effectiveness Ratio of 
gatifloxacin as compared against ceftriaxone is calculated as follows: 
 
($305.97 - $103.78) / 6% = $3,370/extra patient with clinical cure 
 




Calculation ICER (cost per extra 
outcome achieved) 
-2.5% ($305.97 - $103.78) / 
-2.5% 
Gatifloxacin is less 
effective and more costly 
17.6% ($305.97 - $103.78) / 17.6% $1,149 
 
Scenario 3: 7 days IV + 7 days oral 
The evaluation is based on the assumption that the duration of IV therapy is 7 
days in both treatment groups followed by 7 days of oral therapy (based on 
total duration of therapy being between 7 – 14 days). The other assumptions 
are the same as in Scenario 1.  
 
Based on these assumptions, the Incremental Cost-Effectiveness Ratio of 
gatifloxacin as compared against ceftriaxone is calculated as follows: 
 
($613.20 - $92.82) / 6% = $8,673/extra patient with clinical cure 
 
Again, in the sensitivity analysis, the ICERs can range as follows: 
 
Difference in outcome Calculation ICER (cost per extra 
outcome achieved) 
-2.5% ($613.20 - $92.82) / -2.5% Gatifloxacin is less 
effective and more costly 
17.6% ($613.20 - $92.82) / 17.6% $2,957 
 
 
Cost Effectiveness Analysis: for treating CAP in outpatient 
 
Senario 1:  14 days 
The evaluation is based on the data from the clinical trials, the cost per course 
of treatment of Gatifloxacin and Clarithromycin using the assumption that 
more than 90% of the patients in both treatment arms received 7 – 14 days of 
therapy – median being 11 days and mode being 14 days. Therefore, most 
patients received treatment for 14 days.  
 
Based on these assumptions, the Incremental Cost-Effectiveness Ratio 
(ICER) of gatifloxacin as compared against clarithromycin is calculated as 
follows: 
 
($75.6 - $88.76) / 2%  
 
This means that gatifloxacin is dominant over clarithromycin (less costly and 
more effective). 
 
In the sensitivity analysis, the ICERs can range as follows: 
 
Difference in outcome Calculation ICER (cost per extra 
outcome achieved) 
-4.2% ($75.6 - $88.76) / -4.2% Gatifloxacin is less 
effective but also less 
costly 
9.1% ($75.6 - $88.76) / 9.1% Gatifloxacin is dominant 
 
Senario 2:  11 days 
The evaluation is based on the assumption that more than 90% of the patients 
in both treatment arms received 7 – 14 days of therapy – median being 11 
days and mode being 14 days. The other assumptions are the same as in 
Scenario 1.  
 
Based on these assumptions, the Incremental Cost-Effectiveness Ratio 
(ICER) of gatifloxacin as compared against clarithromycin is calculated as 
follows: 
 
($59.40 - $67.87) / 2%  
 
Again, the ICER will show that gatifloxacin is dominant over clarithromycin. 
 
In the sensitivity analysis, the ICERs can range as follows: 
  
Difference in outcome Calculation ICER (cost per extra 
outcome achieved) 
-4.2% ($59.40 - $69.74) / -4.2% Gatifloxacin is less 
effective but also less 
costly 
9.1% ($59.40 - $69.74) / 9.1% Gatifloxacin is dominant 
 
 
Scenario 3:  7 days 
The evaluation is based on the assumption the patients the minimum duration 
of treatment of 7 days. The other assumptions are the same as in Scenario 1.  
 
Based on these assumptions, the Incremental Cost-Effectiveness Ratio 
(ICER) of gatifloxacin as compared against clarithromycin is calculated as 
follows: 
 
($37.8 - $43.19)/ 2%  
 
Again, the ICER will show that gatifloxacin is dominant over clarithromycin. 
 
In the sensitivity analysis, the ICERs can range as follows: 
 
Difference in outcome Calculation ICER (cost per extra 
outcome achieved) 
-4.2% ($37.8 - $44.38) / -4.2% Gatifloxacin is less 
effective but also less 
costly 




Issues pertinent to current evaluation  
 
The recommendation by the company to use gatifloxacin is based on the 
premise that resistance in respiratory pathogens to commonly used 
antimicrobial agents (specifically pneumococcal resistance to penicillin) is on 
the rise.  
 
However, the evaluator believes that the decision-makers should consider the 
following issues before making any decision.  
 
1. Importance of ascertaining how significant this resistance is with 
respect to the clinical condition  
It is well established that antimicrobial resistance is strongly correlated to 
the pattern of antibiotic usage and the particular geographical location.  
For instance, important differences exist between the susceptibility 
patterns of some respiratory tract pathogens to commonly used 
antimicrobial agents between the US and Canada with the Canadian 
strains being more susceptible to currently available agents.4 There is data 
to suggest that most pneumonia caused by isolates defined as not fully 
susceptible to penicillin should respond well to treatment with a beta-
lactam antibiotic using optimal dosing, although treatment failures may 
occur at higher levels of resistance. In addition, resistance to penicillin in 
otitis media may not mean resistance in CAP. Therefore to know what 
susceptibility pattern exists in the hospital is very important to rationalize 
the use of antibiotics better. 
 
2. Interpretation of the IDSA Guidelines 
 
The company seems to be also trying to ‘sell’ the mention of 
fluoroquinolones in the IDSA Guidelines. It is true that the IDSA Guidelines 
recommend fluoroquinolones for empiric therapy of CAP but with the clear 
messages that where indicated, etiologic pathogen directed therapy is 
preferable and a narrow spectrum over a broad spectrum is better when 
the etiology is understood.  Amongst reasons assigned for the need to 
establish etiologic diagnosis prevention of antibiotic abuse and reduction 
of antibiotic expense have explicit mention. In the event of etiologic 
diagnosis having been established or strongly suspected pathogen-
specific treatment is recommended. If it is available later then changing to 
the antimicrobial agent that is most cost-effective, least toxic and most 
narrow in spectrum is encouraged.  
 
3. Issue of safety 
 
A few quinolones have either been withdrawn from the markets or their 
licenses suspended in view of the drug related adverse effects 7. 
Therefore it would be advisable to proceed slowly when adopting another 
new member of the same class.  
 
4. The concern of increasing the chances of resistance and 
unnecessarily pushing up the hospital drug costs 
 
In the absence of a real ‘clinical necessity’ or situation demanding the use 
of this particular drug if gatifloxacin is approved without restriction to either 
indication or specialty then chances are, it would be used even for indications 
where say, ciprofloxacin would suffice. The IDSAGuidelines clearly state that 
resistance patterns of S. pneumoniae (the most commonly implicated etiologic 
agent) should be just one of a gamut of factors guiding empirical antibiotic 
selection. There is also a clear mention of recent reports indicating increasing 
resistance to fluoroquinolones in selective locations correlating with excessive 




Acute exacerbations of chronic bronchitis 
 
An analysis of data from a subset of 211 North American patients who had 
participated in a randomized, double-blind, multicenter trial showed 89% 
(76/85) patients achieved clinical cure with gatifloxacin 400 mg/d as against 
77% (62/81) patients receiving cefuroxime axetil 250 mg bd (p=0.01). 
Treatment was administered 7-10 days. When the entire study population was 
taken clinical cure rates were 86% and 83% in the gatifloxacin and cefuroxime 
groups.8,9   It is unclear from the article whether this difference is statistically 





A randomized, double blind, multicenter trial of adults with acute infection of 
the maxillary sinuses, compared the safety and efficacy of gatifloxacin (400 
mg once a day for 10 days) to clarithromycin (500 mg twice daily for 14 days). 
10
 Inclusion exclusion criteria were clearly specified and the terms ‘clinical 
success’ or failures were defined. Blinding and method of randomization were 
described. Follow-up for reporting of adverse events was done for 30 days 
post-treatment. The basis of sample size calculation was mentioned clearly. 
Of a total of 421 patients 133 from the gatifloxacin group and 144 from the 
clarithromycin group were clinically evaluable. At the test-of-cure assessment, 
93% (124 of 133) of patients treated with gatifloxacin and 90% (129 of 144) of 
the patients treated with clarithromycin had a response defined as clinical 
success. Therefore a 10-day course of gatifloxacin 400 mg once daily was as 
effective as a 14-day course of clarithromycin 500 mg twice daily, in 
outpatients with acute, uncomplicated maxillary sinusitis. This would mean 
that one which works out to be cheaper for the course of therapy should be 
the drug of choice.    
 
An open-label multicenter non-comparative study to evaluate the safety and 
efficacy of gatifloxacin in acute sinusitis revealed an overall clinical efficacy of 
95%.11 However the unblind and non-comparative nature of the study make 
conclusive comparison with other antibiotic treatments difficult . 
 
 
Urinary tract infection 
 
Pooled analysis of data from two double blind trials that enrolled 728 patients 
with complicated urinary tract infections (85%) and pyelonephritis (15%) 
showed positive clinical responses occurring in 93% of patients treated with 
gatifloxacin 400 mg, vs. 91% of those treated with ciprofloxacin 500 mg twice 
daily (each given for 7-10 days), respective bacterial eradication rates were 




Uncomplicated Gonococcal Infections 
 
The efficacy of single doses of gatifloxacin (400 or 600 mg) or ofloxacin 400 
mg in 728 patients with uncomplicated gonococcal infections was investigated 
in a randomized, double blind trial. 13 Bacterial eradication rates in men with 
urethral gonorrhoea were 99, 100 and 100% with gatifloxacin 400mg, 
gatifloxacin 600mg and ofloxacin 400mg respectively; in women with 
endocervical gonorrhoea, bacterial eradication rates were 99, 99 and 
100%(not statistically significant). 
 
Skin and soft tissue infections 
 
Gatifloxacin 400 mg/day for 7 to 10 days showed clinical and bacteriological 
efficacy similar to that of 7 to 10 days’ treatment with levofloxacin 500 mg/day 
in 407 patients with uncomplicated skin and soft tissue infections in a 
randomized, double blind trial. 14 
Clinical cure rates were 91% in the gatifloxacin group and 84% in the 
levofloxacin group (not statistically significant).  
 
 
It should be emphasized that most of the trials were reported only as 
abstracts. Therefore limited details of these trials are available as 






1. Based on the available evidence used in this evaluation, there is no 
indication that Gatifloxacin offers staistically significant advantages 
over the other antibiotics in the treatment of either Community 
Acquired Pneumonia or the other indications.  
2. However, the results from the economic evaluation show that oral 
gatifloxacin is a cost-effective alternative to clarithromycin in the 
outpatient setting. 
3. Because of concerns that resistance among pneumococci will 
rapidly emerge after widespread use of this class of antibacterial 
agents, it might be prudent to reserve the drug for selected patients 
with Community Acquired Pneumonia.  
Appendix 1 
 
Listing of all references used in the current evaluation 
 
References provided by the NUH except for those marked *  
 
1. Fogarty C et al, Treating Community-Acquired Pneumonia in 
Hospitalized Patients: Gatifloxacin vs. Ceftriaxone/Clarithromycin; J 
Respir Dis. 1999; 20(11, suppl): S60-69 
 
2. Ramirez JA et al, Treating Community-Acquired Pneumonia in 
Hospitalized Patients: Gatifloxacin vs. Ceftriaxone/Clarithromycin; J 
Respir Dis. 1999; 20(11, suppl): S40-48 
 
3. Gallagher KM et al, Abbreviated Length of Stay in Hospitalized 
Patients With Community Acquired Pneumonia Treated With 
Gatifloxacin; 39th ICAAC, September 26-29, 1999. Abstract#2246 
 
4. Jones RN et al, Respiratory tract pathogens isolated from patients 
hospitalized with suspected pneumonia: frequency of occurrence 
and antimicrobial susceptibility patterns from the SENTRY 
Antimicrobial Surveillance Program (United States and Canada, 
1997); Diagnostic Microbiology and Infectious Disease 37 (2000): 
115-125 
 
5. Heffelfinger JD et al, Management of Community-Acquired 
Pneumonia in the Era of Pneumococcal Resistance; Archives of 
Internal Medicine 2000; 160: 1399-1408 * Reference retrieved by the evaluator 
 
6. Bartlett JG et al, Guidelines from the IDSA practice Guidelines for 
the Management of Community-Acquired Pneumonia in Adults; 
Clinical Infectious Diseases 2000; 31: 347-82 
 
7. Ball P, New antibiotics for community-acquired lower respiratory 
tract infections: improved activity at a cost? International Journal of 
Antimicrobial Agents 2000; 16: 263-272 * Reference retrieved by the evaluator 
   
 
8. DeAbate CA et al, Gatifloxacin vs. Cefuroxime Axetil in Patients 
With Acute Exacerbations of Chronic Bronchitis; J Respir Dis. 1999; 
20(11, suppl): S23-S29 
 
 
9.  Ramirez A et al, Gatifloxacin Treatment in Patients With Acute 
Exacerbations of Chronic Bronchitis: Clinical Trial Results; J Respir 
Dis. 1999; 20(11, suppl): S30-S39 
 
10. Fogarty C et al, Gatifloxacin vs. Clarithromycin in the Management 
of Acute Sinusitis; J Respir Dis. 1999; 20(11, suppl): S17-S22 
 
 
11. Lopez JA et al, Treating Acute Uncomplicated Bacterial Sinusitis 
With Gatifloxacin; J Respir Dis. 1999; 20(11, suppl): S11-S17 
 
 
12. Cox C et al, A Multicenter Comparison of Gatifloxacin (GAT) 400 
mg QD vs Ciprofloxacin (CIP) 500 mg BID in the Treatment of 
Complicated Urinary Tract Infection (UTI) and Pyelonephritis; 39th 
ICAAC, September 26-29, 1999. Abstract#0612 
 
 
13. Stoner BP et al, Single Dose Gatifloxacin (400 or 600 mg) vs Single 
Dose Ofloxacin (400 mg) in the treatment of Uncomplicated 




14. Tarshis G et al, Oral Gatifloxacin 400 mg QD vs Oral Levofloxacin 
500 mg QD in the Treatment of Uncomplicated Skin and Soft 




Other references retrieved by the evaluator 
 
1. Blondeau JM, Expanded Activity and Utility of the New 
Fluoroquinolones: A Review; Clin Ther 1999; 21 (1): 3-30 
 
 
2. Grossman RF, The role of fluoroquinolones in respiratory tract 
infections; Journal of Antimicrobial Chemotherapy 1997; 40 
suppl. A, 59-62 
 
3.  Blondeau JM, A review of the comparative in-vitro activities of 
12 antimicrobial agents, with a focus on five new ‘respiratory 
quinolones’; Journal of Antimicrobial Chemotherapy 1999; 43 
suppl. B, 1-11 
 
 
4. Piddock LJV et al, Activities of New Fluoroquinolones against 
Fluoroquinolone-Resistant Pathogens of the Lower Respiratory 
Tract; Antimicrobial Agents and Chemotherapy, Nov. 1998, 42 
(11): 2956-2960 
 
5. Perry CJ et al, Gatifloxacin; Drugs 1999, 58(4): 683-696 
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APPENDIX  10 
Expert Opinion 
(Form where opinion of relevant specialty is sought – atypical report and clinical papers are sent 










































































































G 	   

+ %   	     G 	    	
$ '		  	   




, %   P		 .		 G 	    	
$ 	  





		     
K
L
$ 	P	 	     
 
$ /  
	 
    
) R 

  O	P  	
  
 	 ^    G 	    	
 
$  		       
$ 		       
$ M  		      
$ < 			      
$  		      
$ < 		      
0 R  	  	  
		^       

G 	    	
$ M  		    
$ < 	
$  		
- <  
 C 	
 
	^     G 	    	
$ F  
$ F 	
$ F  	
$ / 

1 R C 
			  
	
C  	^     G 	    	
$  		
$ (  		
$ M   		




 	      G 	    	




















  	  		 	  	   	

: R   	
	 	
  >  	

 ^   G 	    	
$  	        
$ F  	
 	    








$ (B  





+* " 	 				
	^ 

   		 				 

++ R 	K	L ^   G 	    	


















$  A 

 		  

 	
+) R   	B 		

  
^    G 	    	












+0    H      	    	 
   
 







+- R C 
 
 			  	
^        G 	    	




$ A H 
	 	 
!  	 
$ '	
$ G  H  > 

	>			
$ KA H L
			 	  





  B 		 	C  
C  
		^       G 	    	






	^      













$ R 	   B  


H   		 	 ^ 

 $ , &&9  %%$ / 9 , +  )  * &9   7  , &$  
' 2  <  		
   		
^ 
$ V  		
 
$ 9 
$ F C    
$ = 		
 
+5 <   KL    	  KL	       	
^ 




+: R  C 













$ # C 	
KB  L
 $ '	 		 	     	 
    
	 	
$ J  	      	   
   

	




 	   


































,, R  	. 	  C 	
^ 
	
     G 	    	
$ 	 	




			   	
 	



























,) R 	  








,0 R  	 
 
 	^ 
G 	    	




































P&T Committee Member Responses 
















 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
